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Twenty percent of colposcopic assessments are inadequate due to a type 3 
transformation zone (TZ3). Despite this, the literature relating to this finding is 
sparse. Management is guided by the referral screening test and, in this thesis, I 
have shown that the presence of a TZ3 is the strongest predictor of false positive 
cervical screening results. 
 
Analysis of colposcopists’ decision-making, both locally and nationally, identified 
heterogeneity of care in women with low grade cytology; there was disparity in 
the total length, clinical setting and technique of cytological follow-up. These areas 
of discordance were affected by anxiety of missing a cancer and paucity of 
guidance, suggesting a need for a national consensus opinion. 
 
To date, no study has evaluated the effectiveness of different cytological sampling 
techniques in a TZ3 assessment. In the UK, routine cervical screening is completed 
by a Cervex-Brush alone. In my thesis, the addition of a cytobrush increased the 
yield of endocervical cells but this was not associated with increased predictability 
of CIN2+ (high grade dysplasia). I propose that cytological follow-up with a Cervex-
Brush alone can be safely undertaken in a primary care setting. This finding is 
relevant for resource allocation which is particularly pertinent in the current 
economic climate within the NHS. 
 
Given the significant risk of CIN2+ in women with high grade cytology and a TZ3 
(80%), it is appropriate to offer LLETZ first line. My results have also shown, for the 
first time, that women with low grade cytology, high risk HPV and a TZ3 have 
double the risk of CIN2+ (36.7%) when compared to women where the TZ is visible. 
In these women, I propose the use of surrogate biomarkers for HPV infection (p16 
and Ki-67) in combination with liquid based cytology; these biomarkers provide a 
>99% sensitivity for CIN2+ and improve the specificity (decrease false positive 
screening) from 19.3% to 71.7%. When compared to dual-stained cytology, 
neither HPV 16/18 genotyping nor p16 & Ki67 in combination with endocervical 
curettings demonstrated an equivocal sensitivity. 
 
The continued investigation of adjuncts which can improve the diagnostic 
accuracy of cervical screening will help;  
i. achieve the World Health Organization’s 2018 global priority of reducing the 
incidence of cervical cancer and  
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In the United Kingdom, the introduction of a national cervical screening programme has 
reduced the overall mortality rate from cervical cancer by 70% to 2.8 per 100,000 
women[3]. Despite this, cervical cancer is still the most common cancer in women under 
the age of 35 and one-third of these women will die within five years of diagnosis[3]. 
Diagnosing and preventing progression of the precursor lesion, cervical intraepithelial 
neoplasia (or CIN) continues to be a national priority. When women with a positive 
cervical screening result are referred to colposcopy, the purpose of this assessment is to 
visualize the area infected by the Human Papillomavirus (HPV), the virus responsible for 
99% of cervical cancers. This assessment is crucial in helping determine who requires 
treatment and who can be safely managed with cytological follow-up. Management 
difficulties arise when the epithelium of interest is ‘tucked inside’ the cervix and not visible 
for assessment. This is known as unsatisfactory colposcopy or a transformation zone type 
3 (TZ3), the incidence of which is approximately 20%[4], potentially accounting for more 
than 34,500 women seen in UK colposcopy clinics each year[5]. 
There is a paucity of national and global guidance in this cohort, which can lead to 
uncertainty in decision-making. Novel interventions which improve the diagnosis of CIN 
in this cohort and national recommendations which improve homogeneity of care are 
needed to reduce the morbidity of false positive and false negative screening. 
 
1.2 Aetiology of cervical cancer 
The pathogenesis of cervical cancer has been studied in depth and although the primary 
aetiological factor, infection with HPV, has been well documented, integration of this virus 
into the host’s genome is a multifactorial process. When considering the aetiology of 
cervical cancer it is useful to study the structure of the normal cervix, as this influences 
the pathogenesis of HPV infection. 
 
 
Chapter 1 Introduction 
2 
 
1.2.1 The contribution of the cervical epithelium 
The ectocervix (external, vaginal portion of the cervix) is covered by stratified, non-
keratinising, glycogen containing squamous epithelium. In the neonatal period the 
endocervical canal is lined by columnar epithelium, which is non-stratified and mucus 
secreting. Folding of the epithelium forms crypts which can extend 5-8mm into the 
stroma. The Squamocolumnar Junction (SCJ) is where these two epithelia meet and 
histologically this appears as a step due to their differing heights. This distinctive feature 
allows histopathologists to identify that sampling of the SCJ has occurred, as cervical 
neoplasia usually begins here[6, 7]. 
The structure of the epithelium (Figure 1.1: Mature squamous epithelium) is integral to 
the development of dysplasia (abnormal maturation). At the bottom of the squamous 
epithelium a basement membrane separates the stroma below from the epithelium 
above. Attached to the basement membrane is a single layer of basal cells which contain 
large nuclei and little cytoplasm. The basal cells divide mitotically under the influence of 
oestrogen to form further basal (or immortal) cells and these differentiate to form the 
higher cell layers of the epithelium. These upper cell layers lose mitotic capability and 
become terminally differentiated (mortal cells) to form: 
 Parabasal cells 
 Intermediate cells; polygonal cells with increased cytoplasm:nuclei ratio. 
 Superficial cells; large, flattened and terminally differentiated cells containing small 
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1.2.2 The Transformation Zone 
Under the influence of oestrogen (adolescence, pregnancy and use of the combined oral 
contraceptive pill), there is an increase in the number and size of the endocervical glands, 
the vascularity of the cervix and stromal oedema. This expansion in cervical volume leads 
to eversion of the columnar epithelium onto the ectocervix, secondary to fixation of the 
lateral cervix.  
Following puberty, the relative acidity of the vagina is increased (pH 4), promoting 
lactobacilli which stimulate the protective conversion of columnar cells into squamous – 
a process known as metaplasia[9].  Metaplasia begins in the crypts and the tips of the 
endocervical villae and occurs in three distinct histological stages[10]: 
1. Reserve cell hyperplasia – small round cells with hyperchromatic nuclei appear next 
to columnar cell nuclei. Their origin is thought to be either from subepithelial stromal 
cells or more likely columnar cells adapting to the acidic vaginal environment.  
2. Immature squamous metaplasia – the reserve cells proliferate to form a multicellular 
epithelium with no stratification. These epithelial cells are susceptible to carcinogens 
(HPV) and most squamous cell cervical cancers (SCC) arise here. 
3. Mature squamous metaplasia – immature cells have differentiated into cells which 
are difficult to distinguish from the original squamous epithelium. 
 
The presence of crypt openings on the ectocervix demarcates the extent of the 
metaplastic epithelium and the original SCJ. The area which is bounded distally by the 
original SCJ and medially by the new SCJ is called the Transformation Zone (TZ). The TZ is 
the area colposcopists need to visualize when women are reviewed in the colposcopy 
clinic as this is where HPV may have invaded during immature metaplasia. Figure 1.2 




















1.2.2.1 Transformation Zone Nomenclature 
The International Federation of Cervical Pathology and Colposcopy (IFCPC) Classification 
is based on the location of the transformation zone in relation to what is visible during 
the colposcopic examination. The TZ can either be visible on the ectocervix (Type 1 TZ: 
Figure 1.3), partially within the endocervical canal but visible (Type 2 TZ) or entirely within 
the endocervical canal and not visible (Type 3 TZ or unsatisfactory colposcopy: Figure 1.4). 
According to a consensus guideline written by the American Committee for Colposcopy 
and Cervical Pathology, a TZ3 occurs in approximately 20% of women assessed in 
colposcopy[4] and can make the diagnosis of cervical cancer and CIN problematic (See 











Figure 1.2: Taken from the International Agency for Research on Cancer[2]; 
‘Location of the SCJ and TZ (a) before menarche, (b) after puberty, (c) during a 
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1.2.3 Human Papillomavirus (HPV) 
In 1983, Harald zur Hausen examined the histology samples of 60 women with cervical 
cancer. His monumental discovery that HPV subtypes have differing carcinogenicity with 
high risk subtypes present in 93 – 99% of cervical cancers[11] led to the publication of many 
large meta-analyses which have corroborated the global epidemiology[12, 13], and reported 
the cellular pathogenesis and immunology of this virus.  
1.2.3.1 Epidemiology 
A meta-analysis spanning five continents and over a million women with normal cervical 
cytology estimated a worldwide prevalence of 11 - 43%, except in sexually active 
adolescents and young women where it can reach 50%[14]. In young women, exposure to 
HPV is high but natural immunity low. Transmission is by sexual contact and the lifetime 
risk of infection for women and men is 80% but this is usually transient and the clearance 
rate in the immunocompetent is 80-90% within two years of infection[15]. It is unclear 
whether the host antibody response completely eliminates HPV and provides lasting 
immunity to the subtype (immunoclearance) or whether viral DNA is kept at an 
undetectable level by immunologic control (latency). The reappearance of HPV genotypes 
has been reported in women over 40 years of age but these infections are generally 
benign[16]. Progression from infection to invasive cancer usually occurs over 10 - 15 years 
and the likelihood of a cancer diagnosis before the age of 30 is rare[3], except in women 
who are immunocompromised or have their first sexual contact at a young age.  
Figure 1.3: Type 1 TZ 
 
Figure 1.4: Type 3 TZ 
(unsatisfactory colposcopy) 
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1.2.3.2 Classification 
HPV is an 8000 base pair double stranded, circular DNA virus. 150 different types of HPV 
have evolved over millions of years, of which the main genera are known to cause genital 
warts, commensal infections and infect anal, oral and cervical epithelia. The 40 types 
which infect the cervical epithelium originate from the alpha 5, 6, 7, 9 and 11 species 
which have been subdivided by the International Agency for Research on Cancer 
according to their carcinogenic potential: ‘1 - carcinogenic, 2a - probably carcinogenic and 
2b - possibly carcinogenic’[17]. This carcinogenic grading of the HPV subtypes was based on 
studies like that of Shiffman et al who recruited 10,000 women into a population-based 
prospective study[18].  
However, the prevalence and carcinogenicity of HPV subtypes can differ dependent upon 
specific populations which may result in underestimation of the risks associated with the 
rarer subtypes. HPV 16 is reported to be responsible for the greatest proportion of 
cervical, anogenital and oral SCCs (50%) due to a reduced rate of immunoclearance 
(Section 1.6.4). HPV 18 is found in 35% of adenocarcinomas and although responsible for 
a lower proportion of SCCs, 10 - 15%, some studies suggest it is a more aggressive 
phenotype. Of the remaining oncogenic subtypes HPV 45 accounts for 7% of cervical SCCs, 
HPV 31 for 3% and the rest combined (33, 35, 39, 51, 52, 56, 58, 59, 66 and 68) are 
accountable for less than 2%. HPV 6 & 11 are low risk subtypes associated with 
condylomata acuminata which are benign exophytic papillary lesions (genital warts). HPV 
genotypes 42, 44, 53, 54, 55 and 66 are also low risk and associated with benign or low 
grade pre-invasive lesions[18, 19]. 
1.2.3.3 Pathogenesis 
The interaction between HPV and the host genome has been extensively studied over the 
past 20 years. Low risk HPV subtypes are seen as extra-chromosomal DNA whereas high 
risk subtypes integrate into the host’s genome producing early and late viral genes which 
have different functions. Late genes encode the envelope proteins L1 and L2, whilst early 
genes encode proteins E1, E2, E4, E5, E6 and E7 which affect cell function and 
replication[20] (Figure 1.5). It is believed that sexual intercourse traumatizes the cervical 
epithelium at the transformation zone, allowing the virus to bind to the basement 
membrane via the envelope protein, L1, and pass into the nuclei of keratinocyte receptors 
in the basal layer via L2[20]. As discussed in 1.2.1, the basal cells are the immortal cells and 
viral integration at this level compromises all higher cell layers within the epithelium.  
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Figure 1.5: HPV genome[21] 
 
The HPV derived proteins E1 and E2 are responsible for early transcription and viral 
replication. E5, E6 and E7 proteins interfere with cell cycle control causing instability at 
3p. E6 binds to E3 ubiquitin ligase leading to degradation of p53, an oncogenic regulator. 
As a consequence, apoptosis of DNA damaged cells is prevented. During integration, viral 
DNA is disrupted and recombination usually occurs with deletions at E1-2, providing E6 
and E7 direct access to the viral promoter and enhancer sequencing[22].  
In an attempt to increase viral replication, E6 activates cyclin D and cyclin dependent 
kinase (CDK) 4/6 which triggers the G1 stage of the cell cycle pathway. This action, 
combined with the degradation of p53, causes exponential cell proliferation (and the 
release of the proliferation marker Ki-67 (Section 1.6.3.1.2). To further increase viral 
replication, HPV protein E7 inactivates retinoblastoma protein (pRb), another oncogenic 
regulator. In its absence activation of E2F occurs; this cell cycle regulatory gene codes 
transcription factors which, following the loss of the oncogenic regulators, are no longer 
counteracted by cell apoptosis  
In an attempt to slow cell proliferation the activation of E2F triggers the production of a 
cell cyclin-dependent kinase inhibitor, p16INK4a (p16)(Section 1.6.3.1.1). p16 blocks the 
CDK 4/6 (cyclin D) proliferation which is promoted by HPV E6 (Figure 1.6). Secondary to 
this blockade, another cyclin dependent pathway (cyclins A/E: CDK2) is activated 
promoting the G1/S transition and the S phase to G2 stage of the cell cycle; this continues 
the exponential proliferation that is associated with neoplastic lesions[23]. An 
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understanding of the molecular changes that occur with HPV infection is integral to 




Figure 1.6: The cellular expression of p16 and Ki67 (diagram author’s own). 
 
Infected cells can remain in a quiescent stage in the basal layer or, when activated, move 
over 4 - 6 weeks from the basal layer to the superficial, terminally differentiated cells of 
the epithelium. HPV replication occurs in the nuclei here, which through constant 
sloughing of the upper layers of the epithelium, allows HPV to go unnoticed by the host’s 
immune system, permitting large scale viral replication[24]. It is still unclear, other than in 
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1.2.3.4 The immune response to HPV 
Antibody-mediated (humoral) and cell-mediated immune responses combat current viral 
infections and prevent future re-infection. The humoral response to HPV is slow and 
results in antibodies against the L1 capsid protein which provides protection for at least 
10 years after sero-conversion[25]. Consideration of these pathways is important when 
addressing the potential for HPV vaccination (Section 1.3.1). 
 
Langerhans’ cells (LCs) are immune cells which are found in the epidermis and help 
prevent infection by presenting antigens to T-lymphocytes[26]. Studies have looked at the 
density of LCs within the normal ectocervix and found a mean of 8 per 100 basal cells in 
the TZ, predominately clustered at the basement membrane. Uniform distribution of LCs 
has been described in the TZ and the rest of the ectocervix but T-lymphocytes are not 
uniformly distributed and studies have been unable to accurately measure these on tissue 
biopsies[27, 28]. Infections and malignancy change the density and distribution of LCs: an 
increase in density and dendritic branching is reported in direct relation to the severity of 
CIN[29]. Conversely, in the presence of HPV there is a decrease in these cells, potentially 
due to a cytotoxic effect[30]. 
 
The immune response during the progression from HPV to cervical cancer has been 
studied and the evidence indicates that blockade of immune signaling pathways is integral 
to this progression, as outlined below[31]; 
1. Cell mediated pathways: 
 The intracellular control mediated by cyclin-dependent kinase inhibitors (p16INK4a and 
p14ARF) is blocked. 
 Suppression of viral oncogene transcription by paracrine control (specifically 
macrophages and TNF-α) is blocked. 
 E6 and E7 proteins inhibit the interferon response which is a key antiviral defense 
mechanism.  
 
2. Humoral pathways: 
 Human leucocyte antigen presentation of viral antigens is inhibited. 
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1.2.4 Cervical Intraepithelial Neoplasia 
The discovery of a cervical cancer precursor lesion, which occurs after integration of 
persistent high risk HPV into the host’s genome, delineated the importance of screening 
for and managing this precursor lesion. This was termed cervical intraepithelial neoplasia 
(CIN). Consideration of the structural changes which occur with CIN is helpful when 
exploring and interpreting new investigative avenues. An understanding of the natural 
history and factors which can affect progression of CIN is also vital when planning 
screening and treatment algorithms.    
1.2.4.1 Histological diagnosis 
Histological assessment interprets the degree of dysplasia within the cervical epithelium 
by identifying nuclear abnormalities such as enlarged nuclei, a raised nuclei:cytoplasmic 
ratio, increased hyperchromasia, nuclear polymorphism and variations in nuclear size 
(anisokaryosis). Mitotic figures are usually only seen in the parabasal layer but as the 
severity of the dysplasia increases these figures are observed throughout the epithelial 
layers. There is a large body of evidence, with consistent findings across the published 
data, which have reported the structural changes observed with different histological 
grades of CIN. This grading is determined by the degree of disturbance of cellular 
maturation and stratification (Figure 1.7).  
 CIN 1: Undifferentiated cells are confined to the lower third of the epithelium, with 
scarcely populated mitotic figures. Koilocytes are seen throughout the epithelium. 
 CIN 2: Dysplasia is observed in the lower two thirds of the epithelium. Increasing 
nuclear abnormalities and mitotic figures are seen throughout the lower third. 
 CIN 3: Loss of stratification and differentiation of cells throughout the full thickness of 




Figure 1.7: Histological 
grading of CIN[1]:  
A - Normal epithelium  
B - CIN1  
C - CIN2 
D - CIN3. 
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Routine immunohistochemistry for CIN consists of Haematoxylin and Eosin (H&E) 
staining. Eosin stains acidophilic structures (cytoplasm) pink and haematoxylin (in 
combination with aluminum salts) stains basophilic structures (DNA in nuclei, RNA in 
ribosomes and endoplasmic reticulum) purple-blue. Many benign changes can be 
mistaken for dysplasia[32] such as reserve cell hyperplasia where the nuclei become 
crowded and larger but retain their normal shape and morphology. With immature 
metaplasia there is a high nuclear:cytoplasmic ratio and in atrophic epithelium the 
parabasal cells predominate and appear hyperchromatic with an increased N:C ratio. 
These benign changes can make differentiation from dysplasia difficult with routine H&E 
staining, leading to the development of novel biomarkers in an attempt to improve the 
diagnostic accuracy of the screening tests (Section 1.6.3). 
1.2.4.2 Natural history 
Many studies have evaluated the natural history of CIN but much of the evidence available 
is limited by short (less than 6 months) follow-up because, ethically, observing the 
potential progression of CIN3 to cancer cannot be sanctioned. The exception was a clinical 
study in New Zealand between 1965 - 1974, where consent was not gained to withhold 
treatment in women with CIN3[33]. Ostor AG, 1993[34] pooled and critically reviewed 
studies between 1950 and 1993 to approximate the regression and progression of CIN. It 
is considered the seminal paper in this area and the findings are outlined in Table 1.1. The 
outcomes from this study are the basis for the current UK recommendation to treat 
CIN2+[35]. 
Table 1.1: Natural History of CIN[34] 




1 60% 30% 10% 1% 
2 40% 40% 20% 5% 
3 32% 56% - 12% 
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1.2.4.3 Risk factors for CIN progression 
The following risk factors are not an exhaustive list but give an indication of how complex 
the progression of CIN can be and the factors which colposcopists need to consider when 
evaluating appropriate management options. The difficulty is that many of these co-
variables are related and although interventional studies could help assess the 
independent effect of these factors, this may not always be ethically possible. 
 Cross-sectional and case-control studies in different continents have reported early 
onset of intercourse, multiple sexual partners and partner’s number of sexual partners 
have a strong association with HPV acquisition and persistence[36, 37]. Integration of 
HPV following early age of first intercourse may be mediated by a large, metaplastic 
ectocervical TZ or an immature immune response[38, 39]. 
 Smoking: There is a significant body of evidence which, having adjusted for 
covariables such as sexual behavior, support the association of smoking with the 
development of cervical cancer. A large meta-analysis reported that smokers are 1.6 
times more likely to develop a cervical SCC when compared to never smokers (95% 
CI: 1.48 – 1.73, p<0.001) and if they smoke fifteen or more per day their risk further 
increases (RR 1.98, CI 1.78-2.21, p<0.001)[40]. Tobacco metabolites such as 
Benzo[a]pyrene, cotinine and nicotine are found within smokers’ cervical mucus and 
it is thought they enable expression of cytochrome P450 enzymes which activate 
carcinogenic nitrosamine leading to DNA damage and immunosuppression[41]. 
Furthermore, the frequency of smoking increases the viral load and longevity of HPV 
by dampening Langerhan cell mediated immune responses[30]. A prospective 
intervention study, which adjusted for confounders, showed the benefits of 
promoting smoking cessation in 82 women with biopsy proven CIN1: at six months of 
cessation 82% of women had ≥20% (4mm2) reduction in low grade (CIN1 / HPV) lesion 
size with a corresponding reduction in tertiary follow up compared to 28% of smokers 
(OR 12.0, 95% CI 3.9 – 32.7)[42].  
 Combined oral contraceptive pill (COCP) use: Large epidemiological and case-control 
studies, which adjusted for other co-variables, have demonstrated an association 
between use of the COCP and cervical cancer. In women who are high risk HPV 
positive, the risk of cervical cancer increases three-fold if the COCP is used for 5 - 9 
years and four fold if use is >10 years (OR 4.03, 95% CI 2.09 - 8.02), when compared 
to never users[43, 44]. COCP use has been shown to increase the size of the ectocervical 
TZ (OR 1.8, 95% CI 1.0 - 3.3)[45] and this may facilitate HPV acquisition. Some studies 
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have postulated that COCPs induce folate deficiency, which affects DNA synthesis and 
repair, but a link between women with folate deficiency and an increased risk of 
cervical cancer has not been shown[46].  
 Immunocompromise: Despite resolution of an active infection (negative serum 
samples), HPV DNA can still be detected in the skin, oral cavity and female genital 
tract[47]. Reactivation of a DNA virus has been reported for hepatitis B, herpes simplex, 
EBV and CMV in immunocompromised patients[48, 49]. It is logical that persistence or 
reactivation may occur in women who are immunocompromised if HPV clearance is 
mitigated by the host’s immune response. Patients who have undergone renal 
transplantation have a five-fold increased risk of cervical dysplasia, a 15% incidence 
of HPV and higher rates of false negative cytology[50]. Women who are HIV positive 
have a five-fold increased risk of cervical SCC, a higher risk of false negative cytology 
and an increased risk of both progression and recurrence of low grade lesions[51, 52]. 
These studies were published before HPV testing and the false negative rates may be 
associated with the quick progression of HPV infection in these patients. 
 Other infective agents: 
o Chlamydia trachomatis (an obligate intracellular bacteria) increases the risk of 
cervical SCC (OR 1.8, 95% CI 1.2 - 2.7) but not adenosquamous cervical cancer (OR 
1.0, 95% CI 0.53 – 1.9). This risk is increased in women with elevated antibody 
titres (>128)[53]. Possible reasons include a humoral rather than cell-mediated 
response (which may reduce clearance of HPV[54]), the bacteria may affect the 
structure of the epithelial cell cadherin-catenin junctions - increasing 
susceptibility to HPV infection[55] - or inflammation secondary to chronic infection 
may produce reactive oxygen species which damage cellular DNA[56]. 
o Herpes Simplex (HSV): A meta-analysis of seven case-control studies (2000 
women) reported that HSV-2 (genital infections) increases the risk of cervical SCC 
(OR 2.19, 95% CI 1.41 - 3.40) and adenosquamous cancer (OR 3.37, 95% CI 1.47 - 
7.74)[57]. No link was made between HSV-1 antibodies (non-genital infections) and 
cervical cancer. Similar pathogenic mechanisms to C. trachomatis have been 
proposed, as well as facilitation of HPV to the basal layer secondary to ulcerative 
lesions[58]. 
 Nutrient deficiency: A meta-analysis of case-control studies, which included 10,000 
women, reported that deficiency in folic acid and vitamins A, E and C may affect 
immune status and increase the risk of cervical cancer[59].  
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 Parity: Many studies have suggested an association with cervical SCC. A large 
multicentre case-control study reported, that in high risk HPV positive women, parity 
greater than four doubles the risk of SCC when compared to nulliparous women (OR 
2.3, 95% CI 1.6 - 3.2)[60, 61]. No correlation was noted with adenocarcinomas[60]. 
Postulated theories include trauma to the cervix and / or hormonal effects which 
evert the TZ. 
 Genetic: Current evidence suggests cervical cancer is not hereditary, but women with 
an affected 1st degree relative have a two-fold increased risk. This may be secondary 
to similar lifestyles, such as high risk sexual behavior or smoking, or they may have a 
genetically dampened immune response to HPV[62]. 
 
1.3 Prevention of cervical cancer 
1.3.1 Vaccination 
A prophylactic HPV vaccine would have many applications; it would be beneficial for 
women at risk of cervical, vulval and vaginal cancer, for women and men at risk of genital 
warts or cancer of the larynx and anus and for infants who contract HPV laryngeal 
infections - which need to be surgically excised to prevent tracheal occlusion.  
Despite a global effort, development of the vaccine was protracted for a number of 
reasons: HPV infections are species specific (they cannot be studied in mice as they do not 
contract the virus), the viral particles are sparse in lesions, low antibody levels to the L1 
capsid protein are produced during seroconversion and live attenuated or killed vaccines 
cannot be generated because in vitro cultures cannot support the complete cycle. 
Moreover, the virus is classified according to genotype (genetic composition) rather than 
serotype (classification of a virus based on their surface antigens)[63]. This has prevented 
the development of a vaccine which provides broad spectrum immunity to all high risk 
types (targeted at the L2 envelope proteins).  
In 2006 a bivalent vaccine targeted at HPV 16 & 18 (Cervarix) was licenced, as was a 
quadrivalent vaccine to HPV 6, 11, 16 & 18 (Gardasil). These are given as intramuscular 
injections at 0, 2 and 6 months. Early studies demonstrated that when eukaryotic vectors 
expressed HPV L1 proteins, virus like particles (VLPs) were generated and an antibody 
response was produced[64]. Intramuscular injections allow the VLPs to enter the 
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vasculature and lymphatics, starting a T helper response with antibody mean titres 14-24 
times higher than natural concentrations one month after the 3rd injection. In contrast, a 
poor inflammatory response is seen with cervical infections as HPV is contained within 
the surface epithelium, thereby reducing the antigen presenting response from 
macrophages and Langerhans’ cells [65]. 
Trials have been undertaken to assess the efficacy of the vaccines; in women who are HPV 
naïve the bivalent vaccine confers a higher and more sustained immune response than 
the quadrivalent vaccine, with immunogenicity so far demonstrated for 8.4 and 5 years 
respectively[66]. Randomised control trials[67] and a recent observational study have 
demonstrated that the prevalence of CIN2+ is lower in women vaccinated against HPV 16 
& 18 (19% vs 36%, p=0.006)[68]. Moreover, the specificity and NPV of screening were 
higher in women who were negative for HPV 16 (92.4 vs 75% and 94.6 vs 64.9% 
respectively)[68]. 
These findings suggest the introduction of a vaccine which provides protection against 
HPV 16 and 18 will be of benefit but cervical screening is still required as older women 
will not be vaccinated, the efficacy of the vaccine in women who are not HPV naïve is only 
30%[69] and although some cross-protection is provided against HPV 31, 33 and 45, other 
high risk subtypes are not covered[70]. Recent studies indicate that high risk subtypes not 
covered by the vaccine, HPV 51[71], 52, 56 & 58[68] and 59[70], are increasing in incidence; 
the introduction of a nine-valent vaccine in 2019 will help address this but modelling 
studies have suggested the full effects of this new vaccine will not be seen until 2035 - 
2040[72].  
What has been reported since the introduction of the quadrivalent vaccine is a failure to 
decrease low grade screening abnormalities[73] and the potential decreased PPV of 
screening from 70% to 20%, by reducing the prevalence of cervical cancer[74]. As the 
vaccine provides protection against HPV 16 and 18, the subtypes currently responsible for 
65% of cervical cancers, a reduction in the prevalence of these subtypes within a 
vaccinated population will influence the number of true positives in women who have a 
positive screening test. The trade-off, as discussed, is the improved NPV of screening as 
more people who test negative for high risk HPV will actually be negative. These studies 
delineate the importance of future research which targets improved triage of vaccinated 
(and unvaccinated) women who have positive screening results.  
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1.4 Screening for cervical cancer 
As previously discussed, the progression to high grade CIN can be multifactorial and 
regression is possible, even with CIN3. However, the mortality from cervical cancer is high 
and excision of high grade CIN can prevent progression to cancer. To improve detection 
of CIN the UK cervical screening programme was introduced in 1988; the mortality rate 
from cervical cancer since its introduction has reduced by 70% from 8.9 per 100,000 
women to 2.6 per 100,000 women in 2016[75]. In women with a TZ3, who have a positive 
screening test, colposcopic assessment is not possible and management is guided by the 
screening result alone. When evaluating methods which may increase diagnostic accuracy 
or when formulating potential treatment algorithms, an understanding of the current UK 
cervical screening programme is necessary. 
 
1.4.1 Cytology 
1.4.1.1 Sample taking, processing and adequacy criteria 
The cervical epithelium is routinely screened in a primary care setting using a Cervex-
Brush alone which ‘brushes’ and collects cells from the ectocervix and 0.5cm of the 
endocervix. With liquid based cytology (ThinPrep or SurePath), the cells are dislodged 
from the Cervex-Brush into a pot of preservative. Liquid based cytology (LBC) superseded 
conventional cytology in 2008 throughout the UK as it has a higher sensitivity (83.9% vs 
72.7%) for squamous cell lesions albeit a slightly lower specificity (82% vs 76%)[76]. The 
improved filtration of blood and mucus from LBC led to a national decrease in inadequate 
samples (9% to 2.8%). Moreover, processing of the slides is automated, which has 
increased lab turnover times[77].  
Currently, the British Association for Cytopathology suggests the following criteria for 
confirming adequacy of an LBC sample: a minimum average cell count (MACC) of 5 - 
10,000 squamous cells and the sample taker must have visualized the cervix. The presence 
of endocervical cells is now only reported in women with previous glandular 
intraepithelial neoplasia (cGIN)[78]. In theory, if the cervix is visualized and the 
transformation zone is on the ectocervix, TZ1 or 2, sampling should be adequate. In 
women with a TZ3, colposcopists may not be reassured by the cytology result if the 
presence of TZ sampling (endocervical cells) is no longer reported. 
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1.4.1.2 Other cytology collection devices 
There is a large body of evidence comparing combinations of Cervex-Brush, Cytobrush, 
Spatula and cotton swabs (Figure 1.8) to determine cytological adequacy rates and 
detection of dysplasia[79]. The evidence about the contribution of endocervical cells in 
predicting high grade disease is contradictory, with some studies promoting their 
importance in reducing false negatives[80, 81] whilst other studies refute this risk[82].  A study 
of 20,000 LBC samples reported improved detection of endocervical cells (TZ) with 
combined Cervex-Brush and cytobrush sampling when compared to the Spatula plus 
Cytobrush or Cervex-Brush alone (89.8%, 86.9% and 77.1% respectively, p<0.001)[83]. 
Although no difference was observed in the diagnosis of high grade lesions between 
devices, improved detection of low grade dysplasia was noted with the combined Cervex-
Brush and cytobrush (4.2%, 2.4% (p<0.001) and 2.9% (p=0.003) respectively). It should be 
noted that the rate of inadequate samples was doubled with the Cervex-Brush + 
cytobrush when compared to the Cervex-Brush alone (1.6% vs 0.8% respectively, 
p<0.001); this may be due to order of device sampling, which was not reported, as a 
cytobrush can increase blood loss which may reduce subsequent cytological yield.  




Figure 1.8: Cytological 
collection devices  
a.) Cervex-Brush (broom)  
b.) Cytobrush  
c.) Ayres Spatula 
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Of the studies which have assessed adequacy of LBC collection devices, none have 
correlated their findings with topographical position of the TZ[79]. Furthermore age, parity 
and hormonal status were not adjusted for and these factors may affect the MACC. In my 
thesis I will compare the use of a Cervex-Brush alone to a Cervex-Brush + Cytobrush in 
women with a TZ3, whilst adjusting for co-variables which may affect the cytological yield, 
to try and address this shortfall in the literature. 
1.4.1.3 Interpretation 
In the UK, cytological grading uses the revised 1986 British Society for Clinical Cytology 
(BSCC) classification system[84]. Samples are divided into high grade cytology (moderate 
or severe), high grade possibly invasive, low grade (mild or borderline nuclear change 
(BNC)) and borderline, high grade not excluded. Referral to colposcopy should be within 
two weeks for possible invasion or high grade cytology and six weeks for low grade 
cytology[85]. Unlike squamous cell cancers, sensitivity and specificity of cytology for 
glandular lesions is poor at 32.7 - 48.1% and 69.4 - 94.4% respectively[86]. Multi-focal 
lesions may be missed and it can be difficult to distinguish benign lesions such as tubo-
endometrial metaplasia from cGIN. 
Of the 172,776 women referred to colposcopy with abnormal screening results in 2015 -
2016, 77.5% (133,859) were for a low grade result and 22.5% (38,917) were for a high 
grade result. In women with high grade cytology, 87.6% were of reproductive age (25 - 44 
years) and of those with low grade cytology, 63.3% were aged 25 – 44[87]. 
1.4.1.4 Frequency of screening 
In the UK alone, £175 million is spent annually on cervical screening and colposcopic 
assessment – the majority of lesions reviewed are benign and likely to regress[88]. A UK 
based case-control study[89] looked at the screening histories of 1300 women with invasive 
cancer and 2500 matched controls to evaluate the ‘protection’ (efficacy of cytological 
screening to prevent cervical cancer) that yearly, 3 yearly and 5 yearly testing would 
provide. Under the age of 25, 60% of women infected with HPV exhibit low grade 
cytological and histological changes and, as previously discussed, with high rates of HPV 
clearance in this cohort, the cost of screening and treatment is not currently thought to 
be economically viable.  
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In women aged 55 - 69, five yearly screening is recommended as protection is 87% for 1 
and 3 years and 83% for five years. For women 40 - 54, screening is 3 yearly as protection 
is 88% at 1 year, 84% at 3 years and 73% at 5 years. In women aged 20 - 39, screening is 
three yearly as protection is 76%, 61% and 30% respectively[89]. These results suggest 
screening in women <40 is not as accurate as in women ≥40. This indicates cancer 
develops faster in these women and findings such as this have led to the recent change in 
cervical screening, HPV testing, to improve the performance and accuracy of screening. 
 
1.4.2 HPV testing 
1.4.2.1 Triage of low grade cytology and test of cure 
Randomised control trials have reported that compared to cytology alone, HPV DNA 
testing has better sensitivity  (94.6% vs 83.9%) and specificity (94.1% vs 69.3%) for 
squamous cell cervical lesions[90]. In 2007 six ‘sentinel sites’ in the UK (including Bristol, 
the setting for the studies in this thesis) instituted management protocols separate to the 
rest of the UK; these sites used HPV testing in 10,051 women with low-grade cytology to 
determine who requires colposcopic assessment and who can be safely returned to 
routine recall (3 or 5 yearly screening). Women who were HPV negative had a 0.5% chance 
of developing SCC between screening intervals; this finding led to recommendations that 
HPV positive women should be referred to colposcopy[91]. Since 2013 HPV triage of low 
grade cytology has been part of routine screening within the UK.  
Although the Sentinel Sites Study reported that the negative predictive value (NPV - 
probability that women with a negative screening result do not have CIN2+) of HPV testing 
in women with low grade cytology is high (95.6%), the positive predictive value (PPV - 
probability that women with a positive screening result do have CIN2+) is low at 16%. This 
poor PPV indicates that HPV testing may not differentiate between transient and 
transforming infections; given that at least 50% of women under the age of 30 years will 
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1.4.2.2 Primary HPV screening  
In the UK, primary HPV screening will be introduced nationally by 2019. If women test 
positive for high risk HPV their screening sample will be further triaged by a cytology test. 
The HPV DNA test currently approved is Hybrid Capture 2 (HC2) as the use of PCR has 
been shown to give a lower sensitivity[93]. HC2 recognizes the gene which codes for the 
HPV L1 protein and gives a pooled result for high risk HPV subtypes, namely HPV 16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Subtyping is not possible with this probe 
set – only a high or low risk result is given. This inability to subtype prevents persistent 
and new infections from being distinguished and stratification by risk of persistence (HPV 
16 & 18). The use of genotyping may therefore be of benefit in women where the PPV of 
screening is poor, such as a TZ3 (Section 1.6.4). 
 
1.4.3 Correlation of screening results with histological outcome 
Recent UK cervical screening statistics reported that women with high risk HPV and high-
grade cytology have an 82% chance of the excised tissue containing CIN2+ and a 2.6% 
chance of cancer. In women with high risk HPV and low grade cytology, this risk is 15.9% 
and 0.1% respectively[5]. The limited data assessing the significance of a HPV positive, 
cytology negative result appears to suggest that risk is dependent on genotype; although 
these women are at low risk for CIN2+ this is not a negligible risk – a UK colposcopy clinic 
assessed 1076 women referred with negative cytology and high risk HPV of whom 355 
had HPV 16, 86 had HPV 18 and 441 had other high risk subtypes. Of these women the 
risk of CIN2+ was 10% in women with HPV 16, 3.3% with HPV 18 and 3.5% with other high 
risk subtypes[94]. 
 
1.4.4 The reliability of colposcopy and directed punch biopsy 
The literature reviewed so far suggests a cervical screening test result can stratify a 
woman’s need for treatment but it is not a definitive determinant of outcome. 
Colposcopic assessment aims to differentiate between women with transient and 
persistent infections by visualizing the area infected by HPV and histologically confirming 
or refuting the presence of CIN2+. The use of colposcopy and colposcopic directed biopsy 
(CDB) has been shown to reduce the mean rate of negative excisional histology from 6% 
to 1.9% (p<0.001) and the mean rate of positive margins following treatment from 28.2% 
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to 21.7% (p=0.002)[95]. Although CDB has a higher PPV for CIN3 (86%) than for CIN 1 or 2 
(16% & 32% respectively)[96], the diagnostic accuracy is still more than double that of the 
screening test for CIN2+. 
In women with a TZ3 colposcopic assessment cannot be completed and the screening test 
is relied upon to guide decision-making. There is currently no evidence which has assessed 
outcomes in women with a TZ3 who have had HPV testing. In my thesis I will initially 
evaluate the incidence of false positive screening (negative LLETZ histology) and 
histological outcomes in women with a TZ3 to determine if improved diagnostic accuracy 
is required in this cohort. 
 





Figure 1.9: Cervical screening and colposcopic assessment algorithm 
 
1.5.1 Repetition of the referral cytology 
Current UK guidance denotes, ‘Cervical cytology should not be repeated at the first 
colposcopy appointment following a referral for cytological abnormality. Where an initial 
cytology sample is inadequate, the repeat cytology sample should be taken no less than 
three months after the date of the first sample’[85]. This recommendation aims to reduce 
the risk of false negative screening as a previous cytology test may have denuded the 
cervical epithelium. Of note, the evidence this recommendation is based upon did not 
correlate outcomes with topographical position of the TZ nor absence of TZ sampling. 
Cytology            
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1.5.2 High grade cytology  
1.5.2.1 TZ 1 or 2 
Although the time of progression from CIN3 to invasive cancer is slow, the progression 
from HPV to CIN3 is not, and as yet it is not possible to predict when CIN3 will invade the 
basement membrane and stroma beneath. Other than the previously outlined risk factors 
(section 1.2.4.3), we do not know what specific factors are associated with the 
progression to cancer. For this reason the NHS Cytology Screening Programme (NHS CSP) 
currently recommends treatment if CIN2+ is identified colposcopically at the first 
appointment (‘a see and treat’) or confirmed with a biopsy[35]. 
1.5.2.2 TZ3 
There is a lack of guidance and expert opinion within the available literature for this 
cohort[35, 97, 98].  Although women with a high grade screening result have an 82% chance 
of CIN2+ and a 2.6% risk of cancer (Section 1.4.3), these histological outcomes were not 
adjusted for TZ type. In this thesis I aim to assess histological outcomes in women who 
are offered a LLETZ for high grade cytology and a TZ3; I will evaluate if their outcomes are 
comparable to women where the TZ is visible and assess if the use of surrogate markers 
for HPV or HPV genotyping improve the accuracy of their screening test result.  
 
1.5.3 Low grade cytology 
1.5.3.1 TZ type 1 or 2 
Women with low grade screening results are referred to colposcopy for assessment as 
this has been shown to detect more cases of CIN2+ than cytological surveillance alone[99]. 
However, due to the moderate specificity of the colposcopic examination, CIN2+ should 
be confirmed histologically prior to excision[85]. If the colposcopic examination is normal 
or ≤CIN1 is detected on biopsy, UK guidance states these women can be safely offered 
cytological follow-up over 24 months as low grade abnormalities have a high rate of 
regression[100] (Table 1.1). However, this policy relies on initial colposcopic visualisation or 
histological confirmation of the lesion, which cannot be undertaken with a TZ3. 
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1.5.3.2 TZ3 
A TZ type 3 in combination with low grade cytology is a common area of clinical 
uncertainty due to the lack of clear evidence and guidance[35, 97, 98]. As with high grade 
cytology, there are no NHS CSP management recommendations and it is my experience 
that recommendations for cytological follow-up versus excisional treatment are hospital 
specific. When cytological follow-up is offered in this cohort, decisions on total length, 
clinical setting and technique vary dependent upon the colposcopist. Health care 
professionals rely on their own experience of managing these women, and the advice of 
the multidisciplinary team (MDT) to determine who requires treatment and this may lead 
to disparities in care[101].  
Attendance rates for colposcopy and loss of patients to follow-up are affected by service 
inefficiencies[102], anxiety[103] and poor accessibility to targeted information[77]. With non-
attendance rates for colposcopy in the UK documented at 24.4%, of which 46.1% are 
follow-up appointments[5], areas of heterogeneity in service provision need to be 
improved. 
Studies which have assessed histological outcomes but not adjusted for TZ type report a 
15.9% risk of CIN2+ in women with low grade cytology. Although smaller than the chance 
conferred with high grade cytology, this is not negligible. It would be reasonable to 
assume that patient and health care provider anxiety may deter conservative follow-up 
and lead to higher rates of excision when compared to women where the TZ is visible. 
Clear guidance and enhanced diagnostic accuracy is needed to improve patient outcomes 
in women with a TZ3 and low grade cytology.  
In this thesis I will evaluate the current management of this cohort within the UK and the 
factors which affect the decision-making process. These outcomes may aid in the 
formation of recommendations on which to base a consensus opinion, potentially 
improving homogeneity of care. Assessment of the histological outcomes in women who 
have a LLETZ for low grade cytology and a TZ3 would help stratify this risk and provide 
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1.5.4 Large loop excision of the transformation zone (LLETZ) 
Loop excision of the cervical transformation zone (LLETZ) was introduced to provide 
accurate histological assessment of CIN[104]. LLETZ uses a monopolar energy source and a 
high frequency current to provide cutting and coagulation. It is the gold standard at 
present for excision of high grade cervical disease (CIN2+ / cGIN) and for diagnosis in 
women with persistent low grade CIN or a TZ3[85]. It is cheap and easy to use, providing a 
98% ‘success’ rate (removal of all dysplasia) after one treatment[105]. 
Squamous epithelium located in the endocervical canal and ectocervix can be affected by 
CIN. This can extend into the crypts, millimetres below the surface. To plan an excisional 
treatment it is important to know the maximum depth of the crypts and the mean 
topographic position that the transformation zone can take. If the excised portion of the 
cervical epithelium does not include the underlying crypts there can be delayed 
recognition of CIN that may become invasive. A meta-analysis assessed the risk of CIN2+ 
recurrence following excisional treatment in 35,000 women and showed a pooled 
prevalence of 18% if the margins were incomplete vs 3% if complete[106].  
Papoutsis et al assessed the effect of excision depth, volume and ratio of cone base to 
ectocervical surface and found that a depth <10mm was the most sensitive of the three 
in predicting positive margins[107]. This finding is supported by other studies which have 
reported an increased risk of recurrence if the excision depth is <10mm in women >35 
years[107]. Boonstra et al assessed the maximum proximal distance that CIN3 extended 
from the ectocervix; it was reported as 13.3 +/- 3.7mm. Although women with a TZ type 
2 and 3 were included in these studies, maximum proximal distance was not correlated 
with TZ type[108].  
As a result of these studies, national NHS CSP guidance for excision depth in women with 
a TZ1 is 7-10mm. For women with a TZ type 3, a deeper excision is recommended - albeit 
with the caveat of considering the higher risk of treatment related morbidity in 
childbearing women[85]:  
‘Type III cervical transformation zone: excisional techniques should remove 
tissue to a depth/length of 15mm to 25mm. Evidence: …….in women under 
the age of 35, excisions >10mm in depth are not associated with improved 
Chapter 1  
25 
recurrence rates. There is, however, an increased risk of preterm delivery 
after loop treatments >10mm in depth.’  
The predicament, as stated, is the treatment related morbidity as the risk of preterm 
labour has been correlated with the depth of excision: a case control study of 11471 
women reported a baseline absolute risk (AR) 6.7% with a 7 - 10mm LLETZ the AR is the 
same as a punch biopsy (7.5%) and the relative risk (RR) 0.98; if 10 - 14mm depth RR 1.28, 
AR 9.6%; and for the depth recommended for a TZ3, RR 2.04, AR 15.3% for 15 -19mm and 
RR 2.40, AR 18% for ≥20mm[109]. This risk does not decrease with time. 
After-effects following LLETZ such as pain and bleeding were compared to punch biopsy 
by the Tombola Study group. Questionnaires revealed that more women reported pain as 
a consequence of a LLETZ than biopsy (67% vs 53%) and also more bleeding (87.3% vs 
79.1%: p<0.001). Moreover, 52.9% of the LLETZ cohort reported severe bleeding 
compared to 21.4% in the biopsy cohort[110].  
Compared to the background population, LLETZ increases the risk of cervical stenosis (3%) 
and this can cause infertility and an inability to take future cytological samples[111, 112]. In 
these women, a second LLETZ may be advised if a test of cure cannot be undertaken or 
mild cytological abnormalities cannot be assessed colposcopically. Even after dilatation of 
the cervix, re-stenosis can occur in 77%[113]. After adjusting for a range of clinical variables, 
age over 50 and a TZ3 (where rates of up to 25% have been reported), are the only 
independent risk factors for cervical stenosis in women who have a LLETZ. 
The introduction of cervical screening and treatment of CIN has reduced the mortality 
rate from cervical cancer but the treatment-related morbidity is considerable, particularly 
in women with a TZ3 where the depth of LLETZ is double that undertaken with a TZ1. 
Improving the diagnostic accuracy of cervical screening in this cohort may decrease false 
positive results and unnecessary treatments. I aim to evaluate the use of adjuncts such as 
HPV genotyping and surrogate markers for HPV to help stratify who may require 
treatment and who can be safely offered conservative management. 
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1.6 Improving diagnostic accuracy in women with a TZ3 
About 80% of HPV positive women referred to colposcopy will have low grade cytological 
changes. Distinguishing between integration and potential regression is difficult even 
when colposcopic assessment is possible. There is a plethora of studies assessing the use 
of molecular and biochemical tests which may improve the diagnostic accuracy of punch 
biopsies and LLETZ histology (section 1.6.3) but these adjuncts have not been studied in 
women with a TZ3.  
 
1.6.1 Mechanical and pharmacological methods 
Before evaluating novel biomarkers it is important to consider mechanical and 
pharmacological methods that may convert a TZ3 to a TZ1 or 2. Completing an assessment 
at specific times during the menstrual cycle has been unsuccessful[114]. Vaginal 
misoprostol has varying success (20 - 78.9%)[115] but patients report nausea, abdominal 
pain and fever. Hygroscopic cervical dilators have a reported success rate of 79 - 94%[116], 
but only women with a TZ2 were included in these studies. 
It is logical given the effect of oestrogen on eversion of the TZ in puberty that the use of 
systemic and topical oestrogen may convert a TZ3 to a TZ1. A randomised control trial 
assessed the use of ten days of ethinyl estradiol (30mg) versus placebo and found that 
eversion of the TZ occurred in 12/17 (70%) of women with a TZ3 (OR 7.8, 95% CI 1.6 - 36; 
P<0.01)[117]. These results were supported by an observational study which gave 178 
postmenopausal women with a TZ3 three months treatment with oestrogen replacement 
therapy and found 130 (73%) had a visible TZ[118]. Furthermore, success rates of 64% have 
been reported in studies using topical oestrogen[119]. It is my experience that this practice 
has not been routinely adopted by colposcopists and this may be due to the side effect 
profile, contraindications or patient acceptability. In this thesis, to aid the development 
of a consensus management guideline, I will assess colposcopists’ experience with 
oestrogen in women with a TZ3. 
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1.6.2 Techniques for sampling the endocervical canal 
Endocervical canal curettage (ECC) can be used to obtain ~1mm3 tissue samples of 
squamous epithelium from inside the cervical canal. The side effects of ECC can include 
mild suprapubic pain and per vaginam spotting. Whilst its use can increase the detection 
rate of squamous dysplasia by up to 18% with a TZ1 or 2, this diagnostic yield is higher 
with a TZ3 (~83%). Specificity is also high at 84 - 97%[120-123]. Despite this, due to the small 
and fragmented nature of the samples inadequacy rates can be up to 19%, inter-observer 
agreement moderate (k = 0.58, 95% CI 0.52 – 0.63) and diagnosis underestimated in up 
to 16% of squamous cell lesions[124-126]. Most of these authors agree that ECC does not 
improve diagnostic accuracy with a TZ1. As discussed in 1.2.4.1, distinguishing benign 
changes from dysplasia can be difficult even when the epithelium is intact and copious. I 
aim to assess whether the use of surrogate biomarkers for HPV can improve the diagnostic 
accuracy of these fragmented samples. 
In regards to the assessment of glandular lesions via ECC, there is a paucity of true 
endocervical disease such as adenocarcinoma in situ reported[120, 127]. The American 
College of Obstetricians and Gynaecologists have concluded that positive curettings may 
be inadvertent contamination of a squamous lesion near the external os rather than 
dysplasia of endocervical cells[128]. Although it has been suggested that ECC can affect the 
distinction between adenocarcinoma in situ and invasive adenocarcinoma[129], similar 
effects on squamous lesions have not been reported[125].  
The use of the endocervical cytobrush (Figure 1.8) was developed to decrease the 
discomfort of sampling the epithelium within the endocervical canal. Despite the ease of 
use, lower cost and 77 - 93% sensitivity, there is a moderate false positive rate (specificity 
63% - 75%)[129-131]. Boardman et al compared endocervical curettings to cytobrush 
samples, in 62 women who either had a cone biopsy or hysterectomy, and randomised 
the order of the sampling procedures. There was no difference in sensitivity (32% vs 44%) 
and although the curettings were more specific than the cytobrush (100% vs 88%), the 
adequacy was poorer (78% vs 98%). The order of sampling did not affect the adequacy 
rates of either specimens[132]. Furthermore, the sensitivity of the cytobrush sample was 
lower in Boardman’s study than has previously been reported; stripping of focal dysplastic 
epithelium by the curette prior to the cytology sample may account for this and suggests 
cytological sampling should occur first.  
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None of these studies correlated their outcomes with topographical position of the TZ and 
it would be of interest to assess the diagnostic accuracy of methods which sample the 
epithelium within the endocervical canal in combination with HPV genotyping and/or 
surrogate biomarkers for HPV. I aim to evaluate whether this combination improves the 
adequacy rates, inter-rater reliability and accuracy of the cytobrush cytology and 
endocervical curettings. 
 
1.6.3 Surrogate markers for integrated HPV 
Investigators over the past decade have studied surrogate markers for HPV integration to 
help differentiate benign from pathological aetiology and to improve the specificity of 
HPV testing. Research has focused on four main areas of which only studies assessing 
points 1 and 2 below have used large clinical sample sizes. These are the areas I will focus 
on: 
1. Cellular proteins which are over-expressed by cells infected with HPV 
2. E6 and E7 HPV mRNA transcripts 
3. Alterations of viral and host genomes 
4. Gene methylation pattern alterations 
1.6.3.1 Cellular proteins over-expressed by cells infected with HPV 
1.6.3.1.1 p16INK4a 
This cellular protein has been the subject of considerable recent study. p16INK4a protein 
(p16) is a cell cycle regulatory protein – a cyclin-dependent kinase inhibitor - which is 
strongly expressed in the majority of CIN2+ lesions following inactivation of pRb by the 
HPV derived E7 protein (Section 1.2.3.3). Benign changes such as squamous metaplasia, 
tubal endometrial metaplasia, nonmucinous secretory endocervical cells and cervical 
endometriomas can sporadically express p16[133, 134]. This does not affect the 
interpretation of histological samples but to assess p16 stained cytology, morphological 
examination of the cells is required[135].  
Studies have shown the use of this biomarker in: 
1. Differentiating benign histological lesions from precancerous changes with good 
sensitivity (98.5%)[136]. 
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2. Differentiating low grade histological lesions (HPV / CIN1) from high grade. The 
intensity of staining increases with the severity of CIN (p<0.001)[136]. 
3. Improving the sensitivity of low grade cytology samples (92.6%).  
In a study of 12,000 cervical biopsies, inter-observer agreement in diagnosing high grade 
CIN was improved with the addition of p16 stained slides to the routine H&E slides (k 0.74 
vs 0.56 respectively; p<0.001). Sensitivity for all grades of CIN was improved (p=0.0004) 
and false negative rates were reduced by 45%[137]. The disadvantages are the low 
sensitivity and specificity of p16 for adenocarcinomas[138] and the poor specificity for 
squamous lesions (74.8%). There is also a lack of longitudinal studies assessing the long 
term predictive potential of p16 for development of high grade CIN and there are no 
studies assessing the use of this marker in small and fragmented epithelial samples like 
endocervical curettings. 
1.6.3.1.2 Ki-67(MIB-1) 
Ki-67, as outlined in section 1.2.3.3, is a proliferation marker and uncontrolled 
proliferation is a marker of neoplasia. Ki-67 is elevated in HPV infected squamous tissue 
but also in regenerating epithelium and metaplastic tissue which are HPV-negative. The 
sensitivity of Ki-67 for CIN in histological samples is 92.2% but the specificity is 56.6%[136, 
138]. Neikerk et al,[139] analysed staining in the different epithelial layers and found that 
high risk HPV positive samples showed Ki-67 staining in the basal, intermediate and 
superficial layers whilst HPV negative samples stained only in the basal layers. To the best 
of my knowledge, due to the poor specificity in histological samples, the sole use of Ki67 
immunocytochemistry has not been assessed. As with p16, its use in conjunction with 
fragmented samples like endocervical curettings has not been evaluated. 
1.6.3.1.3 Dual staining with p16 and Ki-67 
It is hypothesized that the concurrent detection of p16 and Ki-67 within the same cell 
should differentiate transient from transforming infections; during the normal cell cycle a 
proliferation marker and a protein which inhibits cyclin dependent proliferation should 
not co-exist. The use of p16 alone and in conjunction with Ki67 in 1450 cervical 
(histological) biopsies was compared by Galgano et al[136]; the addition of Ki-67 did not 
significantly improve the sensitivity (99.2% vs 98.5%) nor the specificity (78.1% vs 74.8%) 
when compared to p16 alone. However, as stated, the predictability of these biomarkers 
for CIN2+, individually or in combination, have not been evaluated in fragmented tissue 
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samples such as endocervical curettings, where individual scattered cells, as seen on a 
cytology slide, may need to be interpreted. 
When dual staining is used in conjunction with cytological samples, positivity increases 
with the histological grading of CIN; 39.4 - 58.8% staining with CIN1, 70.8 - 91.9% with 
CIN2 and 86.5 - 100% with CIN3[135, 140-142]. Dual stained cytology has been shown to have 
an equivalent sensitivity to HPV testing but higher specificity - positivity increases with 
high risk HPV genotypes (when compared to HPV negative samples); OR 1.0 for low risk 
HPV, OR 6.86 for high risk HPV and OR 9.92 for HPV 16 & 18[135, 140-142]. Dual stain specificity 
is higher in women over the age of 30 years when compared to women less than 30 (60% 
versus 46.1%) and this may be secondary to the transient nature of HPV infection in 
younger women[135, 143]. Furthermore, 12% of samples which contain CIN1-2 can be dual 
stain negative[141] and 12 - 44.1% of negative biopsies can be dual stain positive[109, 135, 140]. 
It has been postulated that these outcomes are potentially identifying transient HPV 
infections or early transforming infections respectively. 
 
Table 1.2: Sensitivity and specificity of p16, Ki67 and HPV testing 
 Borderline       
Cytology 






 Sens                 Spec Sens                  Spec Sens            Spec Sens           Spec 
p16 92.6%         63.2%-71.1%1 92.6%        37.3% -53.3%1 100%       91% – 95%2 98.5%           74.8%3 
Ki-67 - - - 92%                56%4 
Dual-stain 92.2%                      80.6%5 94.2%                        68%5 94.6%               16.6%6 99.2%           78.1%3 
HPV 90.1%                      37.8%1    95.7%                     18.5%1 97%       86.2% - 94%2 - 
1. Denton et al, 2010[144] (n = 810) 
2. Gustinucci et al, 2012[145], (n = 578) & Zhao et al, 2012[146], (n = 13,000). 
3. Galgano et al, 2010[136], (n = 1450). 
4. Kruse et al, 2001[138], (n = 65). 
5. Schmidt et al, 2011[147], (n = 776). 
6. Wentzensen et al, 2015[148] – calculated from the raw data (n = 1509). 
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1.6.3.2 mRNA 
Direct detection of viral gene expression may increase predictability of persistent HPV 
infections when compared to DNA assays. Detection of E6/E7 mRNA may improve 
predictability of dysplasia as these proteins deregulate p53 and pRb. Routine cytology 
samples preserved in PreservCyt produce high yields of mRNA and do not deteriorate over 
time[149, 150]. The SurePath LBC samples of twenty women with known dysplasia were 
compared to RNA removed from fresh cells; the RNA extracted from the samples fixed in 
the SurePath medium produced small diagnostic yields and short storage times (days) did 
not reduce the degradation effect [151, 152]. 
There is a paucity of data from clinical studies and those that are published have used 
different detection assays and targeted different transcripts. Data from cross-sectional 
studies suggests HPV DNA is detected in more benign and low grade samples than RNA – 
indicating that mRNA may have a higher specificity for high grade disease[153, 154]. For 
CIN2+ lesions, 95% were DNA positive and 77% RNA positive[154]. mRNA negative samples 
may identify lesions which are likely to regress but prospective long term follow-up is 
needed to corroborate this. p16/Ki-67 dual-staining is reported to have an equivalent 
sensitivity to mRNA testing for CIN3 (96%) but a higher specificity (48.2% vs 33.8%)[143] – 
although the retrospective nature of this study may have led to mRNA degradation. 
For these reasons I aim to evaluate whether p16 and ki67 (individually or in combination), 
rather than mRNA, can increase the reliability and diagnostic accuracy of methods which 
sample the endocervical canal. 
 
1.6.4 HPV genotyping 
CIN in women infected with Group 1 carcinogenic HPV subtypes is more likely to progress 
to cancer than in women infected with non-oncogenic subtypes. As previously discussed, 
this finding led to the introduction of a pooled high risk HPV DNA cervical screening test 
in the UK. The inability of these pooled tests to genotype the more aggressive subtypes, 
such as HPV 16 and 18, which cause 65% of cervical cancers, may account for the poorer 
specificity and PPV of HPV testing when it is used to triage low grade cytology (86.5%[155] 
and 16%[156] respectively). When adjusted for age, and compared to low-risk subtypes, 
HPV 16 and associated subtypes (HPV 31, 33, 35, 52 and 58) have, respectively,  53% and 
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38% less chance of immuno-clearance (RR 0.47, 95% CI 0.32 - 0.72 and RR 0.62, 95% CI 
0.47 - 0.94 respectively)[157]. Multiple studies support the lower clearance rate of HPV 16 
and also of HPV 18[15, 158] but concurrent infection with multiple HPV subtypes does not 
appear to have this effect[158]. 
A prospective diagnostic test study reported the 10 year cumulative incidence rate of CIN3 
as 17% if HPV 16 was identified, 14% if HPV 18, 3% with other HR subtypes and 1% with 
low risk subtypes. These findings suggest HPV subtyping may be of benefit for women 
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1.7 Null hypotheses and aims of this thesis 
The information outlined in this chapter suggests improving the diagnosis of CIN in 
women with a TZ3 is an important area of clinical research. The aim of this dissertation is 
to improve the management of women with a TZ3 and the objectives were to: 
i. Determine the impact of HPV testing on false positive screening in women with a 
TZ3.  
ii. Investigate factors which affect colposcopists’ decision-making when applied to 
management of a TZ3. 
iii. Formulate management recommendations for women with a TZ3, where 
appropriate, aimed at improving service efficiency and homogeneity of care. 
iv. Investigate the predictability of CIN2+ with surrogate biomarkers for HPV and HPV 
genotyping, in combination with techniques which sample an endocervical 
transformation zone. 
v. Compare the Cervex-Brush alone to a cytobrush and Cervex-Brush to identify the 
optimal cytological collection device in women with a TZ3. 
 
To address these aims, clinical studies in humans will be used:  
i. A retrospective cohort study of 800 women using a clinical database was 
established and utilized to investigate the incidence of negative LLETZ histology 
(false positive screening) before and after the introduction of HPV testing. 
Potential confounders were adjusted for and potential predictors of negative 
LLETZ evaluated. 
ii. Focus groups in one English healthcare region were undertaken to evaluate 
colposcopists’ decision-making when applied to the management of women with 
a TZ3.  
iii. All accredited UK colposcopists were asked to participate in a national survey 
which aimed to ratify areas of consensus in the management of a TZ3 to aid in the 
development of guideline recommendations.  
iv. A prospective diagnostic accuracy study, the ACORN study, examined; 
a. The predictability for CIN2+ of HPV genotyping and p16/Ki67 in combination 
with cytological and histological samples in 101 women with a TZ3. 
b. The effect of different immunostaining and diagnostic categories on the 
predictability of p16 and Ki67 stained histology and cytology slides for CIN2+. 
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v. Finally, I aimed to evaluate whether the addition of a cytobrush to a Cervex-Brush 
improves the accuracy of cervical screening in 105 women with a TZ3 
The null hypotheses tested are: 
i. The incidence of negative LLETZ (false positive screening) is not affected by HPV 
testing nor TZ type. 
ii. In the absence of national guidelines, decision-making in women with a TZ3 is not 
determined by colposcopists’ affect. 
iii. In the absence of national guidelines, decision-making in women with a TZ3 is 
homogenous. 
iv. a) The diagnostic accuracy of a routine cervical screening test in women with a 
TZ3 cannot be improved by the use of (I) HPV genotyping, (II) p16 / Ki67 in 
combination with cytological samples and (III) p16 / Ki67 in combination with 
endocervical curettings. 
b) Inter-rater reliability of the cytological and histological samples are not affected 
by different diagnostic categories or immunohistochemistry categories. 
v. There is no difference in diagnostic accuracy nor adequacy rates when a Cervex-
Brush alone is compared to a cytobrush and Cervex-Brush in women with a TZ3. 
 




2.1 The impact of HPV cervical screening on negative LLETZ 
 
In women with a TZ3 the diagnostic accuracy of the cervical screening test is used to guide 
management. The 2013 UK introduction of HPV triage of low grade cytology aimed to 
improve the accuracy of this cytology result and although the NPV has been improved, 
the PPV is still poor. The aim of this novel study was to evaluate the impact of HPV testing 
on the incidence of negative LLETZ (false positive screening) and to assess potential 
predictors such as the presence of a TZ3. 
This comparative cohort study was completed at University Hospitals Bristol NHS 
Foundation Trust, a sentinel site for HPV testing (Primary and HPV triage of low grade 
cytology). It was a retrospective cohort design; this is defined by the absence or presence 
of an exposure or intervention (HPV screening in this instance), rather than the absence 
or presence of an outcome, as with a case-control study. In comparison to a prospective 
study, this method is achievable within the study time constraints as the outcome and the 
intervention have already occurred. The disadvantages of this design can include the 
impact of missing data (accurate documentation is required), selection bias, the need for 
a large sample size and confounding factors. The use of a randomized control trial which, 
in this study, would compare women who are offered a screening test which is not as 
sensitive or specific as the reference standard, would not be ethically appropriate.  
I applied for and was granted R&D approval by University Hospitals Bristol on 20th July 
2014 (ref OG/2014/4626) and ethical approval by NRES Committee South West – Cornwall 
and Plymouth, on 30th May 2014 (ref 14/SW/0127); see Appendix 2. 
 
2.1.1 Sample size calculation 
To determine the sample size before and after the institution of HPV screening I worked 
with my statistical supervisor (AW) to perform a power calculation. Alpha or the type 1 
error rate is the probability of rejecting the null hypothesis when it is actually true; this 
was set at 0.05. Beta or the type 2 error rate denotes the power of the study and is the 
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probability of accepting the null hypothesis when it is actually false. Detecting a true 
difference >80% of the time is considered satisfactory for medical research[159]. 
 
A study can be powered to detect a difference of any size but due to the novel nature of 
this study clinically relevant mean values and standard deviations were not available to 
calculate effect sizes. Several power calculations were undertaken assuming a negative 
LLETZ rate of 14% from Livasay et al[160] and examining reductions of negative LLETZ to 7% 
and 9% (my alternative hypothesis (H1)). The incidence from Livasay et al was used as they 
reported the mean incidence of comparable studies (retrospective cohort studies prior to 
HPV testing). The estimated effect size of 50% was based on the improved sensitivity of 
HPV testing; although I considered that the poor specificity of HPV testing may increase 
the negative LLETZ rate, the addition of a cytology result in women who test positive for 
high risk HPV improves this specificity[155]. 
 
As I needed to extract the pre-HPV screening cohort data manually, different sampling 
ratios were assessed (Table 2.1); to show an effect size of 7%, with alpha at 0.05 and 
power at 90%, I would need to analyse clinical records from 401 women in both cohorts.  
 
Table 2.1: Power calculation for different sampling ratios  
      EFFECT SIZE    SAMPLE RATIO POWER 
p1 - p2*  pre:post 80% 90% 
9% 1:1 166:166 221:221 
7% 1:1 300:300 401:401 
9% 1:2 117:234 163:320 
7% 1:2 216:432 294:588 
9% 1:3 100:300 139:417 
7% 1:3 187:561 258:774 
*p1 is the proportion of women with negative LLETZ histology in the pre-HPV testing cohort and p2 
is the proportion in the post-HPV testing cohort. 
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2.1.2 Population 
Women aged 25 – 64 who had a LLETZ before the introduction of HPV testing (2007) and 
after the introduction (2012) were eligible for inclusion. Women outside of this age range 
are currently not eligible for cervical screening in England. Women who had a LLETZ during 
the Sentinel Sites Study (2008 – 2010)[91] were excluded; Bristol was a pilot centre for HPV 
triage in the UK and management of these women, including frequency and type of follow 
up, was different to national protocols instituted after the publication of this study.  
 
2.1.3 Exposure 
Women in the pre-HPV testing cohort were referred to colposcopy for all grades of 
cytological abnormalities. Women in the post-HPV testing cohort were referred to 
colposcopy with; i) a positive high risk HPV result as part of primary HPV testing which 
was then triaged by a cytology test or ii) HPV triage of a low grade or negative cytology 
result (section 1.4.2). Testing for HPV was by Hybrid Capture 2 which provides a pooled 
result of 13 high risk subtypes. 
 
2.1.4 Outcome 
The definition of a positive LLETZ was a histological specimen which contained CIN of any 
grade, cGIN or cancer. The definition of a negative LLETZ varies between studies[160-164]; 
following a review of the evidence base and discussion with the colposcopy 
multidisciplinary team the definition for a negative LLETZ in this study was ‘a histological 
specimen in which there is no evidence of CIN’, rather than no CIN / no HPV, because high 
risk HPV positivity is not a definitive determinant of outcome. As part of routine practice, 
LLETZ samples reported as negative are reviewed independently by two consultant 
histopathologists and additional blocks processed to confirm the absence of CIN.  
 
2.1.5 Potential confounders 
A confounder is an influence which is separate to the exposure which can account for the 
outcome. Potential patient confounders which could affect the LLETZ histology by 
increasing the chance of CIN regression or progression, as outlined in section 1.2.4.3, 
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include age, smoking status, parity and contraceptive use. Differences in the incidence of 
negative LLETZ may have been affected by policy changes rather than HPV testing so 
variables that relate to this were also collected. National guidelines in the UK[85] provide 
recommendations on intervals from cytological screening to colposcopic assessment, 
diagnostic standards for colposcopy and criteria for LLETZ. The indications for LLETZ were 
divided into those who had had a biopsy prior to LLETZ (persistent CIN1 for greater than 
24 months, CIN2 / 3 or cGIN) and those who had a see and treat LLETZ (no prior histology). 
Indications for ‘see and treat’ LLETZ included high grade cytology with confirmatory high 
grade colposcopic findings, high grade cytology with a TZ3 or persistent (≥12 months) low 
grade cytology with a TZ3.  
 
Clinical records and colposcopic images were assessed, by me, to confirm the TZ type and, 
as specified by the IFCPC nomenclature (Section 1.2.2.1), this was coded as a TZ type 1, 2 
or 3 [165]. The size of the lesion (coded out of four quadrants) and to improve analysis, the 
interval in weeks from cytology to colposcopy and from colposcopy to treatment were 
coded as 0 - 4 weeks, 5 - 8 and more than nine. 
Negative LLETZ histology can be reported if dysplasia is present deeper in the endocervical 
canal than the LLETZ sampled or if vaginal intraepithelial neoplasia (VAIN) ‘contaminates’ 
the cervical cytology. To assess for this, and to validate the negative LLETZ outcome, I 
recorded and evaluated any post-LLETZ cytological or histological results. 
2.1.6 Data collection 
To ensure that selection bias is not introduced a target population should be defined and 
the sample should match that target population. Participants were selected from a 
colposcopy database by an independent Information Analyst using ‘treatment type - 
LLETZ’ and ‘appointment date’ as search terms. There are different methods of sampling 
aimed at reducing bias, for pragmatic reasons, I chose cluster sampling. This is where a 
group from the target population was chosen at random by the Information Analyst and 
all of that group was used for the sample. I initially searched for the medical records using 
the list of hospital numbers and then entered the participant’s information under an 
anonymous study number in a separate database.  
 
From 2011 onwards, colposcopist’s manually entered all clinic data onto an electronic 
colposcopy specific database which incorporated all relevant cytology, histology and clinic 
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findings including photographs of the TZ. The direct electronic transfer of data into Excel 
should have prevented any transference errors as the quality of data is monitored by the 
Information and Performance team. Pre-2008, I found data collection more problematic 
and time consuming; cytology and histology results were stored on an electronic system 
but clinic findings were stored either in paper medical records or archived discs. 
 
To reduce transference errors and improve the quality of the data collection, double data 
entry was completed, the first worksheet by myself and the second by two O&G 
Registrars. To ensure we all entered the same field values and to reduce erroneous or 
missing data both the registrars were made familiar with the study protocol and I provided 
training on where to find the data and how to enter it. I constructed a table of definitions 
(potential confounders, intervention and outcomes – Appendix 4, Table S4.1) and 
generated an Excel Spreadsheet which included the code definitions for each variable. 
‘Cleaning’ the data in this way simplifies the data and facilitates data analysis. Numerical 
data was stored as raw data, continuous variables were grouped for ease of analysis and 
categorical data was given a numerical code. For example, referral cytology was coded as 
Negative (‘0’), Low grade (‘1’) or High Grade (‘2’) according to the revised 1986 BSCC 
Classification System[84]. Two databases were kept; one included the raw data and the 
second the coded data. 
 
2.1.7 Analyses 
To analyse the collected data I compared the double entered data to identify and correct 
missing or erroneous entries. I described and compared the demographic and clinical 
characteristics of the participants and calculated the incidence of negative LLETZ in the 
two cohorts, along with the risk ratio and absolute risk difference.  
 
To assess whether the association between the introduction of HPV testing and the 
incidence of negative LLETZ histology could be explained by the differences in potential 
confounders between the two cohorts, multivariable regression models were used. My 
statistical supervisor guided me through this data analysis to improve my understanding 
of the complexities of these statistical models and to facilitate discussions on how the 
data should be processed and analysed. 
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Relative Risk (RR) and Odds Ratio (OR) are both used to measure the association between 
an exposure or independent variable (HPV testing) and a binary outcome or dependent 
variable (negative LLETZ). A relative risk estimates the ratio of two probabilities - the 
probability of the outcome occurring in the exposed population divided by the probability 
of the outcome occurring in the unexposed population. So a relative risk of 1.2 would 
mean that the risk is 20% higher in the people exposed compared to the people 
unexposed. An odds ratio estimates the ratio of odds in the exposed versus unexposed 
groups. The odds of an outcome occurring is calculated as the probability of the event 
divided by the probability of the event not occurring. Most people find odds more difficult 
to interpret compared to risk, however, the odds ratio and risk ratio are approximately 
the same when the prevalence of the outcome is low (<10%). When the prevalence 
(negative LLETZ) is higher than approximately 10% (as in my study), the odds ratio will be 
further away from the null value of one compared to the risk ratio, making the association 
appear larger. I have presented the confidence interval for the RR as the inclusion of the 
null value (1.0) within the confidence interval is a strong indicator of an underpowered 
study or a lack of evidence to support the alternative hypothesis[166].  
When adjustment for potential confounders is needed (as is the case in most 
observational research), regression models are often used. Logistic and Poisson 
regression are two types of models that can be used for binary outcomes. Logistic 
regression allows the association to be presented as an odds ratio whereas a Poisson 
model will allow a risk ratio to be presented. Logistic regression is most commonly used, 
almost as a default, because of its statistical properties, for example, sometimes a Poisson 
regression model will not be possible to estimate in situations where a logistic model will 
be. Nonetheless, when the outcome is relatively prevalent and it is important to convey 
risk clearly, a Poisson regression may be preferred.   
Two sets of poisson regression models were estimated: the first adjusted for each of the 
potential confounders in turn and the second adjusted for all potential confounders. I also 
explored predictors of negative LLETZ in the HPV testing cohort. First, in unadjusted 
models I examined the association between each of the following with negative LLETZ: 
age, parity, contraceptive, cytology result, interval from cytology to colposcopy and TZ 
type. Next, I included those variables where there was some evidence of an association 
with negative LLETZ (p<0.05). All approaches resulted in the same final model. Stata v13.1 
(Statacorp) was used for all analyses. 
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2.2 Evaluation of decision-making in women with a TZ3 
This was a qualitative study, utilising a series of focus groups. I applied for and was granted 
ethical approval by NRES Committee South West – Frenchay on 14th April 2015 (ref 
14/SW/0128 - Appendix 2) and gained a small grant (Appendix 1) to cover the cost of the 
qualitative software (Nvivo; QSR International), expenses such as petrol and parking at 
the individual trusts and refreshments for the colposcopists. 
 
2.2.1 Method of data collection 
Focus groups are used to investigate views or experiences and are distinguished from 
interviews through the examination of the interaction between participants[167]. The 
interaction between colposcopists will be useful in providing a broad understanding of 
the issues involved in managing women with a TZ3. Focus groups can also be useful in 
stimulating discussion from quiet participants and reducing the interaction of the 
facilitator[168].  
The methodology applied to the focus groups was adapted from the available 
literature[168-170]: 
 Three groups or more.  
 Preferably four to six participants per group – smaller groups can decrease group 
interaction but increase facilitator involvement if there are quiet or disruptive 
individuals. Large groups (more than 10) can be difficult to analyse if multiple 
conversations occur simultaneously. 
 Homogenous participants; it may be preferable to have groups consisting of strangers 
to reduce unspoken assumptions that occur within workplaces that will not be 
recognised or reported by the researcher[171]. However, with a small population this 
is not always practical. Moreover, grouping cohorts into general population groups 
such as geographical units (block sampling) can improve interaction by replicating 
social dynamics[170]. Backgrounds may be similar but attitudes, which is the focus of 
interest in this study, may not be. 
 A semi- structured interview with moderator involvement. 
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2.2.2 Selection of participants 
Sampling was primarily criterion based; I included participants if they were active 
accredited members of the British Society for Colposcopy and Cervical Pathology (BSCCP). 
As a Colposcopist, membership is a pre-requisite to practice as the BSCCP standardizes 
training and audits quality of service provision. The secondary sampling strategy was 
purposive in nature; this is a selective, non-probability sampling method which is used 
when the population to be sampled is small. In two waves of recruitment, I emailed the 
lead colposcopist in each South West of England NHS trust my study information sheet 
and consent form (Appendix 3), and followed this up two weeks later if I had not received 
a response. Lead colposcopists are responsible for quality assurance within their 
department and if they agreed to take part they forwarded the information to all other 
colposcopists within the unit to request participation (Appendix 4, Figure S4.1).  
Colposcopists’ intention to participate was confirmed during the emails to organise the 
focus groups. This allowed an abundant cooling off period (2 -3 weeks) prior to signing the 
consent form. Immediately prior to the focus groups, I gained written consent from all 
participants to be audio-recorded and for anonymized quotes to be utilized in 
publications. The participants were made aware that they could withdraw their 
involvement at any time but data up until the point of withdrawal would be kept for 
analysis. 
To assess heterogeneity within my study population, such that a range of demographics 
and opinions were included to improve the generalizability of the findings, data regarding 
the number of patients assessed in each unit per annum and colposcopists’ years of 
experience and job title were collected. Different health care professionals such as nurses, 
oncologists, GPs and general gynaecologists can accredit as colposcopists; their 
background experience may shape their attitudes and opinions and affect the decisions 
they make. As management protocols and educational experience may vary within the 
different units, I collected the demographic location of the colposcopists’ training centre. 
To maintain anonymity, age and gender were not collected.  
Data saturation[172], such that no new opinions or attitudes were identified, was achieved 
with a total of twenty-three colposcopists from four centres. At this point, recruitment 
ceased. 
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2.2.3 Interview procedure 
Free flow conversation provides a wealth of knowledge but to ensure that the research 
agenda was addressed, a topic guide was used to improve comparisons between groups, 
prompt the flow of conversation and focus the discussion to allow an exploration of the 
decisions that are made when reviewing women with a TZ3 and a range of clinical and 
cytological variables[169]. I designed the topic guide (Table 2.2) following a literature review 
and discussions with my qualitative supervisor (RB) and three experts in the field (who did 
not participate in the focus groups). I defined an expert as a colposcopist who was 
respected and nominated by their peers for their expertise in colposcopy, as these 
practitioners manage complex as well as routine cases.  
These semi-structured focus groups enabled me to cover the core set of questions but 
also allowed for a flexible and dynamic discussion that could be expanded upon by the 
participants. To understand the colposcopists’ decision-making process I asked the 
participants to identify the criteria they used in management decisions by asking ‘why’ 
and ‘how’. 
 
Table 2.2: Focus group topic guide 
Unsatisfactory Colposcopy (TZ3) Topic Guide 
Conservative management 
- Why 
- Effect of age  
- Effect of parity 
- Effect of HR HPV 
- Length of follow up 
- Place of follow up 
- Technique of follow up (what) 
Depth of LLETZ 




Adjuncts to improve diagnosis 




- Effect of age 
- Effect of parity 
- Effect of HR HPV 
Quality monitoring 
- Reporting methods 
- Interpreting the reports 




- Alternative uses 
- Other methods of everting the TZ? 
Issues regarding colposcopy management 
- National guidance 
- Patient focused. 
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Due to the amount of technical content discussed within the focus group, the challenge 
of conducting these sessions was reduced by being an accredited colposcopist myself. A 
facilitator (my supervisor or a gynaecology registrar) were also present to aid transcription 
by recording the speaker order and noting non-verbal communication. The focus groups 
were conducted in private rooms at the participants’ hospital and lasted 40 - 50 minutes. 
Refreshments were provided to facilitate participation during colposcopists’ lunch times.  
I wrote my field notes immediately after the focus group to aid in the interpretation of 
the transcripts and to contextualise the discussion – these, for example, included notes 
on the environment, the atmosphere and the interaction between participants. All of the 
interviews were transcribed by myself with the aid of the speaker list. It takes 
approximately one hour to transcribe ten minutes of audio; in total, 20 hours to transcribe 
all audio files and a further four hours per transcript to validate, format and correlate with 
the field notes. This process was important to maximise my immersion within the data.  
All participants were anonymised and I sent the transcripts to the respondents and the 
facilitators for validation. One participants’ statement was refined to expand upon how 
their anxiety of missing a cancer affected their decision-making, but this clarification of 
their reasoning did not change my original interpretation of the dataset.  
 
2.2.4 Analyses 
There are multiple methods of analyzing qualitative data and to find the best fit analysis I 
undertook a literature review and discussed my findings with an experienced qualitative 
researcher at the University of Bristol. I selected thematic analysis (TA) as it is one 
approach that can be used to identify, analyse and organise patterns of opinions within a 
data set[173]. The experiences of participants can be analysed without evaluating how they 
experience reality (such as with interpretive phenomenological analysis (IPA)). TA 
provides the flexibility to allow participants to expand upon their concerns without 
deviating from the decision-making process (which was the aim of this study). Narrative 
analysis provides depth on a specific area but not the breadth of information I required 
from my participants[173]. 
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TA was chosen in preference to grounded theory as data was collected through the use 
of focus groups (rather than interviews) and the emphasis was on decision-making and 
not on social processes[172]. Although grounded theory is inductive in nature and useful 
for areas not previously researched, researchers do not access the literature prior to 
analysis to prevent it being shaped by preconceptions (reflexitivity) rather than being 
‘grounded’ in the data[174, 175]. However, to design the topic guide and assess whether 
previous studies had already investigated my area of interest, I completed an extensive 
literature review. To reduce the reflexitivity of my own experiences and knowledge of 
colposcopy, my inclusion of qualitative researchers who had no training within 
colposcopy, nor the existing literature, should have balanced my own unknown 
preconceptions during data analysis[176].  
To complete the thematic analysis I used the six stage TA process, as described by Braun 
and Clarke[173]. Analysis was conducted iteratively after each interview so that future focus 
group questions were informed by prior analysis. This helped ensure saturation was 
reached because the same opinions and adequate depth was attained. This process was 
used rather than a rigid pre-designed coding structure or framework of behavioural 
determinants (as with framework analysis) to reduce bias. After familiarization with the 
data set and extensive discussion with my supervisor and a second postdoctoral 
qualitative researcher (who had no clinical involvement in the approached colposcopy 
units), I developed a coding list and we individually coded the first transcript. This coding 
framework (Chapter 4, Table 4.1) was then applied to future transcripts and revised once 
more as further datasets were analysed. 
To achieve a rigorous analysis, consistency of interpretation was assessed; a qualitative 
researcher and I independently coded the last three transcripts, compared results, 
discussed divergences and if disagreements arose, settled these with my qualitative 
supervisor (RB). The qualitative software package NVivo 10 was used to aid analysis by 
improving organisation of the data. I then compared the transcripts with the field notes 
to define tone and potential meaning to the words transcribed. On completion of the 
coding, I met with the research group to discuss and refine key themes following in-depth 
consideration of potential alternative interpretations, through the use of mind maps and 
iterative lists (Chapter 4, Figure 4.1). Illustrative quotes and descriptive accounts were 
linked to these themes, interpreted in relation to the literature (a semantic approach)[173] 
and mapped to the relevant theoretical constructs within this framework. 
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2.3 Developing a questionnaire for evaluating TZ3 management 
To expand upon the outcomes from the focus groups I developed a questionnaire which 
aimed to assess UK colposcopist’s decision-making when applied to women with a TZ3. 
The incorporation of questions (items) which have been developed for questionnaires 
which evaluate different areas (domains) of interest - for example using items which 
assess gynaecologist’s management of women with menorrhagia - may not measure what 
I intend them to measure. Furthermore, the use of items which assess the domain of 
interest but are developed for a different population can reduce the validity of the 
questionnaire as the items may not be interpreted by the new population in the same 
way[177].  
I applied for and was granted ethical approval by NRES Committee South West – Frenchay 
on 14th April 2015 (ref 14/SW/0028). To develop my knowledge base I attended a 
University of Bristol ‘questionnaire design and validation’ course, I completed an 
extensive literature review and discussed my study methodology with a statistician and a 
trial methodologist whose research has focused on the development and application of 
patient-reported outcome measures. 
 
2.3.1 Questionnaire design 
To form a conceptual framework I collated the domains and corresponding items from 
the focus group outcomes and from the existing literature. The black script in Figure 2.1 
illustrates the initial conceptual framework. Following review of this initial framework by 
experts in the field (section 2.3.2.1 – content validity), I developed the items after 
assessing the literature which describes this methodology[178-181]. 
Items were written in one sentence where possible, asked for one piece of information 
and ambiguous words such as ‘frequently’ and ‘regularly’ were excluded. Closed 
responses were used to facilitate coding and analysis. The format of the items included 
binary responses (Yes/No), multi-nominal or discrete responses and a matrix of dropdown 
options so that respondents could evaluate several items using the same set of measures. 
Initially I did not include Likert scales, as although easy to understand and analyze, the 
aim of this study was the development of national guidance based on consensus opinion. 
To facilitate this, ordinal scales can provide less ambiguous answers (Section 2.3.3: 
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Reliability). To triangulate the outcomes with the focus groups, I included a freehand 




















Management of a TZ3 
Domain: Repeating 




Domain: High grade 
cytology referral 
Item:  Management options 
Item: Depth of LLETZ 
Domain: LLETZ for 
low grade cytology 
Item: Who? 
Item: When? 
Domain: Use of 
oestrogen 
Domain: 
Conservative follow up 











Domain: Depth of LLETZ 
Item: Technique 
Item: Why? 
Figure 2.1: Questionnaire conceptual framework: The initial framework (black 
script), the domains that were added following the Delphi consensus (white 
script) and the corresponding items which assessed each domain. 
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2.3.1.1 Potential predictors of decision-making 
Patient age and parity were major factors which had affected decision-making in the focus 
groups and I deliberated on how to categorize these variables for the survey. Although 
progression of CIN is comparable in older and younger women with low grade cytology, 
this risk is increased in older women with high grade cytology[182]. Parity is a risk factor for 
progression and this tends to be higher in older women[60]. Furthermore, the RCOG 
classification of ‘advanced maternal age’ is women aged ≥40[183] and the HPV primary 
screening proformas used in the sentinel sites advised LLETZ, irrespective of the cytology 
result, in women aged ≥40 who had a TZ3 and high risk HPV (Appendix 4, Figure S4.2). For 
these reasons the final demographic categories were:    
 25 - 39, no children 
 25 - 39, family not complete 
 40 years or older, family not complete 
 Completed Family, any age 
 
A sub-theme identified in the focus groups was the endorsement of a shallower LLETZ 
than nationally recommended[35] (Section 4.3.4.5). To provide targeted guidance I wanted 
to clarify if this was restricted to regional practice and/or limited to a specific patient 
demographic. Categories for depth of LLETZ included ≤6mm, 7-10mm, 11-15mm and 
≥16mm; these were based on the outcomes reported by Castanon et al, 2014[109] who 
linked depth of LLETZ to risk of preterm labour (Section 1.5.4). 
Respondent demographics included job title, years of experience in colposcopy and 
gender. The initial categories for job title were general gynaecologist, gynaecological 
oncologist, nurse colposcopist and gynaecology registrar. In the focus groups these 
professionals placed different emphasis on the factors that affected their decision-making 
and this information may be useful for guideline implementation.  
Correlation of experience with management decisions may be valuable for guideline 
development and it could be argued that more weight should be applied to 
recommendations from health care providers who have more experience in this area. 
However, measuring competence and experience can be problematic; most decision-
making in colposcopy contains limited variables and is formulaic, all colposcopists have to 
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attain the same basic competencies and re-accredit three yearly. If multiple items that 
assess competence are included, the rate of missing items would increase. 
Health Care Professional’s gender has been shown to influence clinical decision-making; 
female clinicians can have longer consultation times, especially when speaking to other 
women[184, 185], and more of this time is devoted to counselling the patient whereas male 
colleagues may spend more time discussing technical aspects[186]. As a major outcome of 
this study was to assess whether conservative or surgical management options are initially 
offered, evaluating the association between gender and management choice would be 
useful for guideline implementation.  
 
2.3.1.2 Structure of the questionnaire 
The most important items were placed at the beginning of the questionnaire. 
Demographic questions, such as gender, can be considered intrusive if they are not 
contextualised. They are also the least interesting questions for respondents who may 
become disengaged if they are answered first. A long questionnaire with multiple items 
testing the same domain can reduce response rates and increase the risk of false 
positives[180] as respondents may become ‘tick happy’. To adjust for this, the questionnaire 
was initially restricted to 14 items with a maximum of three items testing the same 
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Table 2.3: The domains and items for the first version of the questionnaire 
DOMAIN Corresponding Items 
Initial management of low 
grade cytology and a TZ3 
Practice: 1 multi-nominal  
Attitude: 1 multi-nominal 
Repeating the referral cytology Attitude: 1 discrete response 
Conservative follow-up for low 
grade cytology 
Practice: 1 multi-nominal 
Depth of LLETZ in women with 
low grade cytology and a TZ3 
Practice and knowledge: 1 discrete response 
Attitude: 1 multi-nominal 
Initial management of high 
grade cytology and a TZ3 
Practice: 1 multi-nominal 
Depth of LLETZ in women with 
high grade cytology and a TZ3 
Practice and knowledge: 1 discrete response 
Attitude: 1 multi-nominal 
Non-routine measures to 
improve the adequacy of the 
examination 
Practice: 1 discrete response 
Use of oestrogen Attitude: 1 discrete response 
Respondent demographics Job title & gender: 2 discrete responses 
Years of experience: 1 continuous scale 
 
2.3.2 Validity 
2.3.2.1 Content validity 
This is the extent to which the questionnaire measures all domains relating to the 
construct of interest. Eight experts in the field reviewed the initial conceptual framework; 
colposcopists who were respected and nominated by their peers for their clinical or 
quality assurance experience. This panel consisted of six Consultants (three general 
gynaecologists and three gynaecological oncologists) and two nurse colposcopists from 
three different NHS Trusts within the South West England Region. Three were male and 
five were female, three were leads for quality assurance in their departments, two were 
lead colposcopists and two had published recent relevant literature in the field.  
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In a modified Delphi technique[187] (yes /no responses were used rather than a Likert scale) 
I asked these experts to include or exclude domains which they felt encompassed all 
possible decision-making options for this cohort of women. This method is a practical way 
of bringing together experts who have competing clinical duties and work in separate 
trusts. The first round of feedback added two additional domains which can be viewed as 
the white script in Figure 2.1.  
Repetition of cervical cytology within three months of the referral sample is not 
recommended by the NHS CSP[35] but some of the experts felt there may be scenarios, 
such as absence of endocervical cells on the cytology report, when a repeat test may be 
taken. The second stage of feedback led to a clear consensus on the included domains.  
Following development of the questionnaire, the first version was emailed to the BSCCP 
for review. The committee consists of experts in the field; health care providers with 
experience in colposcopy and related research, cervical screening quality assurance and 
questionnaire development. The second version, as accepted by the BSCCP committee, 
consisted of 14 items (Section 5.3.1.1).  
2.3.2.2 Face validity 
To improve the robustness of the study and response rates, face validity of the second 
version was assessed by colposcopists from the South West England Region, which I chose 
for logistical reasons. Face validity is the extent to which the items are interpreted as 
intended and incorporates clarity of wording and layout. There is no accepted consensus 
for sample size in this stage of psychometric evaluation (average 10-20)[178-181]. To reduce 
prior sensitization I aimed to recruit colposcopists who had not assisted with the 
conceptual framework or participated in the focus groups. I emailed these potential 
participants a PIS and consent form (Appendix 3) and followed this up two weeks later if 
I had not received a response.  
In a private setting, I gained written consent and observed these colposcopists completing 
the questionnaire. I interviewed them to evaluate their interpretation of the items, the 
layout (spacing, font and graphics), sequencing, terminology and phrasing. ‘Closed’ items 
were evaluated for omnicompetence. Data was transcribed verbatim. Acceptability of the 
items was ratified by assessing the response rate and any missing data. Items were 
considered for deletion or rephrasing if 10% of participants did not complete an item or 
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more than 50% of participants scored either the highest or lowest values (floor/ceiling 
effects) i.e. responses were not evenly distributed.  
2.3.2.3 Construct validity 
This is the association between the questionnaire and evidence relating to a TZ3; it is 
another method of assessing ‘how much the questionnaire measures what it intends to 
measure’[188]. For example, current BSCCP standards[35] denote that cytology samples 
should not be repeated at the first appointment and a deeper excision is required to 
remove a TZ3 - albeit with the caveat of considering the higher risk of treatment related 
morbidity in childbearing women[85] (Sections 1.5.1 & 1.5.4). With a paucity of guidance 
relating to a TZ3, I compared respondent’s choice of treatment depth and the proportion 
of respondents who repeated the referral cytology to the above BSCCP standards. To 
complete this psychometric component I used the datasets from the test-retest reliability 
participants (Section 2.3.3.1); Fisher’s exact test was used to evaluate this unpaired 
categorical data. 
2.3.2.4 Other considerations 
 Convergent validity: This measures the relationship between the questionnaire and 
the hypothesis surrounding the construct it is measuring i.e. how well does the 
questionnaire and theory converge or reflect things that are known to be true. This 
could not be evaluated as there is no gold standard questionnaire or indeed any other 
questionnaire which assesses these concepts. 
 Criterion validity: This is the association between the questionnaire and an existing 




2.3.3.1 Test-retest (stability) 
The COSMIN 2011 checklist, which evaluates the methodological quality of studies 
assessing measurement instruments, was used to determine if the final version of the 
questionnaire provided consistent and reproducible results [189]. Repeat measures can be 
by the same participant (intra-rater reliability), as in this study, or independent measures 
of the same variable (inter-rater reliability)[190]. Using Glimmpse online software, which 
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specializes in sample size calculations for repeated measures, 19 participants were 
required based on a two tailed test (negative values are also of clinical interest to 
determine if respondents are misinterpreting the questions) with an effect size of 0.8, 
alpha of 0.05 and power of 0.9.  
To reduce sensitization of the data, I recruited colposcopists who had not attended the 
focus groups. These colposcopists were sent a PIS and consent form (Appendix 3) and 
those that agreed to participate were asked to complete the same questionnaire two 
weeks apart. Too short a timeframe may allow participants to remember their previous 
answers and too long may lead to a change in the stability of the participant’s clinical 
practice. Two weeks has been reported as an optimal timeframe[191] and if participants 
reported a perceived change in their standard management practice prior to completion 
of the second questionnaire, they were excluded. Test conditions were similar for both 
questionnaires; participants were asked to complete them in a quiet environment at a 
time when they would not be rushed.  
2.3.3.1.1 Analyses 
When measuring levels of agreement that are not due to chance between discrete 
variables (ordinal or nominal data), a Kappa statistic is commonly used. For ordinal 
variables such as a Likert scale, a weighted Kappa was used; as unlike an unweighted 
kappa it does not treat all disagreements similarly. For example, in an unweighted kappa 
analysis of a 5 point Likert scale a score ratings of three on one day and two on another 
would be considered as complete disagreement whereas in fact they are close and may 
be considered to partially agree. A Kappa value of zero is agreement that occurs due to 
chance, values of 0.61 - 0.80 suggests ‘very good’ agreement and 0.81 - 1.00 ‘excellent’ 
agreement[192]. A linear weighting scheme was used; this is common for ordinal data as it 
allows those observations that do not agree absolutely, but agree a little, to contribute 
some agreement. All analysis was done using Stata v13.1 statistical software. 
 
2.3.3.2 Parallel forms reliability  
This assesses whether the same outcomes are identified when multiple items that 
measure the same construct are administered to one group and the same number but a 
different variation of question on the same construct is given to a second group. The aim 
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is to observe similar scores between groups. This is a labour intensive approach as 
multiple items on the same construct need to be developed, validated and administered. 
It also assumes there is a large population to recruit respondents from - in addition to 
those who will be recruited to complete the final questionnaire. For these reasons, I chose 
to evaluate test-retest reliability. 
 
2.3.4 Other considerations 
2.3.4.1 Internal consistency 
This is the extent to which items within a scale are inter-related. This methodology is less 
time consuming than parallel forms, inter-rater or test-retest reliability as only one data 
set is required. The disadvantage is that multiscale items (Likert scales) are required [193] 
and in my questionnaire discrete responses or multi-nominal scales were used to facilitate 
the identification of a consensus opinion.  
2.3.4.2 Sensitivity 
Some surveys are designed to detect a change in symptoms, attitudes or behaviour over 
time. To measure this, patients complete a questionnaire before and after an intervention 
or at different points in time (a cross-sectional design). As the focus of interest in this 
study was the opinions and behaviour of colposcopists at one set point in time, sensitivity 
analysis was not applicable. 
 
2.4 Current Practices in the management of a TZ3: A UK Survey 
Following development of the questionnaire I used quantitative analysis to describe the 
responses and to identify areas of consensus and discordance. 
2.4.1 Administering the questionnaire 
Survey Monkey software was used as the online platform for the final version of the 
questionnaire. Although formatting of the questionnaire for this software was time 
consuming, this platform maintained confidentiality and prevented breach of data 
protection laws as I sent a cover letter by email (Appendix 4), which contained the URL 
and study information, to the BSCCP secretariat who forwarded it to their members. 
Telephone conversations are time consuming and participants can be distracted and 
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terminate the call. Mailed questionnaires are also time consuming, expensive for the 
researcher and missing items will affect the statistical power.  
Electronic methods are an effective way of surveying a large cohort, require minimal 
expense and can be designed so that all the items need to be completed. I presumed that 
all participants had access to a computer as email addresses are provided to the BSCCP. A 
Cochrane review[194] assessed 481 RCTs and concluded that survey response rates can be 
improved by the following variables (which were included); addition of the researcher’s 
contact details, position and an explanation of the importance of the research in the cover 
letter, resending of the questionnaire at two weekly intervals, the use of text response 
rather than visual, a white background and a deadline.  
 
1200 BSCCP accredited colposcopists were emailed the invitation to participate on 
March 24th 2016 and a reminder was sent by the BSCCP secretariat two weeks later. 
 
2.4.2 Sample size 
The larger the population sampled the smaller the sampling variation (margin of error) 
and the smaller the chance that the questionnaire results will differ from the true 
population average. Table 2.4 shows the association between the number of respondents 
and the margin of error. For example, if 500 respondents answered the question relating 
to repetition of the referral cytology and 90% adhered to national guidance I could be 85.5 
– 94.5% certain this reflected practice within the UK. 
 
 
Table 2.4 Association between number of respondents and margin of error 
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2.4.3 Data input and classification of variables 
As with the database in the negative LLETZ study, to aid data input into the statistical 
software package, Stata, each item was coded and a table of definitions compiled. An 
ExCel database for entering the codes was designed prior to validation of the 
questionnaire. Before data was transported from Excel into Stata (for statistical analysis) 
I checked and ‘cleaned’ it; assessed for missing or incorrect entries. Variables were 




A range of descriptive statistics were used to describe the frequencies and percentages 
from each item. McNemar’s test was used to compare paired categorical variables and a 
chi squared test or Fisher’s exact test (for variables that had cell counts less than five) 
were used for unpaired categorical variables. Cochran’s Q test was used to assess for 
equality of proportions. A risk difference with confidence intervals was used to describe 
the difference in proportions.  
Multivariable logistic regression was used to assess the association between management 
decisions and respondent demographics such as years of experience, job title and gender. 
An odds ratio (OR) was used to report the strength of the association between the 
exposure and the outcome variables; it reports the odds that a specific outcome will occur 
in the presence of an exposure variable compared to the odds of the same outcome 
happening in its absence. If the ratio equals 1 there is no difference between the two 
arms. If the OR is <0.5 then, for example, the odds of an outcome, such as repetition of 
the referral cytology outcome in women with a TZ1 (exposure) is 50% less than in women 
with a TZ3.  
An odds ratio was used as the information in this study is for clinicians and not patients; 
communicating risk is not as important as in 2.1.7. Furthermore, as lots of models will be 
required and poisson regression can be unstable, logistic regression (which uses OR to 
report association) was used.  
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2.5 The use of biomarkers and HPV genotyping to improve 
diagnostic accuracy in women with a TZ3 
 
2.5.1 Study design and population 
This prospective diagnostic accuracy study was conducted in a single NHS Trust in the 
South West England region from August 2014 – February 2016. To plan the methodology 
I used the QUADAS checklist for diagnostic studies, applied for and was granted ethical 
and R&D approval, respectively, by NRES Committee South West – Frenchay on 25th May 
2014 (ref OG/SW/0028) and University Hospitals Bristol NHS Trust (ref OG/2013/4461) 
respectively (Appendix 2). To cover the cost of the immuno-stains, genotyping and 
supervision of a laboratory technician I applied for two grants (Appendix 1). 
Women 25 - 64 years of age referred to the colposcopy clinic with a range of cytological 
squamous abnormalities, who were having a LLETZ for a TZ3, were approached for 
participation. All women had high-risk HPV as Bristol is an NHS CSP ‘sentinel site’; chosen 
to institute Primary HPV Screening from 2012 prior to the national roll-out in 2019[195]. 
These excisions may have been a ‘see and treat’ LLETZ for high grade cytological 
abnormalities or a pre-booked LLETZ for persistent low grade screening.  
Eligibility (presence of a TZ3) was assessed prior to LLETZ. Participants were excluded if; 
 Endocervical sampling had occurred within the previous twelve weeks as this 
increases the risk of false negatives. 
 The referral cytology was glandular - ECC can affect the distinction between 
adenocarcinoma in situ and invasive adenocarcinoma[129]  
 A pregnancy test was positive - ECC can increase the risk of miscarriage, preterm 
labour and/or infection[196]. Although the use of a cytobrush in the first trimester is 
reported to be safe[131]. 
 The potential participant was immunocompromised - ECC is thought to increase the 
risk of ascending infection[120].  
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2.5.2 Sample size calculation 
These are rarely reported in diagnostic studies as it is difficult to conceptualise the effect 
size in primary studies. My aim was to estimate accuracy with precision and therefore a 
power calculation was performed. As the NPV for HPV testing is >99%, the sample size 
was calculated to detect adequate test sensitivity of 0.95 - alpha was set at 0.05 and 
power at 95%. Outcome data from the negative LLETZ study (Chapter 3[197]), which 
assessed the histological outcome in women with a TZ3 and high risk HPV, was used to 
calculate the sample size. It was estimated that 97 complete data sets would be needed 
based on 47/72 (65.3%) of women who had CIN2+ with a TZ3 [198]. 
2.5.3 Recruitment 
Women with high grade cytology were sent participant information sheets and consent 
forms (Appendix 3) two weeks before their appointment. I then checked the clinic lists 
daily for potential participants and approached them for written consent after they 
‘booked in’.  In my unit the majority of women with low grade cytology and a TZ3 are 
offered cytological follow up and then a LLETZ 6 - 12 months later if dyskaryosis is still 
persistent. I kept a record of these women and sent information sheets with their 




























LLETZ appointment and 
PIS sent 
Attends clinic Index tests immediately 
prior to LLETZ 
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Data collected on co-variables included age, parity and smoking status as these factors 
can affect HPV clearance (Section 1.2.4.3). Age was grouped as 25 – 39 years and ≥40 
(based on the RCOG advanced maternal age criteria[183] and the 2012 HPV primary 
screening treatment protocol – Appendix 4). Hormonal status (atrophic changes can affect 
the cytology result), smoking status, the referral screening test result, ability to pass the 
cytobrush and curette, interval in weeks from the referral cytology to the index tests and 
the LLETZ result (including presence of the TZ, histological limiting factors and depth) were 
also recorded. 
 
2.5.4 Sample taking 




Trauma to the fragile endocervical cells by a cytobrush can increase blood loss leading to 
false negative or inadequate cytology samples[199]. To reduce this risk I used a standard 
Cervex-Brush (RoversR Cervex-Brush; 70671-001) to sample the ectocervix prior to the use 
of a standard Cytobrush (Medscope Cytological Brush). The cytobrush was inserted in the 
endocervical canal to a depth of 2.0cm. Both cytology samples were stored in the same 
Figure 2.3: Order of endocervical sampling 
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LBC container (PreservCytR 20ml solution; 70097-003; Hologic UK) and labelled with the 
participant’s study number only.  
Citonest (x2-3 ampules) was infiltrated, as for standard LLETZ. ECC was performed with a 
Kevorkian Young Biopsy curette which incorporated a 12 x 3mm basket (Wholesale 
Surgical Instruments Inc; 6-12760) to improve collection of the epithelial fragments and 
to aid in gauging depth. Curettings were taken from four quadrants (anterior, posterior, 
right and left lateral), from 2.0cm distally to the external os. The curettings were stored 
in 4% formaldehyde (30ml CellStor Pot, CellPath) and labelled with the participant’s ID. 
 
Routine LLETZ was then performed in one pass (to reduce distortion) and to a depth of 15 
- 20mm, in line with BSCCP recommendations[35], and to allow an accurate comparison 
with the curettings. LLETZ was chosen as the reference standard as this is the gold 
standard diagnostic test and treatment method for women with CIN. All index and 
reference standard tests were completed by myself. 
Although I had chosen four quadrant ECC rather than circumferential sampling, to 
facilitate correlation with the LLETZ histology, the Ethics committee were concerned that 
the curettings would affect the integrity of the LLETZ, changing standard post-LLETZ 
management. I suggested to the committee the recruitment of five women booked for a 
hysterectomy who had a TZ3 and normal cytology. The histology could then be assessed 
for denudation before further participants were recruited. If more than two of the five 
samples showed epithelial stripping that prevented satisfactory analysis of the cervical 
epithelium, the study was to be terminated. Two participants were agreed upon as 
epithelial denudation of a LLETZ, secondary to handling of the tissue, is a recognized 
complication of standard excision. 
The PIS, consent form, clinic advertising, GP letters, checklists and participant letters that 
I designed can be viewed in Appendix 3 and Appendix 4. In addition, data collection 
proformas, lab proformas, safety assessment forms and clinic folders all needed to be 
completed which meant the first patient was recruited in August 2014. 
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2.5.5 Sample processing 
2.5.5.1 Referral, index and dual-stained cytology 
The referral LBC sample was either initially tested for HPV DNA by HC2 which contains 13 
high risk HPV DNA probes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) and then 
had routine ThinPrep cytology processing as per the HPV primary screening protocols or 
had HPV triage (with HC2) if the sample was reported as low grade dyskaryosis. 
The index cytology had routine Hologic ThinPrep processing and then immunostaining 
according to the manufacturer’s instructions, using the CINtec (dual-stained p16 & Ki67) 
Cytology Kit (ref 9521, Roche, mtm laboratories). Both of these tests are completely 
automated. For dual-stained cytology the LBC bottle is centrifuged, an aliquot removed 
and ‘stamped’ onto a slide, minus the ‘circle’ that is synonymous with Thinprep.  These 
slides can be stored at room temperature for three days before immunostaining to allow 
concurrent runs of 100 samples. The immunocytochemistry assays come in pre-prepared 
containers (‘kit’) which are slotted in prior to each run. This takes approximately 3 hours.  
Primary mouse monoclonal antibody (E6H4) directed at p16 and a rabbit monoclonal 
antibody directed at Ki-67 are added at room temperature and processed over 60 
minutes. Secondary reagents include horseradish peroxidase (HRP) which converts 3,3’-
diaminobenzidine (DAB) to produce the brown p16 staining and a reagent which joins to 
alkaline phosphatase to produce the pink/red Ki-67 staining by converting Fast Red 
chromogen. To validate the procedure, a control slide (containing positive and negative 
p16 and Ki67 cells) was used for each staining run.  
The only part of the process which is not automated is the cover slips; aqueous solution 
is applied to the slides to protect the cells from xylene / alcohol. The slides are dried in an 
oven as air drying can lead to cracking of the aqueous solution and difficulty in interpreting 
the slides (Appendix 7, Figure S7.1). The slides are then placed in xylene for a couple of 
minutes and glue is applied. Xylene is the final processing step and removes debris from 
the slide. This liquefies on top of the xylene allowing a cover slip to be applied and air 
bubbles to be ‘brushed out’. 
There were initial difficulties in acquiring the CINtec kits. ROCHE, an American company, 
is the producer of these kits and studies are currently in progress to assess the viability of 
this dual-staining process. Multiple correspondence was needed between myself and the 
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board at ROCHE to justify the purchase and use of their product before the company 
released their own studies. An agreement was reached that I could purchase 
immunostaining kits, which process 100 slides, at a cost of £3819.71 per kit. ROCHE would 
absorb the cost of the slips and any other reagents as part of their current study, ‘The 
Sentinel Study’, which is assessing the use of dual-staining in women with low grade 
cytology. In exchange, they requested that ROCHE be acknowledged on any future 
publications.    
2.5.5.2 HPV genotyping 
The virology department at Manchester Royal Infirmary is the only laboratory in England 
who currently test for the full HPV array. To facilitate testing, I organized a material 
transfer agreement between North Bristol Trust (where the cytology samples were 
stored) and Manchester Royal Infirmary. 
As recent studies have shown that high risk HPV is detected in samples with scanty TZ 
sampling[200], I took a 0.5ml aliquot (Figure 2.4a) for HPV genotyping after the routine 
cytology and dual-stained slides were processed. I took these aliquots to Manchester and 
observed the genotyping process under the supervision of Dr Alex Sargent, Consultant 
Virologist. Papillocheck (Greiner Bio-one) is a micro-array based kit which is used to detect 
the E1 gene of the HPV genome. Target HPV DNA was amplified by PCR and hybridized to 
specific DNA probes (as outlined below) to detect 24 HPV genotypes (6 low and 18 high 
risk; 6, 11, 40, 42, 43, 44/55 & 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 
73, 82). Analyte cutoff ratios of ≥1 were reported as positive. 
Viral and DNA extraction were done in air extraction stations in a ‘clean’ room to reduce 
contamination. 250μl of the study sample was added to a HPV primer mix which amplifies 
the DNA fragments. The first step is thermocycling of the sample/primer mix; BioMerieux 
EasyMag system has specific cycles (temperature / length) for different viruses – for HPV 
the cycle takes 3 hours. The PCR sample was then stored at 4oC overnight to prevent 
degradation.  
The following day the amplified PCR samples were vortexed and 5μl added to 30μl of 
hybridization buffer (Figure 2.4b). To prevent cross-contamination, the pipettes were 
disposed of between samples. The PCR / buffer mix was left for 15 minutes, during which 
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time a computer template of the PCR scanner ‘chip’ was produced to facilitate the 
automated transfer of results. Ten study samples could be processed in the same run. 
To remove unbound DNA and reduce interference on the PCR scanner, the hybridized mix 
is buffered (washed vigorously) - Figure 2.4c. The sample is pipetted onto a chip 
containing DNA probes which hybridize to the corresponding amplified DNA, labelling it 
flourescently. The chip has 12 windows (DNA-microarrays) – 10 for study samples and a 
positive (HPV 16) and negative control (Figure 2.4d).  
When pipetting the PCR sample onto the chip, if the pipette or technician touch the chip 
the process has to start again due to contamination. The chip is stored securely for 15 
minutes to allow binding as even gentle vibrations of the bench can prevent this process. 
The chip is then inserted into an automated Greinier Bio-one PCR scanner (Figure 2.4e). 
The fluorescent light from the bound products is detected using the CheckScanner at 
excitation wavelengths of 532 and 635nm. The results are evaluated by CheckReport 
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Figure 2.4: HPV genotyping  
a) study aliquots for genotyping  
b) hybridization of the PCR sample  
c) buffering to remove unbound 
DNA  
d) ‘chip’ containing DNA probes 




2.5.5.3 Endocervical curettings 
The curettings were processed in batches of ten at University Hospitals Bristol NHS Trust, 
by myself, under the supervision of a senior laboratory technician. Processing was 
dependent upon size. In stage 1, samples <1mm were centrifuged, the formalin discarded, 
liquified agar jelly pipetted over the remaining pellet and the sample transferred into a 
cassette before the agar could solidify. If the pellet was poured directly into a cassette 
without the agar, the sample would fragment and dissipate during the dehydration 
process. A potential limitation of this stage was the speed in which the agar solidified 
within the pipette; if I was slow in transferal to the cassette, scattered (possibly dysplastic) 
cells could be retained within the pipette leading to false negative samples. 
If the sample was ≥1mm it was poured directly from the histology pot through a funnel 
into a muslin bag. The funnel needed to be rinsed with formalin to ensure tiny fragments 
were not retained and to prevent cross contamination with any subsequent samples 
(Figure 2.5a). The bag was then placed in a cassette and put through the first automated 
processing run (fixation and dehydration) prior to impregnation with wax. This run 
consisted of: 
- Formalin – 68 minutes - to fix the tissue 
- 85% ethanol – 70 minutes – to remove the water in the tissue 
- 80/20 Ethanol/Isopropanol – 140 minutes – to dilute the ethanol to isopropanol which 
is gentler on the tissue 
- Isopropanol (IPA) – 210 minutes – to clear the ethanol from the tissue and make it 
miscible with wax 
- Wax impregnation – 210 minutes 
 
Stage 2 was the processing of the fixed and dehydrated tissues into a solidified wax block 
(Figures 2.5b and 2.5c). The cassettes containing the tissue suspended in agar jelly were 
covered with molten wax and placed on a cold plate to solidify. The cassettes containing 
the muslin bags were covered in molten wax and transferred to a warm plate to prevent 
total solidification. This allowed transfer of the wax encased tissue fragments from the 
bag to a second cassette. Another potential limitation of this processing method was the 
speed of wax solidification - to prevent dysplastic cells ‘sticking’ to the forceps and being 
excluded from the final sample, the forceps were warmed between the transfer of each 




Stage 3 was slicing of the blocks to provide levels for staining. Due to the expert nature of 
this stage and the high probability of destroying the samples during slicing, this process 
was completed by the laboratory technician. The blocks were kept on a cold plate to 
improve handling and four levels (of 3μm depth) were cut (Figure 2.5d); the first for H&E, 
the second for p16 staining, the third for Ki-67 and the deepest level for a second H&E. 
The second H&E slide was to assess if dysplastic fragments were ‘hiding’ deeper within 
the block. To improve transfer of the wax slices onto the slide they were placed in a warm 
bath to prevent crinkling of the wax (Figure 2.5e) and baked at 60o for 25 minutes to 
improve adhesion. 
As with the cytology samples, a control slide was used for each staining run. Primary 
antibodies against p16 and Ki-67 were applied prior to the secondary antibody 
application, which resulted in the distinctive staining pattern. The slides were cover 
slipped by an automated machine. To assess the slide quality, I checked them against the 
block to ensure the general size of the sample was the same and to ensure the slides were 
numbered with the correct participant ID. 
2.5.5.4 LLETZ 
Routine processing and reporting of the LLETZ was undertaken and the six 
Histopathologists were unaware these women were enrolled in the study.  
All samples were processed within two weeks of collection to allow speedy correlation of 
the study outcome and the LLETZ result. If a mismatch occurred, such as the index tests 









     
 








Figure 2.5: Processing of the 
endocervical curettings 
a) transfer of the curettings into the 
cassettes 
b) transfer of the fixed and 
dehydrated tissue into wax blocks 
c) wax blocks containing tiny tissue 
fragments 
d) cutting of the levels 





2.5.6 Sample interpretation 
2.5.6.1 Referral, index and dual-stained cytology 
The NHS CSP’s definition of adequacy and the UK’s BSCC grading classification system 
were used to interpret the cytology[84]; slides were reported as borderline suspicious of 
high grade, low grade dyskaryosis or high grade. Standard interpretation of the referral 
cytology included three ‘full screens’ lasting 5 minutes by two cytologists and one 
consultant pathologist as all referral cytology samples were reported as dyskaryotic. 
Interpretation of the study slides (cytology and dual-staining) were done by two 
independent consultant cytologists, in two separate trusts, who were blinded to the 
participant’s demographics, referral cytology and LLETZ result. 
I adapted the scoring protocol for the dual-stained cytology slides from the 
manufacturer’s handbook (CINtec Plus Cytology Interpretation, Roche 2013) who 
recorded a positive result as ‘…one or more cervical epithelial cell(s) stained with a brown 
cytoloplasmic stain (p16) and a red nuclear (Ki-67) stain irrespective of morphologic 
abnormalities’. Magnification was x10 to screen and x40 to allow assessment of the dual-
stained positive cells in the same plane of focus. Although screening could stop at the first 
positive cell, as during a normal cell cycle pathway p16 and Ki67 expression is mutually 
exclusive (section 1.6.3.1.3), in practice, both cytologists continued screening until a 
second positive cell was identified. To develop my knowledge and to ground myself in the 
data, I watched all screening under a double headed microscope and recorded the results. 
2.5.6.2 HPV genotyping 
Samples were considered positive for high risk HPV if one of the 13 IARC classified type 1 
carcinogens was identified (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68).  
2.5.6.3 Endocervical curettings 
Adequacy rates for endocervical curetting H&E slides are poorly defined in the literature. 
I initially used an adapted definition by Boardman et al, 2003[132] – ‘at least one strip with 
at least ten endocervical cells that can be viewed at x10 magnification’ -  in combination 
with the criteria for cervical punch biopsy by Heatley et al[201] - ‘evidence of metaplasia, 
squamous cells and stroma’. These samples were reported by participant number and 
interpreted as normal, CIN1, 2 or 3, cGIN (low or high grade) or carcinoma. All histological 
grades ≥CIN2 were grouped as CIN2+ for ease of analysis and because all results ≥CIN2 
meet the national criteria for treatment. p16 histological staining was graded according 
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to an abbreviated version of Lesnikova et al’s[202] definition; ‘0 – no staining, 1 – weak 
staining and 2 – strong straining’. Ki-67 nuclear staining was graded according to a 
classification adapted from Galgano et al[136] and van Niekerk et al[139]; ‘0 – no staining, 1 
– parabasal staining, 2 - full thickness staining’. The curettings were interpreted by two 
consultant pathologists in two separate NHS trusts who were not aware of the 
participant’s history or LLETZ result. Due to the expert/novel nature of interpreting these 
small and fragmented samples, I viewed the samples under a double headed microscope 
with these experts and recorded all outcomes. 
2.5.6.4 LLETZ 
Routine reporting of the LLETZ was undertaken and the histopathologists were unaware 
these women were enrolled in the study. Results were recorded as normal (which for the 
purposes of the study included metaplasia and inflammation), CIN1, 2 or 3, cGIN or SCC, 
but for analytical purposes and because results ≥CIN2 meet the national criteria for 
treatment, results <CIN2 and ≥CIN2 were grouped. 
 
2.5.7 Analyses 
Descriptive statistics, such as means & SD or median & IQR for continuous variables and 
frequency & proportions for categorical variables, were used to describe the study 
sample. To compare my study characteristics to national data (where 80% have a TZ1 or 
2) differences in proportions and their confidence intervals were reported.  
The inter-rater reliability of predicting CIN2+ by different diagnostic and staining 
categories was measured by a Kappa statistic, as explained in section 2.3.3.1.1. The most 
predictive immunostaining categories were then used to assess the diagnostic accuracy 
of the index tests. 
To determine the diagnostic accuracy of the referral and index tests, sensitivity and 
specificity were calculated as well as PPV and NPV (Table 2.5). PPV and NPV relate to the 
performance of the test and will vary depending on the population screened; if the test is 
used in a population which has a high prevalence of disease (such as CIN) the chance of 
false positives will be lower for a given sensitivity. Sensitivity and specificity relate to the 
accuracy / characteristics of the test and are stable across different populations. To 
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calculate sensitivity, specificity, NPV and PPV a diagnosis of low grade cytology (<CIN2) or 
high grade cytology (CIN2+) by diagnostic test were reported as accurate if the LLETZ 
sample reported a corresponding histological diagnosis. Participants with inadequate 
samples were excluded. Where suitable, McNemar’s test was used to compare the 
sensitivity and specificity of the index tests. 
 
Table 2.5: Calculation of sensitivity, specificity, PPV and NPV 





True Positive (a) False Positive (b) Test positives (a + b) 
Index test 
negative 
False Negative (c) True Negative (d) Test Negatives (c + d) 
TOTAL Total CIN2+ (a + c) Total <CIN2 (b + d)  
Sensitivity = a / a + c  PPV = a / a + b 
Specificity = d / b + d  NPV = d / c + d 
 
Hypotheses for diagnostic studies can be tested using more than one accuracy measure. 
When this occurs adjustment for multiple testing needs to be completed to reduce 
potential type 1 errors. Overall accuracy of the tests (a + d / a + b + c + d) was not 
calculated as this gives an equal weighting to true positives and true negatives. This means 
a test which has better specificity than sensitivity could in theory have a better overall 
accuracy than a test which has a higher sensitivity than specificity. Although specificity is 
important to reduce treatment related morbidity, sensitivity in my study is of higher 
importance; missing a cancer carries a higher morbidity than is associated with the 
treatment. For these reasons the area under the curve was not measured when the index 
tests were evaluated and adjustment for multiple testing was not required[203]. 
Patient characteristics can affect the accuracy of diagnostic tests. To assess for this, 
logistic regression models were calculated with CIN2+ (as predicted by LLETZ) as the 
dependent variable and patient’s age, parity, hormonal status, smoking status and time 
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between referral cytology and LLETZ as the independent variables. The analysis was 
restricted to complete cases (97/101) to allow comparison across tests and across models 
with different predictors.  
Univariable models assessed whether each potential predictor explained the LLETZ 
outcome. A series of bivariable models then assessed the index tests in combination with 
each potential predictor. Wald tests were used to determine if their inclusion explained 
the LLETZ result over and above what would be expected from natural sampling 
variability.  
A series of bivariable models which included (a) HPV 16/18, (b) dual-stained cytology and 
(c) immunostained curettings were evaluated to determine whether the inclusion of each 
potential predictor modified the prediction ability of the diagnostic test. Receiver 
operator curve (ROC) plots and area under the ROC curve (AUC) statistics for (a) initial 
models evaluating the individual tests and (b) models with the test and other significant 
predictors were produced. The area under the curve measures the ability of the test to 
identify women with and without CIN2+; values of 0.90 - 1 are considered excellent, 0.80 
- 0.90 are good, 0.70 - 0.80 are fair and <0.70 are poor. 
The most predictive tests were then assessed in combination with the screening test 
result to determine the impact on diagnostic accuracy. Only participants with complete 
(and adequate) datasets were used. Sensitivity, specificity, PPV, NPV and likelihood ratios 
for a positive and negative test were calculated.  
Likelihood ratios are another method of assessing the usefulness of a test in identifying 
the probability of CIN2+. A positive likelihood ratio (PLR) is sensitivity / 1- specificity and 
a negative likelihood ratio (NLR) is 1 – sensitivity / specificity. A value greater than 1 
implies the test result is associated with CIN2+ and a minus value implies the absence of 
CIN2+. They are slightly harder to interpret than sensitivity and specificity as the value 
needs to be correlated to a given probability of the presence or absence of disease (Table 
2.6). For example, a PLR of 5.0 in women with a positive dual-stained cytology result 





Table 2.6: Likelihood ratio and probability of disease 
LIKELIHOOD RATIO CHANGE IN PROBABILITY 
Negative Values  
0.1 - 45% 
0.2 - 30% 
0.5 - 15% 
1 0% 
Positive Values  
1 0% 
2 + 15% 
5 + 30% 















 The impact of HPV screening on negative LLETZ 
 
3.1 Introduction 
The current literature has focused on HPV screening test performance and referrals to 
colposcopy rather than the impact of a positive test on colposcopists’ decision-making. 
Negative LLETZ is an important performance indicator in colposcopy and quality 
management of a cervical screening programme. It occurs when no CIN is identified in the 
histological specimen and the reported incidence in women with biopsy confirmed CIN2+ 
varies from 5.9% to 41%[105, 160-164]. This large variation is secondary to differing criteria for 
treatment. Given that 56% of women referred to colposcopy in England are aged 25 - 35 
and 12.9% of these referrals will result in a LLETZ[87], a reduction in false positive cervical 
screening could reduce unnecessary treatments and the associated morbidity (See 1.5.4). 
There is contradictory evidence following the introduction of HPV triage of low grade 
cytology as to the potential effect on the incidence of negative LLETZ. Women who are 
negative for high risk HPV can have higher rates of negative LLETZ[162, 163]. Conversely, HPV 
positivity does not differentiate between transient and transforming infections, which 
accounts for the poor specificity of HPV testing in women with low grade cytology[156]. 
The aims of this study were to: 
(i) evaluate whether HPV testing, as undertaken in the sentinel sites, has reduced the 
mean rate of negative LLETZ histology and  
(ii) examine predictors of negative LLETZ in women who test positive for high risk HPV. 
It is my experience, as a colposcopist, that women with a TZ3 appear to have higher rates 
of negative LLETZ than women where the TZ is visible. By addressing this shortfall in the 
literature, this novel study will determine the clinical significance of negative histology 
after HPV testing and provide recommendations on whether women with a TZ3 should be 






This was a retrospective cohort study (as outlined in section 2.1). Two independent 
cohorts who attended for a LLETZ procedure, before and after the introduction of HPV 
testing, were compared. For each cohort, 401 individuals were randomly selected from a 
colposcopy database. Clinical and colposcopic variables were extracted. The incidence of 
negative LLETZ was estimated in each cohort. Regression analysis was used to adjust for 
potential confounders and to explore predictors of negative LLETZ. 
 
3.3 Results 
All 802 women had complete data sets for the clinical and colposcopic variables collected. 
The majority of women were aged 25 - 40, parous, non-smokers, had a high grade cytology 
referral and satisfactory colposcopy (TZ1 to 2). A full description of the clinical 
characteristics is given in Table 3.1. 
Compared to the pre-HPV cohort, more women in the post-HPV screening cohort were 
younger than 30 and older than 50 years and more women used contraceptive. The two 
cohorts were similar with respect to parity, smoking habits, referral cytology, histological 
limiting factors and visibility of the TZ. However, in the pre-HPV cohort more women had 
an excision depth less than 7mm and the interval from cytology to colposcopic assessment 
was longer (mean 7 weeks (SD 4.21) vs mean 5.4 weeks (SD 4.44); p<0.001). 
The LLETZ histology was also compared between cohorts in Table 3.1; the incidence of 
negative histology was higher in the pre-HPV testing cohort but there was no difference 
in the rates of CIN1-3, cGIN or invasion between cohorts. The criteria for LLETZ, as advised 
by the NHS CSP publication No 20[35], are described in Table 3.1; there was no observed 
difference in criteria based on the outcome of a punch biopsy but in the absence of 
confirmatory histology, twice as many women had a LLETZ in the post-HPV testing cohort 
for high grade cytology in the presence of a TZ3.  Table 3.2 describes the criteria for 
treatment in the women with negative LLETZ histology; there was no evidence of a 




Table 3.1: Description and comparison of patient and clinical characteristics in 
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6 - 10 per day 

































Cytology to Colposcopy 
Interval: 
0 - 4 weeks 






























































Criteria for LLETZ: 
Punch biopsy: 






















No prior histology: 
High grade cytology & TZ3 
High grade cytology & HG colp 




































14 (3.4%) } 0.86 
Negative Histology 134 (16.7%) 80 (19.9%) 54 (13.4%) 0.01 
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Table 3.2: Criteria for treatment in women with negative LLETZ histology in the pre- and post-HPV testing cohorts 
 





Previous Punch Biopsy: 

















No confirmatory histology (See and Treat LLETZ): 
 High Grade Cytology and a TZ3 
 High Grade Cytology and high grade colposcopy 

















3.3.1 Association of HPV testing with negative LLETZ histology 
The incidence of negative LLETZ was 19.9% (80/401) in the pre-HPV cohort and 13.4% 
(54/401) in the post-HPV screening cohort, giving an unadjusted relative risk of 0.68 (95% 
CI: 0.49 to 0.93); see Table 3.3. The largest confounder in Table 3.3 was the interval from 
cytology to colposcopy; after adjusting for this variable there was no evidence of an 
association between HPV screening and negative LLETZ (RR 0.83; 95% CI: 0.60 to 1.15). In 
the final fully adjusted model that controlled for differences in age, smoking, 
contraceptive use, parity, referral cytology, biopsy result prior to LLETZ and histological 
limiting factors, there was a 25% reduction in negative LLETZ in women who had HPV 
screening. 
 
Table 3.3: The association between HPV screening and the risk of negative LLETZ 
(n=802). The crude association is provided along with the association after 
adjusting for each potential confounder and a final model adjusting for all possible 
confounders. 
 Relative Risk 
(RR) 
95% CI P-value 
Unadjusted 0.68 0.49 – 0.93 0.01 
Adjusted for: 
Age 0.66 0.48 – 0.90 0.01 
Smoking 0.68 0.49 – 0.94 0.01 
Contraceptive 0.71 0.51 – 0.97 0.03 
Parity 0.70 0.51 – 0.95 0.02 
Referral Cytology 0.69 0.50 – 0.94 0.02 
Cytology to Colposcopy Interval 0.83 0.60 – 1.15 0.26 
TZ type 0.62 0.46 – 0.84 0.002 
Biopsy result 0.66 0.48 – 0.90 0.01 
Excision Depth 0.69 0.50 – 0.94 0.02 
Limiting histological factors 0.69 0.50 – 0.94 0.01 
 
Adjusted for all potential confounders 0.75 0.55 – 0.97 0.04 
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3.3.2 Predictors of negative LLETZ in HPV positive women 
Table 3.4 reports the association of a range of variables with negative LLETZ among 
women who underwent HPV screening. In the unadjusted model, women >40 had 3 times 
the risk of negative LLETZ compared to women <30, women with two or more children 
had almost 3 times the risk compared to nulliparous women, women with low grade 
cytology had more than three times the risk compared to women with high grade cytology 
and women who had a TZ3 had four times the risk compared to women where the 
transformation zone was visible. The risk of negative LLETZ was reduced in women who 
had confirmatory histology prior to LLETZ and in women using the COCP. 
In the final model in Table 3.4, the presence of CIN2 on punch biopsy reduced the risk of 
negative LLETZ by 75% when compared to women where prior histology was not available. 
After adjusting for parity, women with a TZ3 had almost three times the risk of a negative 
LLETZ when compared to women where the TZ was visible and women with low grade 
cytology had almost four times the risk when compared to women with high grade 
cytology. The risk of negative LLETZ was highest among women with low grade cytology 
and a TZ3 (RR 10.4, 95% CI 5.9 - 18.4, p<0.001). It should be noted that while this risk is 
high in both relative and absolute terms (+40%; 95% CI 27 - 54%, p<0.001), only 22/401 
(5.5%) women who had HPV testing, had both low grade cytology and a TZ3.  
Of note, the risk of negative LLETZ from a TZ3 was shown to be independent of a low grade 
or high grade cytology referral. The marginal probability of negative LLETZ with high grade 
cytology, based on the final model in Table 3.4 was 6% (0.06, 95% CI 0.04 - 0.09). Among 
women with low grade cytology this was 23% (0.23, 95% CI 0.09 - 0.21).  
The association between clinical variables and a TZ3 was explored. When compared to 
women who were aged less than 30 years a strong positive linear relationship was 
observed between increasing age and a TZ3: among women aged 31 to 40 RR 1.26, 95% 
CI 0.69 – 2.29, among 41 to 50 year olds RR 2.72, 95% CI 1.57 – 4.73 and in women older 
than 50 years of age RR 4.17, 95% CI 2.41 – 7.21. Compared to women who did not use 
any form of hormonal treatment there was no difference in the incidence of a TZ3 and 
use of progesterone (RR 0.93, 95% CI 0.60 – 1.44) but use of oestrogen had a protective 




Table 3.4: Predictors of negative LLETZ in the post-HPV testing cohort (n=401) 
 Unadjusted associations Adjusted final model 
RR 95% CI p RR 95% CI p 
Age 
≤30 
31 to 40 









0.69 - 2.69 
1.60 - 5.67 
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Cytology to Colp Interval 
0 to 4 weeks 
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Biopsy prior to LLETZ 
None 










0.52 - 2.54 
0.08 - 0.80 
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0.08 - 0.79 































   





3.3.3 Follow up cytology in the negative LLETZ cohorts  
In women who had HPV testing and negative LLETZ histology, follow up cytology was 
available for 83.3% (45/54); 35/45 were HPV negative six months after LLETZ and none 
developed dyskaryosis during the follow up period (mean 39.6 months, range 6 to 44 
months). Of the 4/45 women who were HPV positive but cytology negative at their six 
month test of cure, one had CIN1 whilst the remainder had negative cytology during 
follow up (mean 30 months). Of the 6/45 women who had dyskaryosis at their 6 month 
test of cure, (two high grade and four low grade), two had vaginal intraepithelial neoplasia 
(VAIN) and the remainder HPV (mean follow up 33 months, range 28 to 36 months).  
In the women who had a negative LLETZ prior to HPV testing, follow up cytology was 
available for 85% (68/80). Seven of the 68 women had dyskaryosis at their 6 month follow 
up, (one high grade and six low grade) of whom two had VAIN, one cGIN, one CIN1 and 
three HPV (mean follow up 7 months, range 6 to 18 months). 61/68 had negative cytology 
six months after LLETZ, of whom ten developed dyskaryosis (all low grade) during the 
follow up period (mean 66 months, range 6 to 102 months). Three of the ten women 
women had VAIN, one CIN2 and the remainder HPV.  
In summary, 6% (3/45) of women with a negative LLETZ in the HPV testing cohort had 
positive histology (CIN1+) following excision and 11.7% (8/68) in the cytology only cohort 
(diff 5.7%, CI -6.6 – 16.2%, p=0.3).  
 
3.4 Strengths 
In this study, double data entry and a complete data set for both cohorts removed bias 
caused by erroneous and missing data. To control for confounding, variables which could 
explain the observed association between HPV testing and negative LLETZ were collected 
and controlled for. HPV screening results and the colposcopic assessment were recorded 
before the LLETZ outcome was known and clinical data was prospectively documented, 
minimizing recall bias. A sample size calculation, along with the strict triage described 
above, helped ensure sufficient power.  
The study was timely; HPV testing had been in use long enough to meet the sample size 
but not too long for practice to change dramatically, as evidenced by the similarities 
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between the cohorts. Missing CIN during the treatment or when interpreting the histology 
could account for a negative LLETZ result. However, rates of positive histology following 
a negative LLETZ (an indicator of residual disease) were compared and there was no 
evidence of a difference between the cohorts. Furthermore, the negative histology 
samples were assessed by two independent histopathologists, with extra levels, to ensure 
that all cases met the inclusion criteria - indicating that the same proportion of CIN should 
be ‘missed’ between cohorts.  
 
3.5 Limitations 
In the pre-HPV testing cohort photographic images were not taken as part of routine 
practice prior to LLETZ, preventing assessment of lesion size. However local policy 
advocated, in both cohorts, a strict selection criteria for treatment by recommending 
confirmatory biopsies if a significant change in lesion size and / or grading occurred. In 
using historical controls it could be argued that the observed decrease in negative LLETZ 
histology was associated with a change in clinical practice rather than the introduction of 
HPV screening. To address this, potential confounders were collected and controlled for. 
Moreover, following the results of the sentinel sites study it would be unethical to conduct 
a randomized control trial when high quality studies have shown that cytology alone has 
poorer sensitivity for detecting CIN than HPV cervical screening. 
Cluster sampling was used but the optimal method is randomisation; bias will however 
have been reduced by a clear definition of the target population and the avoidance of 
judgement sampling. Although a 25% reduction in negative LLETZ was identified between 
cohorts, the confidence interval was wide, as the effect size was smaller than predicted 
(section 2.1.1) suggesting larger sample sizes are needed to improve precision. 
 
3.6 Conclusions 
Despite a 25% reduction in negative LLETZ following the introduction of HPV cervical 
screening, the incidence is still high, at 13.4%. These results delineate the importance of 
improving the specificity of cervical screening in women with a TZ3 and the need for 
national guidelines to optimise their management. In the next three chapters, to aid 
guideline development, I will assess areas of consensus and discordance in the 




















 Assessment of colposcopists’ decision-making in 
relation to a TZ3 
4.1 Introduction 
The PPV of detecting CIN2+ in women who have high risk HPV and low grade cytology is 
only 16%[91]. To differentiate between women with transient and transforming HPV 
infections, women with a positive cervical screening test are referred to the colposcopy 
clinic. Management difficulties arise in the presence of a TZ3. To provide diagnostic 
histology a LLETZ can be undertaken, but as shown in Chapter 3, women with low grade 
cervical screening have a 10 fold increased chance that the excised tissue will be normal 
when compared to LLETZ histology in women with a TZ1 -2.  
There is little evidence to guide the management of women with a TZ3, specifically 
recommendations on when to offer cytological follow-up or excisional treatment [35, 97, 98], 
and this may lead to disparities in care.  
Clinical decision-making is a complex process and the inconsistent nature of intuitive 
management has led to the development of evidenced based practice[204]; this aims to 
minimize morbidity and optimise outcomes. When a paucity of evidence exists, decision-
making under conditions of uncertainty can be influenced by patient choice or risk factors 
and health care provider attitudes, experience, age, gender or culture[205, 206]. 
Colposcopists play an important role in leading research and policy change in cervical 
screening programmes and there is currently no literature to suggest how their opinions 
and experiences shape the management or counselling of patients with a TZ3.  
The aim of this study was to identify factors that affect colposcopist’s decision-making, 
specifically recommendations for excisional treatments over cytological follow-up, to 
interpret these findings in line with decision-making theory and to detect areas of 







As outlined in Chapter 2, this was a multi-centre qualitative study utilizing a series of focus 
groups in an English healthcare region. This is the first study designed to assess these 
outcomes and was qualitative in nature to provide depth of information. Sampling aimed 
to ensure heterogeneity of experience and healthcare provider demographics. A topic 
guide covered a range of clinical and cytological variables and was compiled following a 
review of the literature and ratified by three expert colposcopists. Using an iterative 
approach, thematic analysis was selected as the most appropriate method to identify the 
factors affecting decision-making. 
 
4.3 Results  
4.3.1 Study population 
Twenty-three of a potential twenty-eight colposcopists from four units participated in 
four focus groups. The colposcopists who declined gave conflict with their clinical 
workload as the reason for non-participation. The participants represented a range of 
years of experience, geographical training backgrounds and specialty. There were five 
nurse practitioners, four gynaecological oncologists, three lead colposcopists, seven 
gynaecology consultants, two pathologists and two gynaecology registrars. Years of 
experience in colposcopy ranged from 1 to 34 with the mean number of years 11.2. 
Fourteen participants trained in the South West England region, three in London, two in 
the West Midlands, two in the Northern region, one in the North East and one in the 
Eastern region.  
Two of the units partook in the sentinel sites study and prior to recruitment they had eight 
years of experience managing women referred with HPV triage of low grade cytology and 
three years’ experience with primary HPV testing. The remaining two units had two years’ 
experience of HPV triage of low grade cytology following the national roll-out in 2013. 
All of the transcripts were coded as outlined in Section 2.2.4 and the coding tree which 
links these codes to the themes identified is shown in Table 4.1. The themes were defined 
following in-depth consideration of potential alternative interpretations and these can be 
viewed in Figure 4.1: Mind Map of the Identified Themes and Subthemes.  
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Table 4.1: List of codes, subthemes and themes 
Codes  Subthemes Themes 
Excisional Treatment Impact of a high grade 
cytology result 
Anxiety of missing a 
cancer MDT 
Anxiety Lack of confirmatory 
histology 
 
Laboratory protocols A HPV positive status 
increases the risk of 
treatment. 
The screening test 
result 
 
False negative screening 
MDT 
Shift in pathology? Repetition of the 
referral cytology Shift in opinion? 
Improves cytology 
Side effect concerns 
Assists excision margins 
 
Factors predisposing to excision Stratifying risk factors for high 
grade disease 
Patient 
Characteristics MDT referral 
Risk of over-treatment 
Patient choice Patient choice 




Community; lab reliable Clinical setting for cytological 
follow-up 
Paucity of guidance 
engenders reliance 
on prior clinical 
experience 
Colposcopy; not lost to follow up 
Colposcopy; no diagnosis yet Oestrogen use 
Community; save resources 
Colposcopy; cytobrush use Depth of LLETZ 
Paucity of evidence 
12m: immuno-clearance Length of cytological follow-up 
lacked consensus 6m: no diagnosis 















Theme: Anxiety of 
missing a cancer 
Theme: The 
screening result 
Theme: Paucity of 
guidance 




Lack of confirmatory 
histology 
Use of oestrogen 
Patient Choice 
Risk factors            
e.g. age / parity 
Depth of LLETZ 
Prior clinical experience 




Technique Setting Length 
Theme: Patient 
Characteristics 
Figure 4.1: Focus group mind map 
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4.3.2 Theme 1: Anxiety of missing a cancer 
4.3.2.1 Lack of confirmatory histology   
In our study, irrespective of a high grade or low grade cytology result, if the TZ was not 
visible and a diagnostic biopsy not possible, most participants were deterred from 
advocating long-term cytological follow-up.  
14: ‘They’ve come to colposcopy and it’s been pointless because you’re not getting 
the information you want from that examination. Yes, there is a good chance it 
could clear up but I just feel a bit nervous about leaving them because there could 
be high grade there that you can’t see...Its knowing whether it’s there or not, 
that’s the nightmare.’ 
03: ‘With unsatisfactory (colposcopy) I have no idea of what is going on in the 
canal. I can’t see it, I can’t biopsy it. I think that the reason that many of us do a 
LLETZ in this scenario is because we, and the patients, want information that the 
examination isn’t giving us.’ 
This suggests an affective component to decision-making; fear of missing high grade 
dysplasia (CIN2+) induces a pessimistic outlook of future events if women are not offered 
a LLETZ. It appears that this is of higher importance than concerns relating to treatment 
morbidity, even in women with a low grade cytology result. 
4.3.2.2 Impact of a high grade cytology result 
In these women most participants strongly advised, with patient consent, a LLETZ 
irrespective of age or family status. Affect and cognition had a major influence on 
decision-making; anxiety of missing a cancer if treatment was not undertaken was driven 
by the plethora of evidence which reports a significant risk of the excised tissue containing 
CIN2+. When making decisions that could result in dangerous outcomes and negative 
emotions, participants made safe choices. 
02: ‘If you think of these women having a cancer, there’s a cancer that we just 
can’t see, it’s tiny, it’s inside the canal. If you repeat the cytology and you are 
giving it at least three months, then we don’t know if those three months could 
make a 1a1 into a 1a2 or even a 1b1 - who knows that? So that’s my worry, I look 
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at what’s the worst possible scenario here and with high grade cytology it’s more 
than likely that there will be high grade disease inside.’ 
 
4.3.3 Theme 2: The screening test result  
4.3.3.1 High risk HPV increases the risk of LLETZ  
Although colposcopists did not reflect on the global impact of HPV testing within 
colposcopy, they did discuss how a high risk HPV result, in conjunction with low grade 
cytology, would influence their decision-making. Sixteen colposcopists suggested a high 
risk HPV result increased the chances of underlying high grade disease. This belief 
appeared to reduce the uncertainty in their decision-making as all participants agreed that 
this perceived increase in risk, with the potential of missing a cancer, was leading them to 
advocate LLETZ in this cohort.  
22: ‘I think, in the younger ones, how long do you wait to see if the HPV is going to 
resolve? And I think that now we are using HPV testing that has upped the ante. 
So, you know that they’ve still got active HPV and the longer that stays the more 
likely they are to have an abnormality. So, I do talk to them about having a LLETZ.’ 
07: ‘I think, you know, the sensitivity has gone up and you do see high grade 
histology with low grade smears...and I would probably, in the older women, I 
would be much more pushed to do just a small LLETZ.’  
Colposcopists appear to be highly risk adverse and choose, what they view, as the least 
dangerous outcome such as treatment morbidity over the chance (even if small) of 
missing a cancer. Being ‘pushed’ into advocating a treatment suggests they would have 
preferred to manage women with low grade screening results more conservatively but 
are worried about the potential risks of doing so. Pathologists and lead colposcopists (who 
are responsible for quality assurance) suggested that colposcopists’ behaviour was 
shaped by their experience of reviewing women with high risk HPV. Rather than 
recognizing the benefits of an improved screening test, they suggested colposcopists 
believed women were at increased risk of CIN2+ and this decreased recommendations for 
long-term cytological follow-up. 
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14: ‘There is a shift in expectations and opinion rather than pathology.’ 
21: ‘What you’re doing is weeding out the women with borderline or low grade 
smears who have no pathology because they are HPV negative...a patient who has 
a mild smear with high risk HPV is at no greater risk than they were 10 years ago.’ 
 
4.3.4 Theme 3: Patient characteristics 
4.3.4.1 Stratifying risk factors for high grade CIN  
When patients present with individual characteristics known to increase the risk of cancer 
such as smoking, poor attendance, older age and / or increased parity, behavioural 
decision-making is influenced by analytical thinking. Rational judgement denoted that in 
women with low grade screening, the decision to treat was easier if women were 
stratified as high-risk - the possibility of developing a cancer outweighed the risk of 
treatment-related morbidity.  
14: ‘If she’s a heavy smoker and she’s clearly never going to give up, then that 
predisposes me towards treatment’.  
04: ‘...I think you’re going to be more likely to do a small LLETZ on someone you’re 
going to be concerned about their attendance. It’s an individual thing.’ 
01: ‘If she had had her family or was an older lady, I would do a loop (LLETZ) for 
diagnosis.’ 
4.3.4.2 A multi-disciplinary approach  
Young women who have not started their families and present with low grade cytology 
and risk-adverse behaviour (non-smoker, safe sexual behaviour) are at low-risk of high-
grade dysplasia but high risk for treatment-related morbidity. A multi-disciplinary 
approach was advocated by fourteen colposcopists in three focus groups for these 
women.  
13: ‘A young nulliparous woman I would bring to the MDT to get a consensus that 
it was the right thing to do a LLETZ, to be honest, in case they have problems in the 
future. If it was an MDT decision I’d feel happier.’ 
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This suggests participants are concerned that their affect is influencing their rational 
thinking and by sharing decision-making with an expert group they assuage this emotional 
response. The participants who advocated the MDT suggested this choice was influenced 
by the introduction of HPV screening. They indicated this had resulted in women being 
referred to colposcopy earlier, reducing the time needed to clear the infection and 
subsequently increasing the chance of over-treatment. Cognition (their knowledge of the 
natural history of HPV infection) and intuition (prior experience of reviewing women pre- 
and post-HPV screening) appears to affect behaviour. 
16: ‘We’re treating them sooner because they are coming to us sooner.’ 
14: ‘But that’s a potential disadvantage isn’t it....?’ 
16: ‘Not if there’s high grade in it.’ 
14: ‘But, we might be over-treating the women who potentially might get better.’ 
17: ‘CIN2 in a young girl has a 40% chance of regression, doesn’t it.’ 
4.3.4.3 Patient choice  
This was discussed as a major factor affecting decision-making in all of the focus groups. 
Colposcopists acceded to patient treatment wishes, even in women at high risk of 
treatment morbidity and low risk of disease, if the woman was informed of and 
understood the potential implications of their chosen management option. This suggests 
that the cognitive factors influencing colposcopist’s decision-making can be superseded 
by the patient’s affect and cognition.  
03: ‘You know, it’s a discussion with the patient explaining the pros and cons’. 
17: ‘I had a woman the other day, actually, who wanted a LLETZ. Her mum died of 
cervical cancer, she actually had a low grade smear, but she said ‘just cut it away’. 
I was like ‘but you’re 25, let’s just do a couple of smears’ and she said ‘just cut it 
away’. So I spoke to the consultant on call and they said ‘do what the patient 
wishes’.’ 
None of the participants mentioned scenarios in which women had declined treatment 
and the subsequent impact of this choice. 
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4.3.5 Theme 4: Sparse guidance engenders reliance on experience 
4.3.5.1 Clinical setting for cytological follow-up 
In women with low grade screening results who were deemed suitable for cytological 
follow-up, there was a lack of consensus regarding where to review them. Eight 
participants (including four of the five nurse colposcopists) advocated GP follow-up. 
09: ‘If they’ve got abnormalities already on the current smear, there’s no good 
reason why you should have to bring them back to colposcopy. If it was a low 
grade smear I would probably send her back to her GP because we’ve got direct 
referral to colposcopy and we all use the same lab.’ 
This suggests trust in the reliability of the laboratory and a belief that outcomes will be 
the same regardless of where the cytology is taken as the technique is standardized. 
Conversely, fifteen colposcopists, who were all doctors, differed in this opinion; 
12: ‘I hear what you’re saying about having a good reliable lab but patients aren’t 
often very reliable and so I’d like to know that she’s been followed up and make 
efforts to do so.’ 
07: ‘We haven’t made the diagnosis yet, she still sort of belongs to us. We can’t 
discharge her to the community without working out whether there is something 
to get concerned about or not.’ 
The doctors suggested they had a responsibility to ensure a decision / diagnosis was made 
and a cancer not missed by personally reviewing these women. Doctors tend to review 
more complex cases and the adverse outcomes of missed diagnoses. This may have 
influenced their management choice. It appears that emotion can be more influential that 
cognitive elements when the risk of cancer is factored into decision-making. The role of 
emotion and responsibility were strengthened by the paucity of guidance surrounding the 
optimal technique of smear taking in women with a TZ3. 
17: ‘They don’t do endocervical smears (with the GP) so how can you specify that? 
You see I would do a cytobrush and broom. With a type 3 transformation zone 
you’re more likely to get a better specimen with a brush and broom, aren’t you?’ 
14: ‘I agree with you, but has anyone proven that.’ 
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17: ‘No, not that I know of.’ 
It appears that in conditions of clinical uncertainty, intuitive decision-making - affect, 
perception, rational judgement and prior experience – aids colposcopists in their 
assessment of risk. 
4.3.5.2 Length of cytological follow-up  
For those women whom participants recommended cytological follow-up, rather than 
LLETZ, there was a discrepancy in the number of months advocated before repeating the 
cytology. Thirteen colposcopists suggested six months and if at this time any grade of 
dyskaryosis was reported, and a TZ3 was still present, they would recommend a LLETZ.  
16: ‘I would prefer to see them in 6 months. They’ve come to colposcopy and it’s 
been pointless because you’re not getting the information you want from that 
examination. Yes, there is a good chance it could clear up but I just feel a bit 
nervous about leaving them because there could be high grade there that you 
can’t see.’ 
03: ‘...I do think it’s kind of two strikes and you’re out, the referral cytology and a 6 
month follow up, because they clearly still have got continuing HPV.’ 
01: ‘I can’t see what’s going on, so I think if there is still an abnormality on the 
referral back in, the 6 month follow-up smear, I would rather know what was 
going on in the canal…..do a LLETZ, because of anxiety and we are not getting to 
the bottom of it.’ 
Anxiety about missing high grade disease, compounded by the perceived risk that 
persistent HPV confers, deterred long-term follow-up even in women with low grade 
screening. Conversely, six colposcopists discussed individualizing care based on patient 
risk factors. If women were young and/or nulliparous with low risk factors, participants 
recommended 12 month cytological follow-up.  
09: ‘The 12 month repeat allows the immune system to battle HPV, as studies 
showed there is a greater clearance at 12 months rather than 6 months.’ 
Chapter 4 
93 
14: ‘The debate we’re having here is whether 6 months or 12 months is better and 
the issue or question is whether this lady might have a high grade dysplasia 
underlying. The likelihood of that becoming a malignancy in the 6-12 month phase 
is (pause) in the order of a fraction of a percent.’ 
This suggests a combination of cognitive and intuitive decision-making based on prior 
experience, perception of risk and knowledge. 
4.3.5.3 Repetition of the referral cytology 
Two of the colposcopists who could not attend the focus groups provided the researchers 
with a scenario they considered an area of clinical uncertainty; due to the topographic 
position of the TZ, would colposcopists repeat the referral cytology at the first colposcopy 
appointment? The majority of the colposcopists adhered to national guidance and did not 
repeat the cytology. However, some participants suggested they had concerns that the 
referral cytology collection device may not have adequately sampled the TZ due to its 
endocervical position. 
01: ‘I think if we speak to any cytologist they’ll always say you should not repeat 
the smear within 8 weeks because you’ve already sampled it and you’ve already 
taken off the epithelium and then you really need to wait for it to re-grow or 
you’re going to get a false positive / false negative and you’re going to be back to 
square one.’ 
16: ‘I would wait three months. I know not everybody does.’ 
17: ‘If it was a poor sample with a TZ3 then I would re-smear.’ 
4.3.5.4 Oestrogen use is based on prior experience 
The use of oestrogen has been discussed in the literature as a potential pharmacological 
method which can convert a TZ3 to a TZ1. Colposcopist’s discussed their 
recommendations for its use which appeared to be linked to prior experience.  
12: ‘The thing with oestrogen is you’re never too sure about the compliance prior 
to it and whether that makes a difference.’ 
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01: ‘If she has an atrophic cervix I would ask her, definitely, to have two weeks of 
oestrogen before her next cytology...not so much because you’re going to pull out 
the transformation zone but, it can help the interpretation of the cytology. Also for 
her comfort...’ 
Despite the evidence suggesting the potential benefits of oestrogen use, most 
participants felt, in practice, it did little to improve the examination findings. The majority 
of gynaecological oncologists did not advocate use but eleven participants, including all 
of the nurse colposcopists, used oestrogen to improve the smear quality and to reduce 
discomfort during the examination. Gynaecological oncologists manage women with 
oestrogen driven cancers and this may have affected their decision-making, particularly 
as they reported no real improvement in examination adequacy; the harm of oestrogen 
use may have outweighed the benefit in their minds.  
Three of the four units used topical preparations and the reasons identified were the side 
effect profile and poorer efficacy of systemic hormone replacement therapy. As was seen 
in theme one, negative emotions led participants to make, what they considered to be, 
the safer management options. 
06: ‘Well I guess topical oestrogens are less harmful than actually giving HRT...and 
it works.’ 
18: ‘Because 30% of women with genitourinary atrophy don’t respond to systemic 
HRT.’ 
4.3.5.5 Depth of LLETZ  
Decision-making in this area was driven by prior experience, perceived individual risk and 
affect.  
14: ‘Greater than 7 less than 10mm, to reduce the risk of cervical dysfunction in 
pregnancy.’ 
07: ‘There’s a chance there’s absolutely nothing wrong with her cervix and you’re 
chucking out a big bit of tissue and if you do really have something wrong with the 
cervix there’s the option of doing a second LLETZ if you’re really concerned.’ 
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02: ‘I think the biggest problem is that because you can’t see the TZ you don’t 
know how far to go...If you do a deeper loop and it is negative that is much easier 
to criticize than if you do a smaller loop and then if it is positive, you do another 
one because that is much more targeted.’ 
As seen in Theme 1 and with systemic oestrogen use, colposcopists make safe choices. 
Women at high-risk of treatment-related morbidity engender negative emotions which 
prompted participants to make autonomous choices and deviate from UK national 
recommendations for optimal depth (15-25mm)[35]. In older women, who are at reduced 
risk of treatment morbidity and increased risk of high grade disease, colposcopists adhere 
to national guidance. These data suggest cognition and rational judgement have a greater 
impact than affect in this patient demographic. 
13: ‘In an older woman I probably would go a bit deeper because they’re more 
likely to have an adenocarcinoma than squames.’ 
04: ‘The older women, 15mm, what you want to avoid, if possible, is the 
inconvenience of bringing them back for a repeat LLETZ and risking non-
attendance.’ 
Conditions of clinical uncertainty can cause anxiety in both health care providers and 
patients. The use of rational judgement and a colposcopist’s experience appear to aid in 
decision-making but affect also plays a strong (and sometimes more dominant) role when 
evaluating risk. The following quote most accurately reflected the overall findings of this 
study; 
03: ‘I think it’s interesting. I think what we’re all talking about is individualization 
of care . . . All you’re trying to do is be safe to gain or achieve the information that 
you need and it does need to be individualized. And I think in our day to day 







Focus groups, rather than interviews or questionnaires, were chosen as the method of 
study as numerous viewpoints on a specific issue can be studied in an interactive setting. 
In my study, comments made by individual participants stimulated group discussions, 
decreasing the interaction of the facilitator (me) and reducing researcher bias. Moreover, 
they provide richer data than a questionnaire by expanding upon the decision-making 
process and enabling targeted suggestions for guidance - which was the key component 
of interest in this study.  
A heterogenous group ensured differing opinions were shared leading to lively debates in 
some of the units. Sensitization, with the possibility of pre-set answers which may reduce 
analytical thinking during the focus groups, was reduced by the provision of a general 
theme in the participant information sheet rather than set questions. Further strengths 
included the use of open ended questions, an extensive coding process and an iterative 
analysis which helped ensure saturation and depth of information was attained. 
Transcribing the audio files grounded me in the data and improved my interpretation of 
these transcripts (as suggested by Braun and Clarke)[207]. None of the participants 
withdrew their data and the respondents verified the validity of the transcripts. Double 
coding of the transcripts and a self-awareness of my own preconceptions by including 




Assessing practice in one geographical region may increase the institutional bias but the 
inclusion of four centres with varying patient populations and participants who trained in 
six of the 12 English regions should improve the generalizability of the data. Moreover, 
there was no difference in opinion based on training location.  
It is important to consider why participants agreed to take part; it could be argued that 
attendees did so to express a particular viewpoint and the data may not resonate with 
national opinions. However, only four of twenty eight colposcopists did not participate 
and this was due to conflicting clinical commitments and involvement with the topic 
guide. Furthermore, two of these gave written statements for clinical scenarios that they 
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wished to be discussed. Although these statements were not used in the analysis, they 
stimulated discussions on the optimal cytological collection device and the risks and 
benefits of repeating the referral cytology at the first colposcopy appointment.   
Age and gender were not collected for confidentiality reasons but gender, as discussed in 
2.3.1.1, can influence clinical decision-making. Assessing this association would be useful 
for guideline implementation and will be explored in Chapter 6. 
 
4.6 Conclusions 
In this study, anxiety of missing a cancer deterred long-term cytological follow-up, 
resulting in higher than anticipated excisional treatments in women with low grade 
screening and a TZ3. Moreover, when a LLETZ was offered, colposcopists undertook 
shallower excisions than nationally recommended as a result of treatment morbidity 
concerns. In areas of clinical uncertainty, when decisions are dominated by affect, clinical 
guidance and targeted evidence can reduce the difficulty and anxiety of decision-making. 
In Chapters 5 and 6, through the use of a national survey that was based on the themes 




 Development of a questionnaire for evaluating 
management of a TZ3 
 
5.1 Introduction 
Management of a TZ3, as identified in chapter 4, is an area of clinical uncertainty. Yet 
these patients account for 20% of the women reviewed in colposcopy annually. This area 
has been poorly researched with no studies to date assessing national consensus for 
management.  Studies which investigate current management of a TZ3 may help to 
stimulate research in areas of discordance and provide guidance in areas of consensus. 
Direct assessment of clinical care through first-hand observation would require extensive 
resources, can be observer subjective and patient specific. Indirect measurement can 
occur through the use of qualitative studies (chapter 4) or questionnaires (chapter 6). 
There are currently no validated tools for the assessment of TZ3 management and, as 
discussed in section 2.3, the use of items which are designed for different domains than 
those intended will reduce the validity and reliability of the questionnaire. 
The aim of this chapter is to describe the development of a questionnaire that assesses 
UK colposcopists’ decision making when applied to the management of women with a 
TZ type 3. 
 
5.2 Methodology 
As outlined in Chapter 2, a questionnaire was developed based on a conceptual 
framework, literature review, contributions from the focus groups and a Delphi consensus 
consisting of eight experts in the field. The psychometric properties were assessed:  
(i) Content, face and construct validity through cognitive interviews with 12 colpocopists 
and an expert committee evaluation.  
(ii) Test-retest reliability was estimated using 20 colposcopists who completed the 





5.3.1.1 Content Validity 
Following the development of the items (section 2.3.1), the BSCCP committee reviewed 
the first version of the online questionnaire and made the following suggestions: 
1. ‘Change all questions that ask the participant to rank their options to a Likert 
scale as ranking can become a guessing game or a click a box exercise, is 
onerous to complete, may reduce response rates and gives a clustered layout. 
The board can understand the reasoning behind a ranking approach but 
consider a Likert scale instead’.  
2. ‘Rather than using a drop down box for binary responses, use circles that 
people can click. The less clicks, the more likely people are to complete it. In 
general people are more willing to complete surveys if they can see the 
answers in front of them and click one box. If they have to make choices it is 
usually the ‘quick’ choices that increase completion of the survey. The options 
for the answers are good though’.  
3. ‘Please add associate specialist to the demographic list’. 
4. ‘One of the management options is to repeat the cervical cytology. The role 
of the BSCCP audit programme is to assess current practice against national 
standards. There is a national standard in regard to not repeating a cervical 
screening sample at colposcopy. We see no evidence that this should be 
challenged on the current peer reviewed evidence base. If you wish to ask 
about the role of repeating cytology in this situation, then please ask why a 
colposcopist would want to repeat the cytology and ask how a repeat test 
would change their practice’. 
 
Multi-nominal and discrete response items had originally been included to reduce 
ambiguity when analyzing management choices and to improve the reliability. 
Ranking of item stems can increase the depth of information provided but can also 
decrease the reliability of the item[179, 180]; increasing the number of variables can 
reduce response rates. Five point Likert scale response anchors were researched[208] 
and scales which assessed levels of importance ‘not at all important, low importance’ 




The outcome from the focus groups and the Delphi consensus identified that 
colposcopists may not adhere to national guidance which recommends that cervical 
cytology should not be repeated within 3 months of the referral cytology. I was 
interested in clarifying whether this was a regional or national perspective as it may 
be a specific educational point that needs addressing in this cohort. To incorporate 
the BSCCP stipulations the survey was amended to include two additional discrete 
response items which asked respondents if and why they may want to repeat the 
cytology and how the outcome of this test would affect their management. The 
second version of the questionnaire now consisted of 15 items with a maximum of 
three items testing the same domain (Table 5.1). 
 
Table 5.1: The domains and items for the second version of the questionnaire 
DOMAIN Corresponding Items Item no  
Initial management of low 
grade cytology and a TZ3 
Practice: 1 multi-nominal  1 
Attitude: 1 ordinal scales 2 
Non-routine measures to 
improve the adequacy of 
the examination 
Practice: 1 discrete response 3 
Use of oestrogen Attitude: 1 discrete response 4 
Conservative follow-up for 
low grade cytology 
Practice: 1 multi-nominal 5 
Depth of LLETZ in women 
with low grade cytology 
and a TZ3 
Practice: 1 discrete response 
Knowledge & Attitude: 1 multi-nominal 
6 
7 
Initial management of 
high grade cytology and a 
TZ3 
Practice: 1 multi-nominal 8 
Depth of LLETZ in women 
with high grade cytology 
and a TZ3 
Practice: 1 discrete response 
Knowledge & Attitude: 1 multi-nominal 
9 
10 
Repeating the referral 
cytology 
Practice & Knowledge: 1 discrete response 





Job title & gender: 2 discrete responses 
Years of experience: 1 continuous scale 





5.3.1.2 Face validity 
Response rates for the qualitative interviews were excellent (100%, n=12). The socio-
demographic characteristics can be viewed in Table 5.2; colposcopists from four units 
participated of whom four were male and eight female. Two nurse colposcopists, three 
gynaecological oncologists, two O&G registrars and five gynaecology consultants 
participated. The mean years of experience was 11.8 (range 2 - 30). English was the first 
language for 83.3% (n=10).  
Table 5.3 describes the completed and missing items from the participants who were 
interviewed for face validity (the raw data of which can be viewed in Appendix 5, Table 
S5.1). Eleven participants (91.6%) completed all of the stems within the items. One 
respondent did not complete their gender nor one stem from the item assessing reasons 
for choice of LLETZ depth. When asked for reasons for non-completion the participant 
reported this was unintentional, supporting use of electronic software which requires 
respondents to complete all items. 
Table 5.2:  Sociodemographic information for cognitive interview participants 





1 1 Oncologist M 15 N 
2 1 Nurse F 7 Y 
3 1 Registrar F 2 Y 
4 1 Gynaecologist F 4 Y 
5 1 Gynaecologist M 30 Y 
6 2 Nurse F 4 Y 
7 2 Registrar F 2 Y 
8 2 Oncologist M 30 Y 
9 3 Gynaecologist F 8 N 
10 3 Gynaecologist F 4 Y 
11 4 Oncologist M 20 Y 
12 4 Gynaecologist F 15 Y 
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Table 5.3: Missing item data from the cognitive interview participants 
Item 
Number 






1 Low grade cytology management 
- 25-39 year old, nulliparous 
- 25-39 year old, parous 
- >40, family incomplete 











2* Why follow-up in colposcopy? 
- To use a cytobrush 
- To prevent loss to follow-up 
- To perform a colposcopy 











3 Possible adjuncts 12 0 
4 Use of oestrogen 12 0 
5 Total months follow-up before LLETZ 
- 25-39 year old, nulliparous 
- 25-39 year old, parous 
- >40, family incomplete 











6 LLETZ depth for low grade cytology 
- 25-39 year old, nulliparous 
- 25-39 year old, parous 
- >40, family incomplete 











7 Reasons for depth in Q6 
- 25-39 year old, nulliparous 
- 25-39 year old, parous 
- >40, family incomplete 











8 High grade cytology management 
- 25-39 year old, nulliparous 









- >40, family incomplete 





9 LLETZ depth for high grade cytology 
- 25-39 year old, nulliparous 
- 25-39 year old, parous 
- >40, family incomplete 











10 Reasons for depth in Q9 
- 25-39 year old, nulliparous 
- 25-39 year old, parous 
- >40, family incomplete 











11 Repeat the cytology? 12 0 
12* Reasons for repeat in Q11 1 0 
13 Demographics 
- Job title 













Responses were assessed for floor or ceiling effects (Table 5.4). Item 4 was excluded from 
the analysis as it consisted of three discrete responses and the odds that more that 50% 
of participants would choose the lowest or highest value was greater than chance. Items 
9 and 11 were excluded from the analysis as these evaluated colposcopists’ adherence to 
national guidance; I would expect >90% of participants to choose a floor or ceiling answer. 
Item 8 does not relate to national guidance but it is expected that most colposcopists 
would offer a LLETZ to a woman who presents with high grade cytology and a TZ3. Of the 
included items, a floor or ceiling effect was not observed so no items were removed. 
 
Table 5.4: Floor to ceiling effect 
Item Responses(a) Lowest values Highest values 
1 – Low grade management 48 2 (4.2%) 0 
2(b) - Why follow-up in colposcopy 20 2 (10%) 9 (45%) 
3 – Possible adjuncts 12 1 (8.3%) 0 
4 – Use of oestrogen 12 8 (66.7%) 2 (16.7%) 
5 – Total follow-up before LLETZ 48 20 (41.6%) 4 (8.3%) 
6 – LLETZ depth for low grade 48 0 2 (4.2%) 
7 – Reasons for depth in Q6 48 11 (22.9%) 0 
8 – High grade management 48 42 (95.5%) 0 
9 – LLETZ depth for high grade 48 0 22 (50%) 
10 – Reasons for depth in Q9 48 2 (4.7%) 0 
11 – Repeat the cytology? 12 11 (91.7%) 0 
12(b) - Reasons for repeat in Q11 1 0 0 
(a)Total responses for the stems within an item  (b) Gated Responses 
 
 
All participants asked for the term ‘diagnostic LLETZ’ to be changed to ‘a standard LLETZ 
of 7-10mm’. Seven Colposcopists suggested ‘3 months cytological follow-up should be 
added to the management options for women reviewed with high grade cytology and a 
TZ3’. Two participants felt the item discussing cytological follow-up was not 
omnicompetent as it should include ‘never’. One participant suggested that the question 
evaluating management of women with high grade cytology should come first; 
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ID 10: ‘Whilst completing the questionnaire I felt that what initially had been 
routine management decisions were becoming daunting and problematic. I 
felt that this then influenced how I completed Q9 (Management of high grade 
cytology and a TZ3) which I had always felt was a straight forward decision 
to treat’. 
All other participants felt the order was correct so this was not changed. One participant 
suggested ‘years of experience’ should be changed from a continuous to an ordinal scale 
in line with the 10K hour rule which links competence to hours of training. When changing 
a questionnaire based on the opinion of one participant, consideration must be given to 
how this advice may resonate with the rest of the cohort. On review of the literature I felt 
a trend may be more accurately pinpointed if categories with a limited number of 
variables were provided; the scale was subsequently revised in line with this 
recommendation. The amended questionnaire was sent to respondents for evaluation 
and no new comments were provided. 
5.3.1.3 Construct validity 
Of the twelve participants, 11 (91.7%) adhered to national guidelines[35] and did not repeat 
the cervical cytology at the first colposcopic assessment (p=0.99) and 100% chose ≥15mm 
depth of LLETZ when the family was complete. The items were not adjusted after 
assessment of this psychometric component. 
 
5.3.2 Test-retest reliability 
Twenty participants were recruited and completed 100% of the items. None of the 
participants felt their practice had changed in the two weeks between questionnaires. 
Table 5.5 outlines the socio-demographic characteristics of the respondents; 30% were 
male and 70% female, English was the first language for 85% and 11 were gynaecologists, 
four were oncologists, four were nurses and one was a registrar. The mean years of 







Table 5.5: Socio-demographics of the test-retest reliability participants 
 





1 Gynaecologist F 8 Y 
2 Oncologist M 30 Y 
3 Nurse F 8 Y 
4 Nurse F 5 Y 
5 Gynaecologist F 7 Y 
6 Registrar F 4 Y 
7 Gynaecologist M 36 N 
8 Oncologist M 14 Y 
9 Gynaecologist F 32 Y 
10 Oncologist F 16 Y 
11 Gynaecologist F 3 Y 
12 Gynaecologist F 14 N 
13 Gynaecologist F 5 Y 
14 Nurse F 2 Y 
15 Gynaecologist M 17 Y 
16 Oncologist M 26 Y 
17 Nurse F 6 N 
18 Gynaecologist M 23 Y 
19 Gynaecologist F 18 Y 
20 Gynaecologist F 12 Y 
 
Cross tabulations were produced to calculate the crude agreement; instability was 
observed in only 3 of 39 variables. Table 5.6 presents the crude agreement and kappa 
values for the test-retest questionnaires; perfect agreement was observed in eight items 
- Questions 1, 3, 4, 5, 6, 8, 9, 10 and 11. Agreement was very good, with kappa >0.84, for 
question 2. For some of the stems in questions 8 & 9 all respondents chose the same 
variable preventing the calculation of a kappa value but this strong consensus of opinion 
gives a stability of 100%. In question 7, kappa values were >0.90 for all responses.  
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Table 5.6: Kappa values for the test-retest reliability 




Q1 Initial management for low-grade cytology 
 1a (25-39 yo, nullips) 
 1b (25-39 yo, family incomplete) 
 1c (>40 yo, family incomplete) 





















Q2 Reasons for colposcopy follow-up 
 1a (25-39 yo, nullips) 
 1b (25-39 yo, family incomplete) 
 1c (>40 yo, family incomplete) 





















Q3 Alternative methods of diagnosis 20 100% 1.0 <0.001 
Q4 Reasons for use of oestrogen 20 100% 1.0 <0.001 
Q5 Length of cytology follow-up 
 1a (25-39 yo, nullips) 
 1b (25-39 yo, family incomplete) 
 1c (>40 yo, family incomplete) 





















Q6 Depth of LLETZ for low grade cytology 
 1a (25-39 yo, nullips) 
 1b (25-39 yo, family incomplete) 
 1c (>40 yo, family incomplete) 





















Q7 Reasons for depth chosen in Q6 

























































































































Q8 Initial management for high-grade cytology 
 1a (25-39 yo, nullips) 
 1b (25-39 yo, family incomplete) 
 1c (>40 yo, family incomplete) 

















Q9 Depth of LLETZ for high grade cytology 
 1a (25-39 yo, nullips) 
 1b (25-39 yo, family incomplete) 
 1c (>40 yo, family incomplete) 

















Q10 Reasons for depth in Q10 








































































































Q11 Repeating the referral cytology 20 100% 1.0 <0.001 




The extensive psychometric evaluation of the questionnaire helped ensure it was 
interpreted as intended and covered all the domains of interest. The sample size for the 
cognitive interviews was large enough to ensure a diverse range of views and to provide 
valuable information on which to evaluate and improve the content and face validity. 
Likewise, the reliability study was sufficiently large enough to give a precise estimate for 
this aspect of the questionnaire. Although the cognitive interviews were conducted in one 
English healthcare region, the BSCCP committee consists of members from across the UK 
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which will improve the generalizability of the questionnaire. Finally, the questionnaire 
performed well across genders, years of experience and job title.  
 
5.5 Limitations 
To reduce ambiguity and improve the likelihood of a consensus opinion, items which 
tested the same construct were multi-nominal or discrete responses rather than ordinal. 
The limitation of these designs, are the inability to assess internal consistency which can 
affect the reliability of the questionnaire. However, the kappa values for the items which 
were evaluated for test-retest reliability were all >0.90 (very good). There were 
unfortunately two items which could not be measured – gated questions (items 2 and 12 
in Table 5.3) – so although the test-retest sample size calculation was achieved, the power 
was limited as only five and one participants respectively answered these gated questions.  
Evaluation of self-perceived practice is easier when the domains of investigation have 
clear guidance but can be more problematic in areas of clinical uncertainty, reliability 
could be reduced if there is no ‘correct’ answer, but this was the focus of the study and 
as such the questionnaire was designed to evaluate this.  
Some of the items are labour intensive and this may reduce response rates. However, in 
comparison to many validated questionnaires it is relatively brief and designed to be 
completed in only 15 minutes. 
 
5.6 Conclusions 
The third, and final, version of the questionnaire can be viewed in Appendix 5 (Figure 
S5.1). The data from this chapter suggests the final questionnaire is a suitable measure of 
the management of women with cytological abnormalities and a TZ3. It will enable the 
evaluation of colposcopist’s practice in Chapter 6, facilitating the identification of a 




 Current practices in the management of a TZ3: 
Results of a UK survey 
 
6.1 Introduction 
Colposcopists lead research and policy change in cervical screening and pathology. Their 
attitudes and knowledge are likely to have a significant effect on national 
recommendations and guideline implementation in a clinical setting. The outcomes from 
the focus groups in chapter 4[101] identified that management of a TZ3 is an area of clinical 
uncertainty due to the lack of clear evidence and guidance. Anxiety was the primary factor 
affecting decision-making and led to heterogeneity in decisions relating to length, clinical 
setting and technique of cytological follow-up.  
Service inefficiencies and poor access to condition specific information can lead to patient 
anxiety and failure to attend follow-up appointments[77, 102, 103, 209, 210]. With non-
attendance rates for follow-up Colposcopy documented at 11.2% in the UK[3], 
homogeneity of service provision needs to be improved. The development of evidence 
based guidelines would optimize outcomes by minimizing the unreliability of intuitive 
management. The aims of this study were to: 
(i) evaluate UK colposcopists’ decision-making when applied to the management of 
women with a TZ3  
(ii) identify areas of concordance to inform a national consensus opinion. 
 
6.2 Methodology 
This was a cross-sectional design. All UK colposcopists (1200) were invited to complete an 
online questionnaire. Two invitations were sent one week apart. The questionnaire was 
developed following a literature review and evaluation by an expert body; this consisted 
of colposcopists who are leaders in research and policy making in this area. The final 
questionnaire contained 15 items which covered a range of clinical and cytological 
variables, oestrogen use, techniques to improve diagnostic yield, cytological follow-up 






Of the 1200 emailed colposcopists, 205 participated providing a 17.1% response rate. 
Participant demographics are presented in Table 6.1 and Appendix 6, Tables S6.1 & S6.2. 
Of the 200 respondents who provided demographic information, 133 (65.2%) 
respondents had more than 11 years of experience. General gynaecologists made up half 
of the participants and there were 27% more female than male respondents. This 
distribution was similar to that seen in the focus groups. 
 
Table 6.1: Participant demographics 





































6.3.2 Initial management of low grade cytology 
For this item, complete datasets were available for 203/205 respondents (Table 6.2). The 
most frequent initial management choice, irrespective of the patient’s age or parity, was 
cytological follow-up (mean 148 (72.9%), range 112 - 171). When compared to 25 - 39 
year olds there was a greater preference for LLETZ in women older than 40 (diff 8.8%, 95% 
CI 5.3 - 16.1%, p<0.001) and in women of any age who had completed their family (diff 
21.7%, 95% CI 18.4 - 33.5%, p<0.001).  
When adjusted for years of experience and compared to gynaecological consultants, who 
were the largest proportion of respondents, there was no evidence of an association 
between colposcopist’s demographics and choice of initial management (Table 6.3). 
Indeed, for patients aged 25 - 39 years old, when comparing management choices of 
gynaecological oncologists and associate specialists to gynaecology consultants, the odds 
ratio could not be calculated as all respondents chose cytological follow-up. These data 
and free-text comments suggest colposcopists perceive increasing age to be a risk factor 
for high grade CIN; 
ID 133: ‘I would not perform a LLETZ in a 25 year old, even if family complete, 
as low grade changes are likely to go back to normal. Over 40 I would perform 
a LLETZ whatever the fertility wishes’  
ID 135: ‘I would manage LSIL/HPV+ conservatively and review colposcopy in 
6 - 12 months, becoming less conservative with increasing age and 
persistence of abnormality.....’ 
 
Referral to the MDT was recommended by an average of 11.9% of respondents with no 
evidence of a difference in this choice between patient demographics (p=0.16). Free-text 
comments suggest colposcopists are concerned about missing high grade disease but also 
about the treatment-related morbidity; 
ID 202: ‘I would like to do a LLETZ because the colp is unsatisfactory but not 
wanting to risk obstetric complications I would want to discuss with 
colleagues.’  
ID 123: ‘Discuss at MDT to confirm low grade changes and to ascertain that 
endocervical cells are present i.e. TZ is sampled’.  
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N; % (95% CI) 
25-39, family 
incomplete 
N; % (95% CI) 
≥40, family 
incomplete 
N; % (95% CI) 
Family  complete, 
any age 
N; % (95% CI) 
LLETZ 
3; 1.5 
(0 – 9%) 
4; 1.9 
(0 – 9%) 
21; 10.3 
(3.2 – 17.4%) 
24; 23.2 




(31.4 - 45.6%) 
84; 41.4 
(34.3 - 48.5%) 
69; 34 
(26.9 – 41.1%) 
46; 22.6 




(16.8 – 31%) 
46; 22.7 
(15.6 - 29.8%) 
34; 16.7 
(9.6 – 23.8%) 
34; 16.7 




(2.7 - 24%) 
19; 9.4 
(2.3 – 16.5%) 
15; 7.4 
(0 – 14.5%) 
14; 6.9 




(4.1 - 18.3%) 
21; 10.3 
(3.2 – 17.4%) 
21; 10.3 
(3.2 – 17.4%) 
18; 8.9 
(1.8 – 16%) 
MDT 20; 9.8 
(2.7 - 16.9%) 
19; 9.4 
(2.3 – 16.5%) 
32; 15.8 
(8.7 – 22.9%) 
26; 12.8 
(5.7 – 19.9%) 
Other 9; 4.4 
(0 - 11%) 
10; 4.9 
(0 – 12%) 
11; 5.4 
(0 – 12.5%) 
18; 8.9 
(1.8 – 16%) 





Table 6.3: Association of management for low grade cytology and TZ3 with respondent demographics when adjusted for experience, job title and gender 
 25-39 nulliparous(a) 
OR (95% CI), p value 
25-39 family incomplete(b) 
OR (95% CI), p value 
≥40 family incomplete(c) 
OR (95% CI), p value 
Family complete(d) 
OR (95% CI), p value 













2.04 (0.17 – 25.1), 0.57 
2.92 (0.25 - 34.3), 0.39 
 
Ref 
2.92 (0.84 - 10.0), 0.90 
0.99 (0.24 - 4.09), 0.99 
1.18 (0.24 – 5.99), 0.84 
 
Ref 
1.26 (0.46 - 3.42), 0.65 
0.56 (0.17 – 1.84), 0.34 
0.44 (0.90 – 2.17), 0.90 
LLETZ vs cytological follow-up 
0 - 10 years(f) 
≥ 11 years 
 
Ref 
1.04 (0.92 – 11.7), 0.97 
 
Ref 
1.57 (0.16 – 15.4), 0.7 
 
Ref 
0.87 (0.34 - 2.24), 0.77 
 
Ref 
1.64 (0.78 - 3.46), 0.19 
LLETZ vs cytology follow-up(g)    Male 
                                                      Female 
Ref 
0.26 (0.02 - 3.20), 0.3 
Ref 
1.01 (0.09 - 10.9), 0.99 
Ref 
0.62 (0.23 – 1.73), 0.36 
Ref 
1.53 (0.69 – 3.36), 0.29 







0.67, CI 0.25-1.82, p=0.43 
OR 1.60, CI 0.67-3.85, p=0.29 
OR 2.07, CI 0.73-5.93, p=0.17 
 
Ref 
OR 0.72, CI 0.27-1.97, p=0.53 
OR 1.96, CI 0.81-4.77, p=0.14 
OR 2.11, CI 0.72-6.19, p=0.17 
 
Ref 
OR 0.97, CI 0.31-3.04, p=0.96 
OR 1.86, CI 0.69-4.99, p=0.22 
OR 1.21, CI 0.38-3.83, p=0.75 
 
Ref 
OR 0.59, CI 0.17-2.04, p=0.40 
OR 1.66, CI 0.57-4.85, p=0.35 
OR 1.07, CI 0.28-4.12, p=0.92 
6 vs 12 month follow-up 
0 - 10 yearsg 
≥ 11 years 
 
Ref 
1.06 (0.56 - 2.02), 0.85 
 
Ref 
1.39 (0.72 - 2.69), 0.32 
 
Ref 
1.53 (0.74 - 3.17), 0.25 
 
Ref 
1.68 (0.78 - 3.64), 0.16 
6 vs 12 month follow-up(g)        Male 
                                                      Female 
Ref 
1.28 (0.65 – 2.49), 0.47 
Ref 
1.64 (0.83 – 3.26), 0.16 
Ref 
1.69 (0.79 - 3.59), 0.17 
Ref 
2.18 (0.94 – 5.05), 0.07 







0.66 (0.23 – 1.95), 0.46 
0.75 (0.28 – 2.02), 0.57 
1.26 (0.33 – 4.84), 0.57 
 
Ref 
0.56 (0.19 – 1.71), 0.32 
0.81 (0.29 – 2.26), 0.69 
1.04 (0.27 – 4.04), 0.96 
 
Ref 
0.43 (0.13 – 1.49), 0.19 
0.49 (0.17 – 1.43), 0.19 
0.89 (0.22 – 3.62), 0.88 
 
Ref 
0.67 (0.18 – 2.55), 0.56 
0.45 (0.15 – 1.39), 0.17 
0.69 (0.16 – 3.04), 0.63 
Colposcopy or GP follow-up 
0 - 10 years(f) 
≥ 11 years 
 
Ref 
1.86 (0.92 – 3.85), 0.08 
 
Ref 
1.93, (0.93 – 4.01), 0.08 
 
Ref 
2.05 (0.94 – 4.46), 0.07 
 
Ref 
1.29 (0.56 – 2.97), 0.54 
Colposcopy or GP follow-up       Male 
                                                      Female 
Ref 
1.22 (0.51 – 2.95), 0.66 
Ref 
1.34 (0.53 – 3.38), 0.53 
Ref 
1.68 (0.61 – 4.64), 0.31 
Ref 
1.43 (0.48 – 4.21), 0.52 
(a): 3/170 selected a LLETZ  (b): 4/170 selected a LLETZ (c): 19/156 selected a LLETZ (d): 43/155 selected a LLETZ      (e): All respondents chose cytological follow-up preventing estimation of an odds ratio i.e. 









6.3.3 Cytological follow-up for low grade cytology 
6.3.3.1 Frequency of follow-up and clinical setting 
Table 6.2 describes colposcopists’ management choices for women with low grade 
cytology by age and family situation. There was a preference for follow-up to be 6 rather 
than 12 monthly (58.1% vs 42.1%; diff 16%, 95% CI 11 – 22.5%, p<0.001) and a strong 
preference for this to occur in the colposcopy clinic rather than the community (76.4% vs 
25.8%; diff 50.6%, 95% CI 43.7 – 53.9%, p<0.001). Table 6.3 shows the association 
between these management choices and a range of respondent demographics, of which 
there was no evidence of an association.  
The importance of the factors which influenced a colposcopist’s decision to recommend 
colposcopy clinic follow-up, rather than primary care, were assessed (Figure 6.1). 
‘Extremely important’ factors were evaluated; the odds of colposcopists recommending 
follow-up in colposcopy to use a cytobrush and Cervex-Brush (broom and brush) was 
twice the odds of colposcopists offering this clinical setting to perform a colposcopy (n=72 
vs 46; OR 2.15, 95% CI 1.29 – 3.57, p=0.003). In comparison to offering colposcopy clinic 
follow-up to reduce loss to follow-up (n=64), colposcopists were slightly more likely to 
offer colposcopy clinic follow-up to use a broom and brush (OR 1.24, 95% CI 1.02 – 2.85, 
p=0.05). There was no evidence of an association between the factor affecting this 
decision-making and years of experience or gender but nurses, when compared to 
gynaecology consultants, were three times more likely to request colposcopy follow-up 
to use the colposcope (Table 6.4). 
Free-text explanations for choice of colposcopy clinic follow-up suggests the absence of 
cytobrush sampling in the community deters colposcopists from recommending follow-
up in this setting and that colposcopists’ feel a responsibility to make a diagnosis. 
ID 124: ‘I would be happy to discharge to GP cytology if I was sure endo & 
ecto-cervical cytology would be done’  
ID 21: ‘By this visit we will have 2 smears to look at’ 
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0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0%
They have high risk HPV (n=138)
To perform a colposcopy (n=138)
To prevent loss to follow up (n=139)











To use a broom and brush 
OR (95% CI), p value 
To prevent loss to follow-up 
OR (95% CI), p value 
To do a colposcopy 
OR (95% CI), p value 
They have high risk HPV  








0.32 (0.10-1.03), 0.06 
1.26 (0.47-3.37), 0.65 
0.71 (0.24-2.09), 0.53 
 
Ref 
0.78 (0.25-2.45), 0.68 
1.91 (0.72-5.06), 0.19 
2.05 (0.68-6.19), 0.2 
 
Ref 
0.53 (0.14-2.09), 0.34 
3.20 (1.18-8.73), 0.02 
1.74 (0.58-5.23), 0.32 
 
Ref 
0.29 (0.08-1.12), 0.07 
1.33 (0.50-3.53), 0.57 
0.88 (0.28-2.71), 0.82 
Years of Experience:(b), * 
0 - 10 years 
≥ 11 years 
 
Ref 
0.37 (0.35-1.48), 0.37 
 
Ref 
1.04 (0.51-2.14), 0.9 
 
Ref 
0.86 (0.39-1.81), 0.67 
 
Ref 






0.75 (0.36-1.56), 0.4 
 
Ref 
0.88 (0.42-1.83), 0.74 
 
Ref 
0.53 (0.25-1.12), 0.09 
 
Ref 
1.35 (0.64-2.83), 0.43 
(a) Adjusted for years of experience 
(b) Adjusted for gender. 





6.3.3.2 Total length of follow-up before recommending a LLETZ 
Figure 6.2 summarises the colposcopists’ preference for total length of cytological follow-
up before a LLETZ is offered for women with low grade cytology. The most frequent 
observation was 24 months of cytological follow-up in nulliparous and parous 25-39 year 
olds (n=76, 38% and n=74, 37% respectively). However, when pooling the 6, 12 and 18 
month responses, this combined proportion was equivalent to the proportion of 
colposcopists who selected 24 months (n=74, 35% and n=75, 37% respectively): p=0.72 
for nulliparous and p=0.99 for parous women. 
Table 6.5 describes the association between respondents’ demographics and the total 
length of follow-up they would recommend before offering a LLETZ. Nurse colposcopists 
had approximately three times the odds of waiting 24 months if the family was complete 
before offering LLETZ when compared to general gynaecologists. When compared to the 
choice of offering LLETZ at 24 months, doctors are more likely to recommend LLETZ by 12 
months in the family complete group (n=45 vs n=115) and in women ≥40 (n=60 vs n=103), 
p<0.001 and p=0.003 respectively.  
Explanations for choice of less than 24 months were not provided. Reasons for 24 months 
included;  
ID 196: ‘They can be safely monitored with cytology and HPV test’  
 
Colposcopists who ticked ‘other’ preferred individualized care rather than a prescribed 
timescale;  
ID 128: ‘Other factors would influence my decision, such as prior screening 
history, patient choice, if they are immuno-compromised (less likely to treat 
due to high risk of persisting HPV) or post-menopausal (risk of stenosis and 
difficult follow up post LLETZ)’  




























0% 5% 10% 15% 20% 25% 30% 35% 40% 45%
Family complete, any age (n=196)
≥40, family not complete (n=199)














OR (95% CI), p value 
25-39, family incomplete  
OR (95% CI), p value 
≥40, family incomplete 
OR (95% CI), p value 
Family complete, any age 








1.26 (0.52 - 3.05), 0.6 
1.24 (0.53 - 2.88), 0.6 
0.67 (0.25 - 1.76), 0.42 
 
Ref 
1.12 (0.46 - 2.74), 0.79 
1.42 (0.61 - 3.30), 0.41 
0.73 (0.27 - 1.91), 0.52 
 
Ref 
1.33 (0.51 - 3.49), 0.55 
1.95 (0.81 - 4.71), 1.49 
1.41 (0.54 - 3.66), 0.47 
 
Ref 
1.71 (0.62 - 4.75), 0.29 
3.16 (1.25 - 7.97), 0.02 
1.57 (0.55 - 4.51), 0.39 
Years of Experience(b) 
0 - 10 years 
≥ 11 years 
 
Ref 
0.89 (0.48 - 1.66), 0.73 
 
Ref 
0.95 (0.51 - 1.79), 0.24 
 
Ref 
1.25 (0.64 - 2.44), 0.51 
 
Ref 






1.57 (0.84 - 2.95), 0.15 
 
Ref 
1.45 (0.77 - 2.72), 0.24 
 
Ref 
1.30 (0.67 - 2.51), 0.43 
 
Ref 
1.04 (0.51 - 2.13), 0.90 
 
(a)  Adjusted for years of experience 





6.3.4 Techniques used to obtain a diagnosis 
Table 6.6 describes the non-routine techniques which are used to improve diagnosis in 
women with a TZ3. The majority of colposcopists, 93.6%, reported use of at least one 
method.  
Topical oestrogen is prescribed more than systemic in postmenopausal (n=182 (89.7%) vs 
n=16 (7.9%); diff 81.8%, 95% CI 75 - 86.8%, p<0.001), and premenopausal women (n=93 
(45.8%) vs n=18 (8.9%); diff 36.9%, CI 28.4-44.8%, p<0.001). Comments included; 
ID 196: ‘systemic may not be enough’ 
ID 70: ‘I have never used the COCP but I suppose it is logical’ 
When compared to postmenopausal women, colposcopists were 43.9% less likely to 
prescribe topical oestrogen in pre-menopausal women (95% CI 35.2 – 51.8%, p<0.001). 
The reasons for this were not provided.  
When adjusted for years of experience general gynaecologists had 2.26 times the odds of 
prescribing topical oestrogen when compared to gynaecological oncologists (90.2% vs 
66.7%; OR 2.26, 95% CI 1.15 – 6.9, p=0.005). Compared to gynaecological oncologists, 
nurses were also more likely to prescribe topical oestrogen (100%; p<0.001), as were 
associate specialists (91.7%; OR 2.18, CI 1.09 – 7.95, p=0.04). Furthermore, women had 
four times the odds of prescribing topical oestrogen when compared to men (OR 4.07, CI 
1.56 - 10.6, p=0.002). 
Although HPV genotyping is used, other surrogate biomarkers for HPV infection were 
rarely advocated (n=35 (17.2%) vs n=7 (3.4%); diff 13.8%, 95% CI 7.8 - 20%, p<0.001). Use 
of these techniques may be affected by resources;  
ID 158: ‘We do not have HPV triage in Scotland but can request if agreed at 
MDT’.  
Only 35 respondents used endocervical curettage and reasons for this were not 
elaborated upon. There was no evidence of an association between years of experience 
and these methods, although the sample sizes may be too small to detect a trend (Table 
6.6 and Appendix 6; Tables S6.3 & S6.4). 
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Table 6.6: Non-routine methods used to improve diagnosis of dysplasia and 















None 13, 6.4% 
(3.4 - 10.6) 
0.07 0.18 0.003 
HPV Genotyping 35, 17.2% 
(12.3 - 22.9) 
0.37 0.35 0.69 
Endocervical Curettage 24, 11.8% 
(7.7 - 16.9) 
0.67 0.46 0.92 
Biomarkers combined with 
cytology 
7, 3.4% 
(1.4 - 6.9) 
0.28 0.56 0.27 
Topical oestrogen if 
postmenopausal 
182, 89.7% 
(84.1 - 92.8) 
0.10 <0.001 0.002 
Topical oestrogen if 
premenopausal 
93, 45.8% 
(38.6 - 52.4) 
0.09 0.03 0.39 
Systemic oestrogen (HRT) if 
postmenopausal 
16, 7.9% 
(4.5 - 12.4) 
0.41 0.76 0.92 
Systemic oestrogen (COCP) if 
premenopausal 
18, 8.9% 
(5.3 - 13.5) 
0.36 0.73 0.21 
TOTAL 204    
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6.3.5 Main reasons for using oestrogen 
The majority of respondents answered this question (n=196, 95.6%) of whom 141 (71.9%; 
95% CI 65 - 78.1%) used oestrogen to improve the adequacy of the colposcopy in women 
with low grade cytology, 44 (22.4%; 16.8 – 28.9%) to improve the adequacy of the repeat 
cytology and 7 (3.5%; 1.4 – 7.2%) to make the examination more comfortable. There was 
no evidence of an association between respondent demographics and their reasons for 
use of oestrogen (Table 6.7). 
Table 6.7: Association (OR) between a colposcopist’s demographics and their use of 
oestrogen to improve the cytology when compared to use of oestrogen to improve the 
colposcopic adequacy 
Respondents Demographics OR (95% CI), p value 
Gender: 




0.89 (0.43 - 1.85), 0.7 
Years of Experience: 




1.02 (0.48 - 2.13), 0.9 
Job Title: 
General gynaecologist (n=100) 
Nurse colposcopist (n=30) 
Gynaecological oncologist (n=21) 
Associate specialist (n=23) 
 
Ref 
0.49 (0.15 - 1.60), 0.2 
0.80 (0.26 - 2.44), 0.7 
1.07 (0.38 - 3.02), 0.8 
 
 
6.3.6 Initial management of high grade cytology 
Data was available for 205 respondents (Figure 6.3 and Appendix 6, Table S6.5). In 
nulliparous women aged 25 – 39, 46.7% (n=96) chose LLETZ, 34.6% (n=71) MDT review 
and 11.1% (n=24) three month colposcopy follow-up. In comparison to nulliparous 
women aged 25 - 39, more colposcopists recommended a LLETZ in parous women aged 
25 - 39 (57.6%, n=118; diff 10.8%, 95% CI 0.79 - 20.6, p=0.03), women >40 years whose 
family was incomplete (69.3%, n=142; diff 22%, 95% CI 12.4 – 30.9%, P<0.001) and women 
of any age who had completed their family (87%, n=179; diff 40.3%, CI 31.6 – 48%, 
p<0.001). One third of colposcopists advocated referral to the MDT in women where the 
family was incomplete, irrespective of age. There was no evidence of an association 
between gender and years of experience with initial management choice (Table 6.8) but 
nurses, when compared to general gynaecologists, were three times more likely to refer 
to the MDT than recommend LLETZ when the family was incomplete. 
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0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Family complete, any age
(n=197)




LLETZ 3m colp follow-up 6m colp follow-up MDT
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Table 6.8: Association between colposcopist’s demographics and choice of LLETZ vs 3 month follow-up or LLETZ vs MDT in women with high-grade cytology 
 25-39, nulliparous 
OR (95% CI), p value 
25-39, family incomplete 
OR (95% CI), p value 
≥40, family incomplete 
OR (95% CI), p value 
Family incomplete 
OR (95% CI), p value 
LLETZ vs 3 month colposcopy follow-up 





0.98 (0.37 - 2.56), 0.97 
 
Ref 
1.19 (0.41 - 3.44), 0.74 
 
Ref 




Years of Experience: (b) 




2.42 (0.83 - 7.05), 0.1 
 
Ref 
5.07 (0.99 - 23.1), 0.05 
 
Ref 




Job title:  (a)(b) 
General Gynaecologist (n=110) 
Nurse Colposcopist (n=31) 
Gynaecology Oncologist (n=26) 
Associate Specialist (n=24) 
 
Ref 
0.76 (0.15 - 3.92), 0.74 
0.37 (0.08 - 1.85), 0.23 
1.61 (0.42 - 6.15), 0.48 
 
Ref 
1.92 (0.45 - 8.03, 0.37 
1.13 (0.22 - 5.82, 0.87 
0.68 (0.07 - 5.86), 0.73 
 
Ref 
2.76 (0.60 - 12.6), 0.18 
0.86 (0.16 - 4.46), 0.85 




1.41 (0.12 - 16.3), 0.78 
* 
LLETZ vs MDT review 





0.94 (0.48 - 1.83), 0.86 
 
Ref 
0.85, CI 0.43 - 1.68, 0.65 
 
Ref 
1.18, CI 0.55 - 2.51, 0.66 
 
Ref 
0.76, CI 0.26 - 2.16, 0.61 
Years of Experience: (b) 




1.10, CI 0.58 - 2.08, 0.76 
 
Ref 
1.11, CI 0.58 - 2.14, 0.74 
 
Ref 
0.83, CI 0,41 - 1.69, 0.61 
 
Ref 
0.64, CI 0.24 - 1.71, 0.37 
Job title:  (a)(b) 
General Gynaecologist (n=110) 
Nurse Colposcopist (n=31) 
Gynaecology Oncologist (n=26) 
Associate Specialist (n=24) 
 
Ref 
2.67 (1.04 - 6.84), 0.04 
0.90 (0.35 - 2.32), 0.83 
1.94 (0.70 - 5.41), 0.20 
 
Ref 
3.11 (1.22 - 7.94), 0.01 
1.14 (0.43 - 3.01), 0.78 
1.29 (0.46 - 3.60), 0.61 
 
Ref 
2.60 (0.98 - 6.94), 0.05 
1.47 (0.50 - 4.27), 0.47 
1.72 (0.59 - 5.02), 0.31 
 
Ref 
1.94 (0.57 - 6.56), 0.28 
0.50 (0.05 - 4.25), 0.52 
1.62 (0.40 - 6.54), 0.49 
(a) Adjusted for years of experience (b) Adjusted for gender   




6.3.7 Depth of LLETZ 
6.3.7.1 Low grade cytology 
Table 6.9 describes the preferred depth of LLETZ in women with low grade and high grade 
cytology in the presence of a TZ3. Where the family was incomplete the majority of 
colposcopists chose 7-10mm depth. The strength of the consensus was similar between 
25 - 39 year old nulliparous and parous women (diff 0.5%, p=0.99) but was weaker in 
women ≥40 (diff 10.8%, p=0.002). Although the most frequent observation was 11 - 
14mm in women who had completed their families, this consensus was weak at 50%. The 
association of colposcopist’s demographics with choice of ≥15mm LLETZ, in comparison 
to choice of ≤14mm, could not be calculated as most respondents chose a depth ≤14mm 
in all patient demographics (99%, 98.5%, 94.9% and 87.7% respectively).  
Of the colposcopists (n=164) who chose a depth ≤10mm in any of the patient 
demographics (Table 6.9 and Appendix 6, Table S6.6), ‘future fertility is an issue’ (n=95, 
58%) was the primary factor affecting choice. In comparison, the following factors were 
less likely to influence this decision; ‘I can repeat the LLETZ if diagnostic for CIN’ (n=67, 
41.2%; diff 16.8%, p<0.001), ‘these women have reassuring histology’ (n=55, 33.4%; diff 
24.6% p<0.001) and ‘the risk of cervical stenosis’ (n=34, 21%; diff 37%, p<0.001). Of the 
colposcopists who chose a LLETZ ≥11mm (n=123), ‘a deeper LLETZ excises an endocervical 
TZ’ was the primary reason for this choice (n=72, 58.8%). In comparison, ‘fertility in no 
longer an issue’ (n=53, 42.7%; diff 5.1%, p=0.03) and ‘they have high risk HPV’ (n=20, 
16.5%; diff 42.3%, p<0.001) were less likely to affect this choice.  
6.3.7.2 High grade cytology 
Irrespective of parity, the majority of colposcopists recommended 7-10mm depth in 25 - 
39 year olds and this proportion was similar to that observed with low grade cytology 
(Table 6.9). In women ≥40 whose family was incomplete, although more chose 11 - 14mm 
when compared to choice in women aged 25 - 39, the greatest proportion still chose 7-
10mm (diff 9.6%, p=0.06). Where the family was complete the most frequent observation 
was 11-14mm, but this consensus was weak at 55%. Compared to low grade cytology, 
respondents were more likely to choose 11-14mm depth in women ≥40 and in those 
whose family was complete. Respondents were also less likely to perform a 6mm LLETZ 
and more likely to complete an 11-14mm LLETZ in 25 - 39 year olds with high grade 
cytology when compared to women aged 25 - 39 with low grade cytology. 
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Table 6.9: Colposcopists’ recommendations for depth of LLETZ in women with low grade or high grade cytology and a TZ3 
 
 Low grade cytology (n=195) 
N (%, 95% CI) 
High grade cytology (n=199) 
N (%; 95% CI) 
Difference in proportions 







22 (11.2; 7.2 – 16.7) 
142 (72.9; 66.2 – 78.9) 
29 (14.8; 10.1 – 20.7) 
2 (1.0; 6.4 – 15.6) 
 
8 (4; 1.9 – 8.1) 
130 (65.3; 58.2 – 71.8) 
54 (27.1; 21.2 – 33.9) 
7 (3.5; 1.6 – 7.4) 
 
7.2 (1.7 - 12.9), 0.007 
7.6 (1.8 - 16.9), 0.1 
12.3 (3.9 - 20.5), 0.003 
2.5 (-0.8 - 6.2), 0.1 
25-39 family incomplete:                




20 (10.2; 6.5 – 15.6) 
142 (72.4; 65.9 – 78.8) 
30 (15.3; 10.7 – 21.4) 
3 (1.5; 3.2 – 4.8) 
 
6 (3; 1.2 – 6.8) 
130 (65.3; 58.2 – 71.8) 
56 (28.1; 22.1 – 35) 
7 (3.5; 1.6 – 7.4) 
 
7.2 (2.0 - 12.7), 0.004 
7.1 (-2.4 - 16.5), 0.13 
12.8 (4.3 - 21.1), 0.002 
2 (-1.6 - 5.8), 0.21 






10 (5.1; 2.6 – 9.4) 
121 (61.7; 54.7 – 69.2) 
54 (27.6; 21.7 – 34.5) 
10 (5.1; 2.6 – 9.4) 
 
3 (1.5; 0.4 – 4.7) 
98 (49.3; 42.1 – 56.4) 
79 (39.7; 32.9 – 46.9) 
19 (9.6; 6.0 – 14.7) 
 
3.6 (-0.3 - 7.9), 0.05 
12.4 (2.2 - 22.3), 0.01 
12.1 (2.4 - 21.5), 0.01 
4.5 (-1.0 - 10.1), 0.09 






2 (1; 1.8 – 3.9) 
70 (35.7; 29.1 – 42.9) 
98 (50.0; 42.8 – 57.2) 
25 (12.8; 8.8 – 18.7) 
 
0 (0; 0 – 0.2) 
50 (25.1; 19.4 – 31.9) 
111 (55.8; 48.6 – 62.8) 
38 (19.1; 14 – 25.4) 
 
1 (-1.0 - 3.6), 0.16 
10.6 (1.2 - 19.9), 0.02 
5.8 (-4.4 - 15.9), 0.25 
6.3 (-1.3 - 13.8), 0.09 
Of the colposcopists who preferred a ≤10mm LLETZ in women with high grade cytology 
(n=189 - Table 6.9 and Appendix 6, Table S6.7), ‘fertility is an issue’ was the primary reason 
(n=105, 55.6%) when the family was incomplete. Other factors which influenced choice in 
all patient demographics included; ‘I can repeat the LLETZ if diagnostic for CIN’ (diff 12.3%, 
95% CI 5.6 – 18.8%, p=0.0003) and ‘the risk of cervical stenosis’ (diff 40.5%, 95% CI 34.5 – 
46%, p<0.001). Of note only 33.3% (17/51) colposcopists who chose ≤10mm depth when 
the family was complete gave a reason compared to 79.7% (110/138) when the family 
was incomplete.  
Of those colposcopists who preferred ≥11mm LLETZ depth (n=149), the primary reason 
was ‘a deeper LLETZ excises an endocervical TZ’ (n=98, 65.7%). In comparison, ‘the 
majority have high grade CIN’ (n=81, 54.2%; diff 11.5%, 95% CI 4.5 – 18.3%, p=0.001) and 
‘fertility in no longer an issue’ (n=50, 33.7%; diff 32%, 95% CI 24.9 – 38.5%, p<0.001) were 
less likely to influence this decision. When compared to factors affecting choice with low 
grade cytology, colposcopists were less concerned about reproductive function and more 
concerned that high disease would be missed with a shallower depth (p=0.02).  
6.3.8 Repeating the referral cytology 
Of 205 participants, 144 (70.2%) would not repeat the referral cytology at the first 
colposcopy appointment. Reasons given included confidence in the screening test result; 
ID 49: ‘no need to repeat if routinely HPV tested’  
ID 131: ‘Women are seen very soon after referral. I would only repeat the 
cytology if it is >3 months as it would risk false negative results.’  
Sixty (29.3%) would repeat the cytology, irrespective of grade. Of these colposcopists, 31 
(51.7%) did so because they believed the Cervex-Brush may not have adequately sampled 
the TZ; 
ID 170: ‘Reporting the presence of endocervical cells used to make 
management decisions much easier.’  
If the smear quality was poor 21/60 (35%) repeated the cytology and 39 (65%) to provide 
reassurance that LLETZ was the correct management option in young women. There was 
no evidence of an association between gender (p=0.7) or years of experience (p=0.13) and 
repeating the cytology. When compared to gynaecology consultants, nurses were 88% 




To the best of my knowledge this is the first nationwide study to assess how UK 
colposcopist’s manage women with a TZ3. This survey was supported by the BSCCP, which 
denotes the relevance of this work, and the information provided will contribute to 
guidance development and direct future research. Areas of consensus had narrow 
confidence intervals and areas of discordance were, in most scenarios, not affected by 
colposcopists’ demographics indicating true areas of clinical uncertainty.  
Sampling was national and this will improve the generalizability of the findings. As 
colposcopy training (knowledge) and revalidation in the UK is standardized, variation in 
practice between the geographical units should be minimised. The outcomes and 
population demographics from this study triangulated with the regional focus group 
study[101] which validates the findings from Chapter 4 (see Discussion – Chapter 8). The 




In comparison to BSCCP endorsed published surveys[211, 212] the response rate was half of 
what I expected and this may be due to timing of release, during a national holiday. Thirty 
one responses were received in the first week. The remaining responses were received 
after the second follow-up email. Regardless, the potential for selection bias needs to be 
considered as colposcopists’ motivation to participate will have led to a self-selected 
sample. This may limit the findings from the study but the participant demographics and 
study outcomes were comparable to the focus groups (source population). Nevertheless, 
colposcopists may believe this is not an area of ambiguity or conversely, due to clinical 
uncertainty, may have felt unable to participate. To investigate this, it would have been 
useful to include an item which assessed if colposcopists felt this was a topical area and / 
or area of clinical uncertainty.  
A small proportion of colposcopists did not answer all item stems and although this would 
have improved the confidence intervals for some of the analysis, online surveys which 
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require an answer to all questions can reduce overall responses rates in areas of 
uncertainty. 
Correlation of experience with management decisions may be valuable for guideline 
development but measuring these variables can be problematic. Questions which 
assessed the volume of patients reviewed in a six month period could have been included 
but some clinicians who review a lower volume of women may manage higher complexity 
patients. Personal experiences can affect management outcomes in areas of clinical 
uncertainty, such as a previous poor outcome leading to a more aggressive selection for 
treatment, but most areas of discordance were not affected by gender, job title or 
experience indicating true areas of clinical uncertainty. 
 
6.6 Conclusions 
This study was designed to help guide a national consensus strategy and, in this regard, it 
identified clear areas of consensus. With low grade cytology and a TZ3, young women 
with low risk factors for CIN progression (non-smokers, reliable attendees and normal age 
of sexual debut) and older women with low parity and low risk factors could be offered 
cytological follow-up, dependent upon patient wishes. Until population specific 
information is available it would appear safest to offer excision to all women with high 
grade cytology and a TZ3.  
Pending studies which assess the diagnostic accuracy of a Cervex-Brush alone and the 
impact of reporting the presence of endocervical cells, colposcopists should not repeat 
the referral cytology. NHS CSP guidelines for depth of LLETZ should be adhered to until 
studies which adjust for age and parity when assessing the distal margin of a TZ3 are 
completed. 
To reduce heterogeneity of care, patient preferences for the management of a TZ3 should 
be assessed, including the use of oestrogen. To inform the clinical setting, interval and 
total length of follow-up prior to offering a LLETZ, prospective studies are needed to 
assess the optimal cytological collection device and the progression rate of CIN in women 
with low grade cytology and a TZ3. The contribution of biomarkers and HPV genotyping 





















 The use of biomarkers and HPV genotyping to 
improve diagnostic accuracy in women with a TZ3 
7.1 Introduction  
In women with high grade cytology and high risk HPV the PPV of detecting CIN2+ is 86.2 - 
94% but with low grade cytology it is only 16%[156]. As reported in Chapters 4 and 6, when 
the PPV of the screening test cannot be improved by colposcopic assessment due to the 
presence of a TZ3, anxiety deters long-term conservative follow-up and increases LLETZ 
rates. As identified in Chapter 3, women who have a LLETZ for a TZ3 have a 10-fold 
increased chance that the excision histology will be normal, when compared to women 
where the TZ is visible, and a higher treatment related morbidity due to the recommended 
depth of LLETZ (15 - 25mm)[85]. These data suggest novel methods which improve the 
diagnostic accuracy of the screening test are needed in this cohort.  
As discussed in section 1.6.2, endocervical canal curettage (ECC) can be used to obtain 
fragments of squamous epithelium from inside the cervical canal but this is not routine 
practice in the UK as inadequacy rates are high[123, 126] and the inter-observer agreement 
moderate. The use of surrogate biomarkers for HPV infection, p16 and Ki-67, (section 
1.6.3) have been shown to improve the diagnostic accuracy of cervical punch biopsies and 
low grade cytology samples when the TZ is visible. Their use in combination with 
techniques which sample an endocervical transformation zone may improve diagnostic 
accuracy and decision-making in women with a TZ3. 
Currently, HPV DNA testing in the UK gives a pooled high-risk result but studies have 
evaluated individual genotypes and shown increased HPV persistence, and a higher risk 
of integration, with HPV 16/18 and associated subtypes (HPV 31, 33, 35, 52 and 58)[157, 213] 
- indicating that genotyping for these subtypes may also increase diagnostic accuracy 
(section 1.6.4). 
The PPV of the screening test can be affected by the method of cytological collection but 
of the studies evaluating liquid based cytology devices[79, 81, 83, 214], none have correlated 
their findings with topographical position of the TZ nor adjusted for age or parity which 
may affect the mean cytological cell count (section 1.4.1.2). 
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The primary aim of this study was to assess the predictability of diagnosis of CIN2+ by 
p16/Ki-67 dual-stained cytology, 24 high risk genotypes and dual-stained endocervical 
curettings in women with a TZ3. The secondary aim was comparison of the Cervex-Brush 
alone to a Cervex-Brush in combination with a cytobrush to determine the optimal 
cytological collection device in women with a TZ3. 
 
7.2 Methodology 
A prospective diagnostic accuracy study was conducted over 18 months in a single NHS 
Trust. Women booked for LLETZ with any squamous cell cytological abnormalities, high 
risk HPV and a TZ3 were recruited. The exclusion criteria were glandular cytology, 
immunocompromise and pregnancy. Index tests were taken immediately prior to LLETZ; 
a Cervex-Brush and cytobrush sample was processed for routine cytology, p16/Ki-67 dual-
stain and 24 high risk HPV genotypes. Endocervical curettings were taken and H&E, p16 
and Ki67 stained. Predictability of diagnosis of CIN2+ was by blind standardised 




Figure 7.1 outlines the study recruitment. Of the total LLETZ undertaken during the 
recruitment period (n=771), 163 (21.1%) had a TZ3. Ten women were ineligible as they 
met the exclusion criteria. As I was the only person recruiting, 47 eligible women were 
missed due to my competing clinical duties and one woman declined participation due to 
anxiety. This meant 105 of 153 (68.6%) eligible participants were recruited and agreed to 
participate. A broom and broom sample was taken from 105 of 101 had adequate 
samples; the os was stenosed in one and of the three with inadequate cytology (2.8%) all 
had extensive atrophy and a narrow os.  
Of the 101 women with adequate cytology, I was unable to pass a curette in four (all were 
post-menopausal with low grade cytology and two had had a previous LLETZ). This 
resulted in a total of 97 matched samples.  
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Total LLETZ Sept 2014 – Feb 2016: 
n=771 
Consented:                 
n=105 (100%) 
Broom & Brush:              
n=101 
 
Endocervical Curettage:           
n=97 
1 pass LLETZ:            
n=97 
Test of Cure:             
n=88 
Unable to pass cytobrush: 
n=1 
Unable to pass curette: 
n=4 
Did not attend for 
follow-up cytology:   
n=9 
Inadequate cytology rate: 
n=3 (2.8%) 
LLETZ for TZ3:                                                          
n=163 (21.1%)                                                  
Ineligible:                   
Glandular cytology, n=5 
Immunocompromised, n=5 
Failed to recruit due to 
competing clinical duties: 
n=47 






7.3.2 Inter-rater reliability 
Table 7.1 reports the inter-rater reliability of the index tests. Overall agreement was good for the index cytology and the dual-stained cytology slides. For the 
H&E stained curettings, the CIN2+ vs <CIN2 diagnostic category showed better agreement than CIN vs Normal histology. For individual p16 and Ki-67 stained 
curettings agreement, was good if strong vs not strong and full thickness vs less than full thickness staining categories were respectively used. For the dual-
stained curettings the agreement was very good for <CIN2 vs CIN2+ when the most predictive staining categories for p16 & Ki67 were used.  
Table 7.1: Inter-rater reliability of the index tests 
Diagnostic Test Staining Categories Diagnostic Categories Kappa 
Value 
95% CI 
Index cytology (n=101) - (i) Low Grade vs High Grade Cytology 0.65 0.52 - 0.78 
Dual-stained cytology (n=101) (i) Positive vs Negative - 0.79 0.65 - 0.92 
H&E stained curettings (n=97) 
- 
(i) CIN (any grade) vs Normal  
(ii) <CIN2 vs CIN2+ 
0.56 
0.76 
0.42 - 0.75 
0.62 - 0.89 
p16 stained curettings (n=97) (i) Strong vs <Strong 




0.51 - 0.81 
0.34 - 0.61 
Ki-67 stained curettings (n=97) (i) Full thickness vs <Full thickness 




0.60 - 0.87 
0.39 - 0.59 
p16/Ki-67 dual- stained curettings(a)  (n=97) 
- 
(i) CIN (any grade) vs Normal 
(ii) <CIN2 vs CIN2+ 
0.69 
0.80 
0.57 - 0.82 
0.68 - 0.93 





7.3.3 Study population 
Table 7.2 outlines the study sample characteristics. All had high risk HPV as part of the 
Sentinel Sites primary screening or through HPV triage of a low grade cytology result. Sixty 
four had low grade cytology (35 BNC and 29 mild) and 37 high grade cytology. The median 
age was 39 years (IQR 34 – 51). Fifty five (54.5%) were of prime reproductive age (25 - 39 
years) and 70.2% were parous. Over 40% (95% CI 32 – 52%) of the pre-menopausal 
women took no hormonal contraceptive.  














Characteristic N (%) 
Age: 
25 - 39 years 



















37 (36.6%)  
Hormonal State: 
None 
Oestrogen (HRT or COCP) 


























The TZ was identified in all LLETZ histology, the median time between the referral cytology 
and LLETZ was 8 weeks (IQR 5 - 11.5) and the median depth was 15mm (IQR 12 - 16.5). 
Histological limiting factors were assessed; five LLETZ samples showed denudation but the 
histology for four of these corresponded with the curettings and all follow-up cytology 
was negative. The fifth sample was reported as HPV on the LLETZ and CIN2 on the 
curettings but the test of cure (TOC) result was negative. 
7.3.4 Outcome histology with a TZ3 
Table 7.3 cross-tabulates the LLETZ outcome with the referral and index test results. 
Where a mismatch between the referral cytology and LLETZ occurred, all cases were 
reviewed and the outcome from the MDT was reported as the final result. The majority 
of women (72.7%, 24/33) with high grade dyskaryosis on the index cytology had CIN2+. 
Of the 11 women with high-grade cytology and <CIN2 at LLETZ, two had CIN2+ identified 
in the curettings and the remainder had a negative TOC. This indicates 78.7% (26/33) of 
women with high grade cytology and a TZ3 have CIN2+. A third (n=20) of the women with 
low grade cytology had CIN2+ at LLETZ and a further 5 had CIN2+ identified in the 
curettings but <CIN2 in the LLETZ histology. This indicates 36.7% (25/68) of women with 
low grade cytology and a TZ3 may have CIN2+; 77.8% were non-smokers, the median age 
was 36 (1QR 30-46), and 65.2% (15) had BNC.  
There is no evidence that the proportion of women with high grade cytology and a TZ3 
who have CIN2+ at LLETZ differ to national screening statistics[87] (of whom 80% will have 
a TZ 1-2); 78.7% vs 84.6%, p=0.13. However, there is evidence that more women with low 
grade cytology and a TZ3 have CIN2+; 36.7% vs 16.1% p<0.001. The one case of squamous 
cell cancer within the study population had BNC reported on the referral and index 
cytology. 
Of note, 17 women were referred with high risk HPV but genotyping reported 12 were 
high risk HPV negative and 5 had low risk HPV. Of these 17 women none had CIN2+, the 
median interval from cytology to LLETZ was 9 weeks (range 4 - 17) and the median age 
was 43 (range 25 - 54). To evaluate the effect of genotyping on diagnostic accuracy, the 





Table 7.3: Cross tabulation of the diagnostic test results with the LLETZ histology 
 
 LLETZ RESULT  
INDEX TEST Negative (n=36) CIN1 (n=21) CIN2+ (n=44) TOTAL 
Referral Screening Test (n=101) 
 HR HPV & Low-grade Cytology 




























Pooled HPV status (n=101) 
 Negative 
 Low Risk 
























































































































































ECC Ki67 (n=97) 
 Negative 
 Basal 









































Of the 37 women referred with high grade cytology, 2 were negative for high risk HPV, 17 
(45.9%) had HPV 16, three (16.6%) HPV 18, fifteen (40.5%) had a variety of other high risk 
subtypes and eighteen (48.6%) were infected with multiple subtypes. Of the 64 women 
referred with low grade cytology, 15 (23.4%) were negative for high risk HPV, 11 had HPV 
16, HPV 18 was detected in three women and non-16/18 HR subtypes in 35. Of these 
women with low grade cytology and high risk HPV, 16 were positive for multiple subtypes. 
7.3.5 Diagnostic accuracy of the individual tests 
Table 7.4 reports the accuracy and performance of the referral and index tests in 
predicting CIN2+ when the most reliable staining categories from Table 7.1 were used. 
The PPV of a pooled HPV test was poor (53%) but the NPV was excellent (100%).  
7.3.5.1 Contribution of a cytobrush to improving diagnostic accuracy 
There was no evidence that the addition of a cytobrush to a Cervex-Brush improved the 
predictability of diagnosing CIN2+ when compared to the Cervex-Brush alone, irrespective 
of the cytological grade (high grade p=0.73, low grade p=0.23). The impact of TZ sampling 
was evaluated; 22 (20.9%) of the referral cytology samples contained squamous but no 
endocervical cells whereas only one (0.9%) of the Cytobrush & Cervex-Brush samples 
lacked endocervical cells (p<0.001). There was no evidence of an association between the 
presence of endocervical cells and a diagnosis of CIN (p=0.21), but the sample size was 22. 
When adjusted for age there was no difference in diagnostic accuracy between the two 
sampling methods for women with low grade or high grade cytology; in women aged 25 - 
39 p=0.99 respectively and in women >40 p=0.68 and 0.98 respectively. There was no 
difference observed in predictability of CIN2+ between nulliparous or parous women 
(p=0.99 and 0.62 respectively) between the different sampling methods. 
7.3.5.2 Dual-stained cytology and HPV genotyping 
The sensitivity of dual-stained cytology for CIN2+ was excellent but the specificity 
moderate. Dual-staining was of most help when assessing fragmented epithelium or 
scattered dysplastic cells (Figure 7.2). All dual-stain positive women (n=64) had high risk 
HPV but 24.1% (20/83) women with high risk HPV were dual-stain negative. Sensitivity 
and specificity of HPV 16 for CIN2+ were moderate and not affected by the addition of 





Table 7.4: Predictability of CIN2+ by the referral and index tests 
DIAGNOSTIC TEST Sensitivity 
n/N, (%, 95% CI) 
Specificity 
n/N, (%, 95% CI) 
PPV 
n/N, (%, 95% CI) 
NPV 
n/N, (%, 95% CI) 
Referral Screening Test 
 HR HPV + Low Grade Cytology  
 HR HPV + High Grade Cytology 
 
18/44 (40.9%, 27.6–55.5) 
26/44 (59.1%, 44.1-72.3) 
 
11/57 (19.3%, 11.1–31.3) 
46/57 (80.7%, 68.6-88.8) 
 
18/64 (28.1%, 18.6-40.1) 
26/37 (70.3%, 54.2-82.5) 
 
11/37 (29.7%, 17.4-45.8) 
46/64 (71.9%, 59.8-81.4) 
Index Cytology 
 Low Grade 
 High Grade 
 
20/44 (45.4%, 31.7-59.9) 
24/44 (54.5%, 40-68.3) 
 
9/57 (15.7%, 7.9-28.3) 
45/57 (84.2%, 71.6-92.0) 
 
20/68 (29.4%, 19.3-41.8) 
24/33 (72.7%, 55.7-84.9) 
 
9/33 (27.3%, 15.0-44.2) 
45/68 (70.5%, 58.1-80.7) 
HR HPV vs <HR HPV 44/44 (100%, 91.9-100) 18/57 (31.6%, 21.0-44.8) 44/83 (53.0%, 42.3-63.3) 18/18 (100%, 82.4-100) 
CINtec (p16/Ki67 cytology) 44/44 (100%, 91.9-100) 37/57 (64.9%, 51.9-76) 44/64 (68.8%, 56.1-78.7) 37/37 (100%, 90.5-100) 
HPV 16 vs other HR subtypes 22/44 (50%, 35.8-64.1) 33/39 (84.6%, 70.3-92.7) 22/28 (78.6%, 60.4-89.7)  33/55 (60%, 46.8-71.8) 
16 & 18 HR HPV 25/44 (56.8%, 42.3-70.3) 30/39 (76.9%, 61.6-87.3) 25/34 (73.5%, 56.8-85.4) 30/49 (61.2%, 47.2-73.5) 
ECC H&E  
 CIN2+ vs <CIN2 
 CIN vs normal histology 
 
24/28 (85.7%, 68.5-94.3) 
31/45 (70.4%, 55.7-81.8) 
 
49/69 (71%, 59.4-80.3) 
39/52 (73.6%, 60.4-83.5) 
 
24/44 (54.5%, 40-68.3) 
31/44 (68.9%, 54.3-80.4) 
 
49/53 (92.4%, 82.1-97) 
39/53 (75%, 61.7-84.7) 
ECC p16 
 Strong staining vs <strong stain 
 Any staining vs no stain 
 
38/47 (80.8%, 67.4-89.5) 
41/64 (64%, 51.8-74.7) 
 
44/50 (88%, 76.2-94.3) 
30/53 (56.6%, 43.2-69) 
 
38/44 (86.4%, 73.2-93.6) 
41/44 (93.2%, 81.7-97.6) 
 
44/53 (83%, 70.7-90.8) 
30/33 (90.9%, 76.4-96.8) 
ECC Ki67 
 Full thickness staining  
 Full thickness & basal vs none 
 
36/42 (85.7%, 72.1-93.3) 
43/69 (62.3%, 50.5-72.8) 
 
47/55 (85.5%, 73.8-92.4) 
27/28 (96.4%, 82.2-99.3) 
 
36/44 (81.8%, 68-90.4) 
43/44 (97.6%, 88.2-99.6) 
 
47/53 (88.7%, 77.4-94.7) 
27/53 (50.9%, 37.8-63.8) 
ECC H&E with p16 and Ki67 
 CIN2+ vs <CIN2 
 CIN vs normal histology 
 
37/44 (84.1%, 70.6-92.7) 
42/61 (68.8%, 56.4-79) 
 
46/53 (86.8%, 75.1-93.4) 
34/36 (94.4%, 81.8-98.4) 
 
37/44 (84.1%, 70.6-92.7) 
42/44 (95.4%, 84.8-98.7) 
 
46/53 (86.8%, 75.1-93.4) 





Figure 7.2: How dual-stained cytology can improve accuracy of the screening test 
ACORN ID 66. The referral cytology was reported as low grade dyskaryosis and the index 
cytology as low grade (BNC) change. The BNC category was a result of some cells 
exhibiting a slightly increased nuclei:cytoplasmic ratio but clumping of the cells (Figure 
7.2a) reduced differentiation of reactive cells from dyskaryotic. HPV 16 and 33 were 
identified on genotyping. Dual-staining was reported as positive (Figure 7.2b) and CIN2 
identified in the LLETZ histology. This case illustrates how dual-stained cytology can 
improve false negative screening (NPV) as many colposcopists would be reassured by the 
cytology result and recommend cytological follow-up.  
    
ACORN ID 71. The referral cytology was reported as BNC and the index cytology as mild 
dyskaryosis with koilocytosis (Figure 7.2c). Genotyping identified HPV 16, 53 and 70. Dual-
staining was negative (Figure 7.2d) and the LLETZ report stated HPV only. This is an 
example of how dual-staining can improve the PPV of screening. It also illustrates that 
infection with high-risk HPV, even HPV 16, does not always equate to CIN2+. 






ACORN ID 68: The referral and index cytology were reported as mild dyskaryosis (Figure 
7.2e). Genotyping identified HPV 58 and 73. Dual-stained cytology was negative (Figure 
7.2f) and the LLETZ report stated HPV only. This is another example of how dual-staining 
can decrease false positive screening (improve the PPV) as Chapters 4 & 6 has illustrated 
that colposcopists will offer a LLETZ to women with a TZ3 who have this cytology result 
for 12 months. 
    
 
7.3.5.3 Scoring Protocols for the immunostained endocervical curettings 
The predictability of CIN2+ by different immunostaining and diagnostic categories was 
evaluated (Table 7.4).  
 H&E slides; If ‘<CIN2 and CIN2+’ were used as the diagnostic categories the sensitivity 
and specificity were moderate. If ‘CIN (any grade) vs Normal histology’ was used, 
there was no evidence of a difference in the sensitivity (p=0.10) or the specificity 
(p=0.63). The contribution to the diagnostic yield of a deeper level was evaluated; one 
case was upgraded from metaplasia to CIN1 but this was also detected by p16 and Ki-
67.  
 p16 slides: If ‘any staining vs no staining’ was used as the scoring category the 
specificity for CIN2+ was poor but the sensitivity very good. If ‘strong vs <strong’ 
staining category was used the specificity improved (p=0.04) but the sensitivity was 
equivocal (p=0.68). 
 Ki-67 slides: ‘Full thickness vs <full thickness’ staining category improved the specificity 
for CIN2+ when compared to ‘no staining vs basal vs full thickness’ (p=0.008). 





7.3.5.4 Accuracy of the H&E, p16, Ki-67 & dual-stained endocervical curettings 
The most accurate staining and diagnostic categories as outlined in 7.3.4.3 were used to 
assess the diagnostic accuracy of the H&E and immunohistochemistry slides (Table 7.4). 
Sensitivity and specificity for the H&E slides were moderate and good for the individually 
stained p16 and Ki-67 slides. Diagnostic accuracy of the H&E, p16, Ki67 and dual-stained 
curettings for CIN2+ were compared; sensitivity was improved with p16 and Ki-67 when 
compared to the H&E stained slides (p<0.001 respectively). Specificity was improved with 
Ki-67 (p=0.03) but this association was not observed with p16 (p=0.06). There was no 
evidence of a difference in sensitivity between Ki-67 and p16 stained slides (p=0.5).  
Diagnostic accuracy of the dual-stained slides was compared to p16 and Ki-67 alone; there 
was no evidence of a difference in sensitivity when compared to p16 (p=0.99) or specificity 
when compared to Ki-67 (p=0.99). However, the inter-rater reliability was better for dual-
stained slides and four slides which stained strongly positive for p16 had basal staining 
only on the corresponding Ki-67 slides; the result was both Pathologist’s downgrading the 
final diagnosis to HPV infection, which was also reported on all four LLETZ histology. For 
these reasons dual-stained histology, rather than p16 or Ki-67 alone, was used in the 
regression models and treatment algorithms. The slides in Figure 7.3 illustrate how the 
use of p16 & Ki67 can improve predictability of CIN2+ in fragmented endocervical 
curettings. 
Figure 7.3: How p16 & Ki-67 immunostains can improve the predictability of CIN2+ 
in endocervical curettings 
                                                                                    
ACORN ID 26: 
 Referral cytology BNC ?high grade 
 Index Cytology BNC 
 HPV 33 & 35 on genotyping 
 Curettings fragmented. CIN ?grade 
identified on the H&E slide (7.3a), 
full thickness Ki67 staining (7.3b) 
and strong p16 staining (7.3c). The 
final diagnosis was CIN2+ 







            
 
 
7.3.5.5 Prediction models 
To stratify which women would most benefit from LLETZ, I was interested to assess which 
patient variables may increase prediction of CIN2+. Univariable models (Table 7.5) 
identified that cytological grade, age and interval from cytology to LLETZ were predictors 
of CIN2+. As a negative dual-stained cytology result perfectly predicted a negative LLETZ, 
there was no variability on which to calculate a regression model. In the bivariable models, 
which examined each predictor after adjusting for diagnosis of CIN2+ by immunostained 
curettings (Table 7.6), there was evidence that women aged 25 - 39, independent of their 
immunostained curetting result, had higher odds of CIN2+. In bivariable models which 
examined each predictor after adjusting for HPV 16/18 (Table 7.6), there was evidence 
that women aged 25 - 39 and those with high grade cytology, independent of their HPV 






Table 7.5: Predictors of CIN2+ in women with a TZ3 – univariable analysis 




p16/Ki67 curettings 33.7 10.8 - 85.1 <0.001 0.85 
HPV 16/18 positive 7.8 2.9 - 20.5 <0.001 0.71 
CINtec * * * * 
Smoking 0.97 0.42 – 2.24 0.95 0.50 
Cytological grade 5.97 2.38 - 14.9 <0.001 0.69 
Parity 0.61 0.25 – 1.44 0.25 0.55 
Contraceptive 0.96 0.43 – 2.17 0.94 0.50 
Age 3.08 1.33 – 7.11 0.008 0.63 
Cytology to LLETZ interval 0.30 0.10 – 0.83 0.03 0.58 
*Unable to calculate as no variation. All women with CIN2+ were dual-stain positive 
 
 
Table 7.6: Predictors of CIN2+ in women with a TZ3 – bivariable analysis 
Variable 
p16/Ki67 stained curettings  HPV 16/18 Genotype 
OR,        
95% CI 
p value AUC 
OR,        
95% CI 
p value AUC 
Smoking 0.58,       
0.17 – 1.97 
0.38 0.86 
0.90,      
0.35 – 2.31 
0.84 0.71 
High grade cytology 1.78,      
0.50 – 6.26 
0.36 0.86 
3.73,      
1.37 – 10.1 
0.01 0.77 
Parity 0.74,      
0.21 – 2.52 
0.63 0.74 
0.51,      
0.19 – 1.36 
0.18 0.74 
Contraceptive 0.59,      
0.18 – 1.95 
0.34 0.86 
0.74,      
0.29 – 1.87 
0.53 0.72 
Age 4.14,      
1.19 – 14.3 
0.02 0.89 
2.59,      
1.02 – 6.51 
0.04 0.76 
Cytology to LLETZ interval 0.11,      
0.01 – 1.38 
0.08 0.87 
0.20,      






In the final models (Table 7.7) the direction of risk for variables which predicted CIN2+ 
were evaluated. In those women who tested positive for HPV 16/18, women aged 25-39 
were 3 times more likely to have CIN2+ when compared to women ≥40 and those with 
high grade cytology were four times more likely to have CIN2+ when compared to women 
with low grade cytology. When CIN2+ was reported on the immunostained curettings, 
these women were four times more likely to be aged 25 - 39 than ≥40.   




Interval p value AUC 
p16/Ki67 curettings  
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The predictive ability (area under the curve or AUC) of HPV 16/18 genotyping and 
p16/Ki67 stained curettings were compared. There is some evidence that immunostained 
curettings improve the predictability of CIN2+ when compared to HPV 16/18 genotyping: 
AUC 0.86 vs 0.71, p=0.01 (Table 7.7). The receiver operator curves and area under the 





Figure 7.4: Receiver operator curves 
ROC curves and AUC for (i) immunostained curettings (Final path – Model 7.4a) and (ii) 
HPV 16/18 genotyping, individually and in combination with their highest risk subgroups 
(Model 7.4b). Comparison of the area under the curve for immunostained curettings and 
HPV 16/18 genotyping can be viewed in Model 7.4c. 
 








7.3.6 Accuracy of the most predictive tests in combination with the screening 
test result 
7.3.6.1 Low grade cytology and high risk HPV 
My data suggests women with low grade dyskaryosis would benefit from dual-stained 
cytology (Table 7.8); CIN2+ would have been identified in 89.5 - 100% of my sample (NPV) 
and, in comparison to standard screening, an unnecessary LLETZ would have been 
prevented in 71.7% (33/46) of the women who had <CIN2 (Figure 6.5b). The use of dual-
stained endocervical curettings would have detected 82.6% (38/46) women with <CIN2 
prior to LLETZ (Figure 7.5c) but only 11/18 (61.1%) of the women with low grade screening 
who had CIN2+ would have been correctly identified (Table 7.8).  
The specificity of the endocervical curettings in women with low grade cytology was 
similar to that of the dual-stained cytology (Table 7.8) but the sensitivity was poorer; 7/18 
(38.8%) of women with CIN2+ would potentially have been missed (Figure 7.5c). The PLR 
for routine cervical screening was poor (7.5% probability that CIN2+ will be detected) but 
improved when combined with dual-stained cytology and dual-stained curettings (PLR 
22.5% and 30% respectively). Indeed, the PLR for both dual-stained cytology and 
curettings triangulate with the incidence of CIN2+ that was observed in women with low 





Table 7.8: Predictability of CIN2+ for the most accurate tests in women with low grade and high grade cytology 
 
Sensitivity               
(%, 95% CI) 
Specificity               
(%, 95% CI) 
PPV                        
(%, 95% CI) 
NPV                          
(%, 95% CI) 
PLR NLR 
LOW GRADE CYTOLOGY 
1. Referral screening test 
 
40.9, 26.3 – 56.7 19.3, 10.1 - 31.9 28.1, 18.6 - 40.1 29.7, 17.4 - 45.8 
0.51,  
0.35 – 0.74 
3.06,  
1.7 – 5.5 
2. Referral test & CINtec* 
(n=64) 
100, 81.4 - 100 71.7, 56.5 - 84.1 58.1, 40.7 - 73.5 100, 89.5 - 100 
3.54,  
2.23 - 5.61 
** 
3. Referral test & p16/Ki67 
curettings (n=64) 
61.1, 35.7 - 82.7 82.6, 69.3 - 90.9 68.7, 44.4 - 85.8 84.4, 71.2 - 92.2 
5.26,  
2.13 - 12.9 
0.44,  
0.24 - 0.79 
Difference (%, CI, p-value) 
1 vs 2 
1 vs 3 
2 vs 3 
 
59.1, 48.6–68.1, <0.001 
20.2, 4.5-34.3, 0.01 
38.9, 26.5-51.1, <0.001 
 
52.4, 37.5-63.9, <0.001 
63.3, 47.3-73.8, <0.001 
10.9, -6.3-27.4, 0.21 
 
30, 8.9-48.2, 0.004 
40.6, 13.4-60, 0.002 
10.6, -18.2-34.9, 0.4 
 
70.3, 51-82.4, <0.001 
54.7, 22.8-69.2, <0.001 





HIGH GRADE CYTOLOGY 
1. Referral screening test 
(n=101) 
59.1, 43.2 - 73.6 80.7, 68.1 - 89.9 70.2, 54.2 – 82.5 80.7, 68.6 – 88.8 
3.06,  
1.71 - 5.50 
0.51,  
0.35 - 0.74 
2. Referral test & CINtec* 
(n=37) 
100, 86.7 - 100 36.4, 10.9 - 69.2 78.8, 62.2 – 89.3 100, 51.1 - 100 
1.57,  
1.01 - 2.46 
** 
3. Referral test and p16/Ki67 
Curettings (n=37) 
100, 86.7 - 100 81.8, 48.2 - 97.7 92.8, 77.4 – 98.0 100, 67.5 – 100 
5.50,  
1.57 - 19.2 
** 
Difference (%, CI, p-value) 
1 vs 2 
1 vs 3 
2 vs 3 
 
40.9, 27.8-50.6, <0.001 
40.9, 27.8-50.6, <0.001 
N/A 
 
44.3, 25.9-59.3, <0.001 
1.1, -15.4-13.8, 0.88 
45.4, 23.2-61.7, <0.001 
 
8.5, -12.1 – 27.6, 0.4 
22.5, 2.7-39.4, 0.02 
14, -4.7-31.3, 0.1 
 
19.3, -30.4-31.2, 0.3 
19.3, -14.2-31.2, 0.1 





* CINtec is p16/Ki67 cytology  
** could not calculate as the sensitivity was 100% 
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The NLR for standard cervical screening in women with low grade cytology and a TZ3 is 
very poor; a result greater than 0 implies that the screening test is not very useful in 
identifying the absence of CIN2+, which triangulates with the poor NPV and sensitivity. As 
a negative dual-stained cytology result perfectly predicted the absence of CIN2+ it was 
not possible to calculate a NLR, denoting the utility of this test for identifying the absence 
of CIN2+.  
7.3.6.2 High Grade Cytology 
In women with high grade cytology, the PPV and NPV of the screening test were improved 
by both dual-stained cytology and curettings. Indeed the NLR could not be calculated as a 
negative result, for both tests, perfectly predicted the absence of disease (Table 7.8). Of 
11 women with <CIN2 who had a LLETZ for high grade cytology and a TZ3, dual-stained 
cytology would have identified (prevented over-treatment) in 36.3% (4/11) women 
(Figure 7.5b) and dual-stained curettings 72.7% (8/11) women (Figure 7.5c).  
The PLR for high grade cytology predicting CIN2+ was not improved by the addition of 
immunostained curettings and reduced, by 15%, following the addition of dual-stained 
cytology. These results triangulate with the poorer PPV / specificity of dual-stained 
cytology for CIN2+ in women with high grade cytology and a TZ3 and the reduced need 
for adjuncts in these women, when compared to women with low grade cytology.  
Figure 7.5: Visual representation of false positive and false negative screening by 
the most predictive tests when compared to the current referral screening test. 






HR HPV                     
n=101 
High Grade Cytology 
n=37 
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Figure 7.6: Treatment Algorithm A – potential management of women with low 




















High risk HPV & Low grade cytology        
PPV 28.1%, NPV 29.7% 
Dual-stain 
cytology 
Positive Result                                  
PPV 71.7% (95% CI 40.7 – 73.5) 
Negative Result                                    
NPV 100% (95% CI 89.5 – 100)             
6m cytology in 
primary care 
LLETZ 
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Figure 7.7: Treatment Algorithm B – potential management of women with high 


















High risk HPV & High grade cytology   
Sensitivity 59.1%, Specificity 80.7% 




No  Yes             
LLETZ Risk of non-attendance or 
risk factors for progression? 
 
Yes             No          
Immunostained curettings  
Sens 100%, Spec 81.8% 
CIN2+ 
 
4m cytology with 
Cervex-Brush 
Yes         No          




Involvement (and endorsement) of a patient participation group whilst I was writing the 
study protocol was extremely useful in ensuring clarity during discussions with the ethics 
committee; this meeting focused on the recruitment process and the potential 
contribution of the study to women’s health care. Of 153 eligible women, 105 were 
recruited. Only one woman declined when approached and indeed women who had seen 
the recruitment posters made participation enquiries, suggesting the value women 
attribute to this research. As the same sample was used for both the index and reference 
tests, the patient demographics were balanced between cohorts. 
Further strengths included whole sample verification using the reference standard and a 
short period of time between the index and reference tests to reduce the risk of CIN 
progression or regression. Furthermore, unlike a retrospective review, which seeks 
women known to have high grade disease, the prospective nature of this study promotes 
a realistic assessment of biopsy confirmed high-grade CIN; incorporation (work-up) bias 
was avoided as the outcome of the index test was not known prior to the reference 
standard.  
Double data entry removed bias caused by erroneous and missing data. A sample size 
calculation, which was achieved, helped ensure sufficient power. Reproducibility was very 
good as shown by the inter-rater reliability of the most predictive tests. Blinding of the 
cytologists and pathologists interpreting the index and reference samples will reduce 
expectation bias. ThinPrep liquid based cytology media was used as dual-stained slides 
processed from samples stored in a SurePath medium have a lower sensitivity[215]. When 
there was a mismatch between the referral cytology and LLETZ histology all slides were 
double reviewed and the diagnosis confirmed or refuted. Finally, the clinical data that was 
used to interpret these test results will be available in 2019 when primary HPV screening 
is introduced in the UK making these results relevant to clinical practice. 
 
7.5 Limitations 
Selection bias needs to be considered. Randomisation is the most effective method but 
with a small target population this may sometimes not be practical. The sample needs to 
be large enough to detect an effect size and randomisation, in this case, may have reduced 
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the final sample size. Whole cohort sampling would ensure an accurate representation of 
the target population and potentially allow the achievement of the sample size 
calculation. This was my aim. Of the 47 women who were not recruited, competing clinical 
duties rather than declining participation, were the cause. This was likely to be random in 
nature, as my duties occurred on different days in the month. This suggests the study 
sample may be representative of the target population but if future studies aim to 
corroborate my results, the use of multiple centres which will allow for randomisation of 
recruitment would reduce selection bias.  
The logistics of consent, taking the samples, completing the LLETZ and trial paperwork 
(labelling the samples, completing the GP letter, photocopying the consent for the 
medical records and participant, registering the samples on the national database and 
completing the baseline proforma), took approximately one hour per participant, which 
the colposcopists were unable to complete during a busy clinic. Although this 
standardized sample taking and reduced missing data, as I did all recruitment and sample 
taking, future studies should assess outcomes based on multiple sample takers. 
Furthermore, of four women who had adequate dual-stained cytology samples a curette 
could not be passed; to prevent crushing of the epithelium I did not dilate the cervix, but 
this could be assessed in future studies. 
Repeating the cytology between 5 - 11.5 weeks of the referral test risks false negative 
results. However, due to limited storage capacity the referral cytology is disposed of by 
the first colposcopy appointment, TZ sampling was present on 99.1% of the index slides, 
the inadequate rates were equivocal to national cytology standards[216] and taking the 
index tests on the same day as the reference test reduces mismatch due to immuno-
clearance. The small number of smokers in the study sample will also reduce mismatch 
between the referral and index cytology but this may affect the incidence of CIN2+ in 
populations which have higher rates of smoking. 
The median depth of LLETZ was 15mm (the minimum recommended by the BSCCP) which 
could have been secondary to shrinkage or human error, however the TZ was reported to 
be present in all samples. Seven of the endocervical curettings (five women with low 
grade cytology and two women with high grade cytology) were reported as CIN2+ but the 
corresponding LLETZ report stated <CIN2; removal of focal CIN2+ with the curette could 
account for this. Sub-analysis identified no difference in specificity if these LLETZ were 
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upgraded to CIN2+, but future large studies should assess the accuracy of the dual-stained 
cytology and curettings in women who have one index test to reduce the impact of sample 
taking on their individual accuracy. I stored the index cytobrush and Cervex-Brush samples 
in the same pot but future studies could store these separately to assess the contribution 
of the cytobrush sample alone. 
Finally, the sample size for the genotyping was smaller than calculated; if the effect size 
was small I may not have detected a difference, accepting the null hypothesis when it may 
in fact be false. 
 
7.6 Conclusions 
The introduction of primary HPV testing will improve the NPV of cervical screening but 
the PPV is still poor in women with low grade cytology and this is compounded in women 
with a TZ3 where histological selection for treatment cannot be undertaken.  
Irrespective of TZ type, the majority of women with high grade cytology (80%) will have 
CIN2+. In those women at high risk of treatment morbidity (young and nulliparous), dual-
stained curettings could be used to detect false positive screening in 72.7%. In all other 
women, my results suggest excision should be offered.  
Women with low grade cytology, high risk HPV and a TZ3 have a two-fold increased risk 
of CIN2+ (36.7%) when compared to women where the TZ is visible. However, excision 
should not be the primary management as the majority of these women (63%) have <CIN2 
at LLETZ. My results suggest the use of dual-stained cytology will prevent overtreatment 
in 58.1% (PPV) of women with <CIN2 but more importantly detect 89.5 - 100% of women 
with CIN2+ (NPV). This will improve the accuracy of routine screening for CIN2+ which has 
a PPV of 28.1% and a NPV of 29.7% in women with low grade cytology and a TZ3. 
In women with a TZ3 the cytobrush + Cervex-Brush increased the cytological yield of 
endocervical cells when compared to the Cervex-Brush alone but there was no difference 
in predictability of CIN2+ in women with low grade or high grade cytology between 
sampling methods. This suggests women who will reliably attend for cytological follow-up 
can be safely referred to primary care for a Cervex-Brush alone. 
 




In this thesis I have explored the impact of HPV testing on the specificity of cervical 
screening in women with a TZ3. I evaluated colposcopists’ decision-making when 
managing women with a TZ3 and provided recommendations for a national consensus 
strategy. I used HPV genotyping and surrogate biomarkers for HPV, in conjunction with 
cervical cytology and histology, to evaluate the sensitivity and specificity of these 
investigations individually and in combination when compared to routine screening. I 
have considered the effect of different immunostaining and diagnostic categories on the 
accuracy of these tests and proposed new scoring protocols. Finally, I have examined the 
contribution that a cytobrush adds to the diagnostic accuracy of a Cervex-Brush in women 
with a TZ3 to guide colposcopists in the optimal technique and clinical setting for 
cytological follow-up. 
In this chapter I will reflect on the main findings, how these can be interpreted in line with 
the current literature and explore potential reasons for the differences between my 
results and those reported from other studies. I will also discuss how I aim to progress 
with my investigations in view of the limitations of my studies and my own personal 
development during the course of this thesis. 
 
8.1 The impact of HPV testing on negative LLETZ histology 
This cohort study of 802 women provides contemporaneous information on the impact 
that HPV testing will have on false positive screening and suggestions for where future 
improvements in the screening programme should be targeted. Negative LLETZ is an 
important performance indicator in colposcopy and quality management of a cervical 
screening programme. This study has provided evidence, for the first time, that the 
incidence of negative LLETZ has decreased following the introduction of HPV testing but 
the prevalence of false positives is still high at 13.4%. Risk factors for negative LLETZ in the 
HPV testing cohort were a TZ3, low grade cytology and parity greater than two. Women 
with both low grade cytology and a TZ3 were most at risk (absolute risk 40%). 
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8.1.1 Potential confounders 
The reported incidence of negative LLETZ in women with biopsy confirmed CIN2+ varies 
from 5.9% to 41%[105, 160-164]. The rates in my study fell within this range. To determine 
whether the differences in the incidence of negative LLETZ can be attributed to HPV 
testing, rather than confounders, variables which can affect the histological outcome 
were compared between the pre- and post-HPV testing cohorts. A negative LLETZ can 
occur when CIN is not removed with the initial treatment or missed during interpretation 
of the histology, but there was no evidence of a difference in the incidence of post-LLETZ 
dysplasia between cohorts. Variables such as referral cytology, limiting histological factors 
and inclusion of the transformation zone in the LLETZ sample were equivocal. The interval 
between the referral cytology and LLETZ were also similar, reducing the impact of 
immuno-clearance on the outcome histology. Furthermore, the routine practice of cutting 
extra levels and double reporting the LLETZ histology when it is initially identified as 
normal, standardizes reporting across the cohorts.  
Focal lesions which may have been removed after punch biopsy can affect outcomes but 
a strict selection criteria for treatment in both cohorts mandated that confirmatory 
biopsies were needed prior to treatment if a significant change in lesion size and / or 
grading occurred. This policy does not account for patient choice such as women who 
prefer excision to repeat biopsy, but this should be documented in the medical records. 
Changes in national policy could affect the incidence of negative LLETZ between cohorts 
but the following NHS CSP recommendations were no different pre- and post-HPV testing:  
(a) ‘Treatment should be offered with a histological diagnosis of CIN2+’  
(b) ‘If a TZ1 - 2 is present and CIN1 is detected, offer cytological follow up for 24 months’[35].  
The difficulty, as illustrated by my results, is when women present with a TZ3.  
 
8.1.2 The impact of HPV testing 
HPV testing is a more sensitive cervical screening test than cytology alone for the 
detection of squamous cell lesions and my results suggest the incidence of false positive 
screening has decreased since its introduction. Recent UK cervical cancer screening 
statistics support my findings[87]; they have reported an increase in the proportion of 
women reviewed in colposcopy with CIN following the introduction of HPV triage of low 
grade cytology i.e. improved detection of dysplasia which reduces the incidence of 
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negative LLETZ. It is not the rate of CIN that is increasing but rather the proportion of 
women referred to colposcopy with no dysplasia that is decreasing. This has important 
clinical ramifications; as seen in 4.3.3.1, unless colposcopists are updated on this new 
information they may perceive women who have had HPV testing to be at increased risk 
of dysplasia which will increase anxiety and the rates of negative LLETZ. 
 
8.1.3 Predictors of negative LLETZ 
My findings support the importance of colposcopic assessment and confirmatory 
biopsies[105, 163] – which reduced the incidence of negative LLETZ by 75% if CIN2 was 
detected. In the presence of CIN3, this protective effect was not apparent and may be 
secondary to the removal of focal dysplasia or a post biopsy inflammatory response. 
Although confirmatory biopsies should be taken if a change in lesion has occurred prior 
to LLETZ, in the presence of biopsy confirmed CIN3, the colposcopist or woman may be 
anxious and prefer LLETZ irrespective. It is essential that colposcopists explain the 
potential benefits to the woman of confirmatory histology if a significant change in the 
lesion has occurred. The importance of adhering to national guidance[35] and routinely 
incorporating vaginal assessment in the colposcopic examination seems clear as 1% of 
women with a negative LLETZ will have VAIN and an unnecessary LLETZ if not completed.  
The use of the COCP reduced the risk of negative histology by 60% when compared to 
those who did not use any contraceptive and this may be a reflection of the higher rates 
of a TZ1-2 seen in this cohort. Despite the improved sensitivity of HPV screening, my 
results indicate that women with a TZ3 and low grade cytology are 10 times more likely 
to have a negative LLETZ when compared to women where the TZ is visible. In women 
with false positive cytology and a TZ3, colposcopic assessment or a reassuring biopsy 
cannot be undertaken and this may account for the increased incidence of negative LLETZ 
observed in this cohort. There are currently no UK recommendations to guide the 
management of a TZ3 in the presence of low grade cytology[35].  
The American Society for Lower Genital Tract Disorders recommends that women with 
low grade cytology should not be treated unless high grade CIN is detected on biopsy[97]. 
As endocervical curettage is not routine practise in the UK, it is difficult to implement this 
policy and provide histological confirmation in the presence of a TZ3 without offering a 
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LLETZ. Colposcopists are reliant on the diagnostic value of the screening test, patient 
preferences and their own experience of managing these women to determine who 
requires treatment. Assessment of how and why colposcopists manage women with a TZ3 
may be of use in reducing negative LLETZ histology by providing evidence to guide a 
national consensus strategy. 
 
8.2 Colposcopists’ decision-making in women with a TZ3 
The exploration of factors which influence decision-making may enable targeted 
guidance; in women with a TZ3 this may aid in the reduction of negative LLETZ histology. 
As such, this study targeted an important issue – the ways in which medical practitioners, 
in this case colposcopists, make decisions under conditions of uncertainty. A qualitative 
approach sheds a useful light on the process of decision-making and to the best of my 
knowledge this is the first study which has addressed this issue.  
Where rational judgement, cognition and affect could be applied, areas of consensus were 
identified; a multidisciplinary team decision, patient preference, a high-risk screening 
result or a low-risk result in combination with patient risk factors such as poor compliance, 
smoking, high parity, older age or persistent high risk HPV resulted in recommendations 
for excisional treatment. In areas of clinical uncertainty colposcopist’s experience, 
knowledge, perception and affect influenced decision-making. When faced with an 
inability to provide colposcopic assessment or diagnostic histology the psychological 
stress of missing a cancer, even in women with low grade screening, deterred prolonged 
or community based cytological follow-up. Anxiety of treatment-morbidity influenced 
excision depth, with the majority of colposcopists deviating from national 
recommendations and reporting a preference for 7-10mm excisions - the depth 
recommended when the transformation zone is visible. A paucity of guidance[35, 97, 98] and 
patient anxiety further compounded decision-making and led to heterogeneity in care. 
 
8.2.1 The effect of clinical uncertainty on decision-making 
Decision-making is a complex process which incorporates knowledge, risk assessment, 
analytical skills, prior experience and affect[217]. Decision-making can be challenging in 
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areas of clinical uncertainty where guidance is sparse[218, 219], when an adverse outcome 
such as a cancer may occur as a result of the decision[220] or if a large number of variables 
need to be contemplated when making a decision[218].  
These themes were illustrated in this qualitative study when participants, particularly 
gynaecological oncologists, suggested that the possibility of removing high grade disease 
outweighed the risk of treatment-related morbidity if women had significant risk factors 
for dysplasia. Whilst conscious of the risk of over-treatment, particularly in younger 
women, participants were more concerned about missing a developing cancer. This 
finding is supported by studies which have shown that in areas of uncertainty, decisions 
are made faster and more easily by relying on emotion[221]. Furthermore, when an emotive 
thought induces anxiety, this can lead individuals to place more weight on the negative 
outcomes than the positive[222, 223]. Once distracted by a negative stimulus it is then 
difficult to divert attention from these negative thoughts[224]. Anxiety has been associated 
with increased amygdala and reduced pre-frontal activity[225]; this suggests that in areas 
of uncertainty the affective components of decision-making may take precedence over 
rational cognitive elements[226, 227]. Clinicians strive to balance the risks and benefits of 
intervention but perception of risk differs dependent upon experience and personality. 
The value of guidance seems clear when rational thought is superseded by affect. 
 
8.2.2 The influence of a high risk HPV result on decision-making 
Uncertainty of decision-making in women with low grade cytology was reduced by the 
perceived increase in risk that a persistent HPV result conferred. However, recent 
evidence has shown that the proportion of women with a low grade screening result and 
subsequent grades of CIN 1, 2 or 3 are no different following the introduction of HPV 
testing[87]. What has fallen is the number of women referred to colposcopy with 
inadequate results and normal colposcopy[87] which, as alluded to in section 8.1.2, could 
be falsely viewed as an increase in individual risk, leading to a more aggressive 
management approach when histological selection for treatment is not possible. Most 
people are naturally risk adverse and look to avoid poor outcomes by selecting the least 
risky option[228].  
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Uncertainty of outcome (inability to visualise the transformation zone) heightens anxiety 
and compounds this risk aversion. When it is not clear whether the alternative decision 
may result in further risk or benefit, willingness to take a risk, in this case prolonged 
cytological follow-up, is avoided[229]. National guidance on the risk conferred by a high risk 
HPV result in women with low grade screening and a TZ3 may reduce the dominant role 
of affect and strengthen the cognitive component of decision-making (see section 8.4.1).  
 
8.2.3 Shared care model 
Patient choice was cited as a major influence affecting decision-making. The majority 
(81%) of referrals to colposcopy are for low grade screening results[87] but patients report 
the same level of anxiety irrespective of the cytological grade[103]. This anxiety is driven by 
fear of cancer, worries that subsequent cytology will be abnormal and future fertility 
concerns[103, 230]. There is a plethora of literature assessing women’s preferences for the 
management of low grade cytology when colposcopy is satisfactory, with the majority of 
studies showing a preference for colposcopic review over cytological surveillance[231, 232]. 
Furthermore, if cytological follow-up is chosen, women have cited a preference for 
‘regular’ screening[233]. When the clinical outcome is uncertain and condition specific 
information is sparse (as with a TZ3), patients can either be influenced by health care 
professional preferences for treatment or their anxiety can prevent attendance for follow-
up[103, 210]. 
Until such time as one outcome is shown to be superior to another or patient preferences 
for management of a TZ3 have been assessed, it could be argued that colposcopists should 
advocate the more cost-effective approach of cytological follow-up. However, in a shared 
care model, determining patient preferences will improve patient satisfaction and 
outcomes[234] – even if this involves, as shown in our study, young women with low grade 
screening and low risk factors for CIN progression choosing excisional treatments over 
cytological follow-up. This illustrates the importance of assessing LLETZ outcomes in 
women with a TZ3 and improving the specificity of screening as the provision of a targeted 
diagnostic test and information may reduce health care provider and patient anxiety, in 
turn reducing negative LLETZ histology and non-attendance rates. 
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To reduce the emotional burden of decision-making, health care providers will defer 
management decisions[235]. In my study, the majority of participants expressed a 
reduction in emotional burden following an MDT decision to offer excision, particularly in 
young and/or nulliparous women. This finding is supported by studies which have shown 
a reduction in colposcopy overtreatment following an MDT review[236]. Although, with a 
paucity of evidence to guide this expert body’s management, homogeneity of care may 
be achieved within departments or regions but may not occur at a national level.  
 
8.2.4 Paucity of evidence affects decision-making 
In areas that lack evidence prior expertise can form the basis of decision-making[237] and 
this can lead to heterogeneity of care. This was evident when participants recommended 
different collection methods and clinical settings for cytological follow-up. Colposcopy 
nurses preferred community follow-up and this may be a reflection of the higher volume 
of patients they see. In contrast, the majority of doctors favoured colposcopy follow-up, 
and this attitude may be influenced by the higher proportion of women with cervical 
cancer they manage. Although current evidence suggests an increased cytological yield 
when using a cytobrush in combination with a Cervex-Brush[238], there is a paucity of 
evidence correlating this yield of cells with improved detection of dysplasia in women with 
a TZ3[239]. This lack of knowledge and the inability of community services to offer a 
cytobrush compounded decision-making, particularly for doctors. Studies which improve 
knowledge in this area may aid rational judgement. 
Prior experience and lack of evidence influenced the depth of excision that colposcopists 
recommended. They offered a LLETZ to aid diagnosis of CIN but they were anxious about 
the treatment-related morbidity and preferred a 7 - 10mm LLETZ rather than the 15 - 
25mm advocated in recent national guidance[35]. Although there is a paucity of evidence 
which adjusts for age and parity when assessing the endocervical position of the TZ, the 
disadvantage of shallower treatments is relying on patients to return for a second 
treatment if CIN is diagnosed or false negative histology if dysplasia is positioned distally 
in the endocervical canal. 
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8.2.5 The quandary of evidenced-based guidelines 
Colposcopists are independent practitioners and it could be argued that guidance may 
not be necessary in scenarios which lack consensus of opinion. Furthermore, it is clear 
that not all clinical scenarios can conform to guidance and removing all uncertainty from 
the medical profession may hinder adaptability, critical analysis, maturity of thought and 
patient choice. Evidence has suggested that experts are ‘wise risk takers’[240], their 
knowledge reduces anxiety and uncertainty allowing them to make decisions which 
deviate from set guidance to individualise care[241]. Despite this, part of a clinicians’ duty 
is to reduce patient anxiety and optimise clinical outcomes - but how can this be achieved 
if the clinician themselves is plagued by anxiety? In situations where there is a lack of clear 
evidence, affect may compromise rational judgements. Homogeneity of care improves 
service provision and clinical outcomes through consistent use of evidenced based 
interventions[242]. Guidelines improve decision-making in areas of ambiguity, recognize 
shortfalls in the literature, provide assurance that clinicians are advocating appropriate 
treatments and promote under-recognised and neglected patient cohorts.  
 
8.2.6 Summary 
The focus groups provided depth of information, assessing not just how colposcopists 
manage women with a TZ3 but why. This part of my research may have been affected by 
geographical bias and to address this, the national survey that I developed aimed to ratify 
my guideline recommendations (Section 8.6) by evaluating the frequency of the opinions 
identified in the focus groups. 
 
8.3 Current management of a TZ3: A UK survey 
This is the first study which has developed a reliable and valid questionnaire to assess how 
UK colposcopists’ manage women with a TZ3. The information provided will add to the 
literature by focusing training needs, clarifying guidance and directing future research.  
There were areas with a clear consensus that supported the findings from the focus 
groups and these included; offering excision to all women with high grade cytology and 
women with low grade cytology who have risk factors for disease progression such as 
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smokers, non-attenders and parous women. In women with low grade cytology and an 
incomplete family, there is a strong preference for colposcopy follow-up. In 
postmenopausal women the majority of colposcopists offer topical oestrogen to improve 
the adequacy of the examination but no other adjuncts, such as biomarkers or 
genotyping, are routinely used. Areas of discordance, which are affected by paucity of 
evidence, include the interval between follow-up appointments, total length of follow-up 
before recommending a LLETZ and a preference for a shallower excision (7-10mm) than 
currently recommended by the NHS CSP. 
 
8.3.1 Initial management of low grade cytology 
The majority of colposcopists, irrespective of experience, job title or gender, reported a 
strong preference for cytological follow-up. The patient’s parity and age decreased the 
strength of this association. As outlined in section 1.2.4.3, existing evidence would 
support stratification of patient risk factors as it has been estimated that smokers are 1.6 
times more likely to develop squamous cell cervical cancer when compared to never 
smokers[40] and parity, greater than four, increases the odds of a squamous cell cancer 
four fold when compared to nulliparous women[60]. 
Evidence is contradictory regarding the association of older age with HPV clearance. The 
5 year risk of CIN3+ has been reported as comparable in women with low grade cytology 
who are aged 25 - 29 years and 30 - 64 years (5% and 5.2% respectively)[243] - this finding 
is supported by other large studies which have adjusted for parity and lifestyle choices[213]. 
Many countries, particularly the USA, recommend that women under the age of 30 should 
not have HPV screening as at least 50% will have a transient HPV infection and this reduces 
the PPV of screening for CIN2+[92] .  
In the UK, 25% of girls have their first sexual contact before the age of 16 and this 
proportion, plus risky sexual behaviour, has been increasing over the last decade[244]. 
Integration of HPV following early age of first intercourse may be mediated by a large, 
metaplastic ectocervical TZ or an immature immune response[38] and this makes younger 
women more vulnerable to acquiring, retaining and transforming a HPV infection. This 
evidence and UK cancer statistics which reported that cervical cancer is the most common 
cancer in women under 35[3] suggest not only a need for HPV screening but a need for 
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methods which can improve the PPV of screening in young women, particularly when 
assessment of the TZ is not possible.  
 
8.3.2 Cytological follow-up with low grade cytology 
8.3.2.1 Clinical setting 
Similar to the focus groups, the data suggest colposcopists have a strong preference for 
colposcopy clinic follow-up to facilitate the use of a Cytobrush in combination with a 
Cervex-Brush. Colposcopists’ rely on the accuracy of the referral cytology to aid decision-
making in women with a TZ3 and they assume, although it is not proven, that TZ sampling 
is required to optimise this result[101]. Three inadequate samples with a Cervex-Brush 
alone are required in the community before a colposcopy referral is instituted which can 
delay assessment of women with potential dysplasia. 
Of the studies evaluating liquid based cytology devices[79, 81, 83, 214], none have correlated 
their findings with topographical position of the TZ. Decision-making in women with a TZ3 
would be enhanced by population specific studies which adjust for topographical position 
of the TZ, age and parity when evaluating cytological collection devices (Section 8.4.2). 
8.3.2.2 Frequency and total length of follow-up before offering a LLETZ 
UK guidance denotes that women with low grade cytology should be reviewed twice at 
12 monthly intervals, prior to offering a LLETZ, if CIN1 or less is identified at colposcopy 
[35]. Of those women who test positive for high risk HPV, 61% can have a positive test six 
months later whereas only 35% are positive at 12 months indicating the utility of waiting 
at least six months before retesting [158]. In women with a TZ3 there is a preference for six 
monthly follow-up. As identified in the focus groups, there is a preference to offer LLETZ 
if dyskaryosis is persistent 12 months after the referral cytology in women ≥40 or when 
the family is complete. In women aged 25 – 39 there was no consensus on the total length 
of follow-up before recommending a LLETZ. 
 In the absence of colposcopic assessment, or confirmatory histology, my findings suggest 
colposcopists’ feel a responsibility to ensure these women are reviewed regularly to 
prevent loss to follow-up and to make a diagnosis. Studies which assess the LLETZ 
outcomes and progression rate of CIN in women with low grade cytology, high risk HPV 
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and a TZ3 are needed to improve homogeneity of care, to optimize outcomes and improve 
service efficiency. 
Whilst not a reported concern in the survey, focus group participants emphasized the 
impact that a high risk HPV result had on their decision to offer a LLETZ, if still persistent 
6 to 12 months after the referral screening test. The involvement of two of the focus group 
units in the Sentinel Sites Study, with the increased exposure to outcomes in women with 
high risk HPV, may have contributed to the perceived increase in risk and preference for 
treatment in women with a 12 month history of high risk HPV (Section 8.2.2). This finding 
illustrates the relevance of improving diagnostic accuracy and providing targeted 
guidance in women with a TZ3 before the introduction of primary HPV testing in 2019 
similarly influences decision-making nationally.  
8.3.3 Repetition of the referral cytology 
In line with national UK recommendations[35], 70.2% of colposcopists do not repeat the 
referral cytology at the first colposcopy appointment. Of note, 29.3% do repeat and the 
main reason reported is the belief that a Cervex-Brush alone may not adequately sample 
a TZ3. Recent UK guidance recommends that the presence of endocervical cells should 
only be reported in women with previous cGIN[78] (Section 1.4.1.1) but this has clearly 
impacted on colposcopist’s management of women with a TZ3, increasing the potential 
for false negative screening on the repeat cytology. Until studies have assessed the 
diagnostic accuracy of a Cervex-Brush alone in this cohort, it would seem safest to adhere 
to national recommendations and rely on the referral screening test result. During 
construct validity testing 91.7% did not repeat the cytology; this increased adherence to 
national guidelines may be a consequence of completing the form in front of me.  
 
8.3.4 The use of adjuncts to improve decision-making 
To aid decision-making the majority of participants use oestrogen, a fifth HPV genotyping, 
10% endocervical curettage and 3% surrogate biomarkers for HPV. Use of these adjuncts 
may be affected by cost, access to these investigations - as only specific laboratories 
undertake HPV genotyping - training in endocervical curettage and experience of 
processing and interpreting immuno-stained cytology and histology. This part of my 
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research would have been improved by the addition of items within the questionnaire 
which assessed colposcopist’s access to and acceptability of these adjuncts. 
The majority of colposcopists (89.7%) recommend topical oestrogen in postmenopausal 
women to improve the visibility of the TZ or the quality of the repeat cytology. 
Gynaecological oncologists are less likely to advocate this practice and this may be a result 
of the larger proportion of oestrogen driven cancers that they manage. Studies have 
shown TZ eversion success rates of 64% and 70% with six weeks of topical[119] and four 
weeks of systemic oestrogen[117], but most of these studies were based on small sample 
sizes and the use of oestrogen relies on patient acceptability or compliance (which has 
not been assessed). Post-menopausal women, who would benefit most from oestrogen, 
are least at risk of treatment morbidity but potentially at higher risk of disease progression 
due to their increased parity.  
In pre-menopausal women with atrophic changes, only 45% of colposcopists offer topical 
oestrogen and only 9% the combined oral contraceptive pill. Factors which could influence 
this choice include an inability to prescribe, health care professionals are medico-legally 
obliged to do a lengthy ‘pill teach’ as it is a contraceptive, patient choice and compliance, 
concerns of loss to follow-up and the side-effect profile – all of which need to be assessed 
during a busy clinic.  
A TZ3 may be more prevalent in postmenopausal women[101] but there are no cross-
sectional studies which corroborate this, particularly in view of the high proportion of 
young women who do not use the COCP. Where oestrogen is not acceptable, applicable 
or does not evert the TZ, the use of HPV genotyping or surrogate biomarkers for HPV may 
be of benefit and their utility are discussed in Section 8.4. 
 
8.3.5 Initial management of high grade cytology 
LLETZ is the primary management choice in all patient demographics but age and parity 
affect the likelihood of this choice. In women whose family is incomplete a higher than 
anticipated proportion of colposcopists, particularly nurses, refer women for MDT review; 
30% of respondents refer women aged 25 - 39 and 20% refer women aged ≥40. Of note, 
10% recommend three month cytological follow-up in women aged 25 - 39. 
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An American study reported that the risk of high grade CIN and cancer is increased in 
women aged 30 - 64 with high grade cytology when compared to women aged 25 - 29 
(47% vs 28%, p=0.04 and 7.3% vs 2%, p=0.004)[182]. UK screening statistics, although not 
adjusting for age or parity, report an 84.5% chance of CIN2+ and a 2.6% chance of cancer 
with high grade cytology[5]. Although neither of these studies adjusted for topographical 
position of the TZ, until population specific evidence is available, particularly in view of 
the young age of sexual debut in the UK, it would seem safest to recommend a LLETZ in 
all women with high grade cytology and a TZ3. A policy of delayed excision does not 
account for patient choice or reliability. Furthermore, patient anxiety, which arises from 
uncertainty of histological diagnosis, is reduced when women with high grade cytology 
are offered treatment at the first appointment[245]. 
 
8.3.6 Recommended depth of LLETZ 
The NHS cervical screening programme recommends a depth of 15-25mm for a TZ3 and 
7-10mm for a TZ1[35]. Irrespective of cytological grade, and as identified in the focus 
groups, colposcopists’ report a strong preference for 7-10mm in women with a TZ3 when 
the family is incomplete. A depth ≤6mm was included as a negative control for the 
construct validity but 10% of respondents reported a preference for this depth in young 
women with low grade cytology. In all women with high grade cytology and in women 
with low grade cytology and a complete family, half of the respondents recommend 11-
15mm. This discrepancy suggests colposcopists are aware of UK recommendations but 
anxiety for future fertility and the ability to offer a second, more targeted treatment if the 
first is diagnostic for CIN2+ appears to supersede this knowledge. 
Although consideration needs to be applied to the risks of preterm labour, the oncological 
consequences of incomplete margins or false negative histology, particularly in women 
with high grade cytology, also needs to be contemplated. As does the risks of non-
attendance for follow-up or repeat LLETZ. It is importance to emphasize that recurrence 
of CIN2+ has a prevalence of 18% with incomplete margins vs 3% if complete[106]. 
In Section 1.5.4 a review of the available literature illustrated that knowledge of the 
maximum depth of the epithelial crypts is important to reduce recurrence of CIN and to 
inform depth of LLETZ. It is also important to know the mean topographical position of 
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the transformation zone to estimate where the crypts may begin. A study which adjusted 
for age but not TZ type reported that total volume of crypt involvement and the mean 
depth of the proximal margin was smaller in women aged 20 - 40 when compared to 
women over 50 (61.5% and 12.5mm vs 88.3% and 16.4mm)[108]. Furthermore, the mean 
depth and the total volume of crypt involvement is reported to be increased with parous 
women when compared to nulliparous (13.5mm and 71.1% vs 12.6mm and 51.8%)[108, 246].  
Although the evidence that UK guidance[35] is based upon did not correlate excision depth 
with TZ type, age or parity, the findings above suggest colposcopists’ may be 
undertreating this cohort of women. This has not been reported before and, although it 
was not an initial aim of my thesis, suggests that colposcopists require evidence that the 
benefits of a deeper excision outweigh the risks. Methods which improve the diagnosis of 
CIN2+ in women with a TZ3 and studies which adjust for age and parity when determining 
the mean topographical position of a TZ3 will aid this decision-making. 
 
8.4 Improving diagnostic accuracy in women with a TZ3 
As far as I am aware, this is the first study following the introduction of HPV testing which 
has been specifically designed to improve the accuracy of screening in women with a TZ3.  
8.4.1 Study population 
The majority of the study population were pre-menopausal women and half were of 
prime reproductive age. These results suggest a TZ3 is not a condition that is solely 
attributed to poorly oestrogenised older women who are at low risk of treatment-related 
morbidity. In chapter 3[247] I reported an association between a TZ3 and age >50 but the 
population these data were based upon also included women in the non-HPV testing 
cohort. Half of the study population in Chapter 7 were not oestrogen deficient (using 
progesterone contraceptive or post-menopausal) and this finding was supported by the 
outcomes in chapter 3[197]. This indicates that the use of oestrogen, even if acceptable to 
the patient, may not be of benefit in everting the TZ. Indeed, in pre-menopausal women 
the focus group and national survey participants did not routinely use oestrogen even if 
atrophic changes were identified[101, 248] – suggesting a need for other adjuncts to improve 
diagnostic accuracy. 
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In comparison to national screening statistics (where 80% of the women assessed will 
have a TZ1-2) there was no difference in the proportion of women reviewed with low 
grade cytology (Mild or BNC)[87] but in my study sample these women had a two-fold 
increased risk of CIN2+. The strength of this association was highest in women with BNC 
suggesting that sampling of a TZ3 may make the cytology trickier to interpret. 
Furthermore, women aged 25 - 39 were four times more likely to have CIN2+ than women 
≥40. This is a significant and relevant finding which has not been reported before. Most 
of the studies assessing age related risks are from the Americas whose populations, 
including age of sexual debut and HPV subtype prevalence, are different from the UK. 
Decision-making, as suggested by the focus group and national survey data, is influenced 
by the referral cytology. In the survey and focus groups, the majority of colposcopists 
offered 25 - 39 year olds 6 to 12 month cytological follow-up. Outcome data from Chapter 
7 suggests women with low grade cytology and a TZ3 would benefit from adjuncts which 
improve the diagnostic accuracy of the screening test before discharging to the 
community, as a substantial proportion (36.7%) are at risk of CIN2+. As discussed in 8.3.1, 
risk factors for acquiring and transforming a HPV infection can differ between countries 
and the young age of sexual debut in the UK may account for these findings and ratify the 
need for population specific guidance. 
 
8.4.2 The contribution of a cytobrush in detecting cervical dysplasia 
My findings suggest that the addition of a cytobrush, irrespective of age or parity, does 
not improve diagnostic accuracy in women with a TZ3 when compared to a Cervex-Brush 
alone. Despite a median interval of eight weeks between the referral and index cytology, 
the yield of endocervical cells was increased with the addition of a cytobrush. However, 
there was no evidence of an association between the presence of endocervical cells and 
increased predictability of CIN2+, nor was there a difference in diagnostic accuracy 
between the referral and index cytology, irrespective of the cytological grade. These 
findings are relevant to clinical practice as they may affect service provision and the 
current management of women with a TZ3. 
This increased cytological yield of endocervical cells when the cytobrush is used in 
combination with the Cervex-Brush has previously been reported[239] but studies which 
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have evaluated the contribution of endocervical cells in predicting high grade disease are 
contradictory. Studies prior to the introduction of LBC promote their importance in 
reducing false negatives[80, 81] whilst other studies do not support this benefit[82]. Zhao et 
al[249] reported an increased detection of low-grade dysplasia with a Cervex-Brush LBC in 
combination with a cytobrush resulting in a US recommendation that cytological follow-
up should occur 12 months, rather than 3 years, after a negative smear that lacks TZ 
sampling[216].  
The UK has not adopted this US recommendation due to the controversy surrounding the 
association of endocervical cells with the detection of dysplasia. Furthermore, as 
discussed in 8.3.6, studies have shown that the topographical position of the TZ is more 
proximal to the ectocervix in younger women[108] which may influence sampling. In my 
study, cytological outcomes were not affected by age or parity, but half of the population 
were aged 25 – 39. To validate my findings larger studies, if the effect size is small, are 
needed to determine the relevance of the cytobrush in older women – particularly in view 
of their potential for a deeper position of the transformation zone. 
In the focus groups and national survey (Chapters 4 and 6 respectively), colposcopists 
report that diagnostic accuracy may be optimised by the presence of TZ sampling[101, 248]. 
This results in;  
a. The majority of colposcopists recommending the colposcopy clinic as the setting for 
cytological follow-up, as cytobrush sampling is not currently offered in primary care 
b. A quarter of colposcopists repeating the referral cytology at the first colposcopy 
appointment.  
These management decisions have economic as well as outcome implications. The cost of 
a follow-up appointment in the colposcopy clinic is £180 whilst a community smear is £40. 
Filling clinic lists with follow-ups who could be managed in primary care increases waiting 
times for women with abnormal screening and places increased burden on an already 
stretched tertiary care system. My data suggests that offering these women cytological 
follow-up in primary care with a Cervex-Brush alone is safe and may consequentially 
improve service efficiency. 
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8.4.3 Pooled high risk HPV testing 
My data supports the plethora of robust methodological studies which have assessed the 
use of primary HPV screening and reported a negligible risk of CIN2+ (very high NPV) in 
women who are negative for high risk HPV[35]. The difficulty for colposcopists is that their 
decision-making is based upon the poor PPV of HPV testing – they will not review women 
who are HPV negative. Indeed, seventeen (16.8%) of the women in this study who were 
referred with high risk HPV had either low risk HPV or a negative result at genotyping. 
None of these 17 women had CIN2+ and potential reasons could be immuno-clearance 
(although the median interval between the referral and index tests was nine weeks) or 
sensitivity of the Papillocheck array. Either way, this illustrates the importance of not 
offering excision based on a pooled high risk HPV result, as was seen in the focus groups, 
but rather the need for improved diagnostic accuracy in women who test positive for high 
risk HPV. This is particularly relevant in view of the imminent implementation of national 
HPV screening. 
 
8.4.4 HPV genotyping 
Irrespective of cytological grade, the predictability of HPV 16/18 genotyping for CIN2+ was 
lower than observed with dual-stained curettings or dual-stained cytology. Although a 
limitation of this part of my study was the sample size of 84, (17 women who were 
referred with high risk HPV had a negative or low risk result at genotyping), a recent large 
multicentre prospective study which grouped TZ types, and was published during the 
period I was recruiting for this study, corroborated this finding[250].  
A potential reason for the reduced specificity of 16/18 genotyping for CIN2+ may be the 
variety of high-risk subtypes that were detected in women with high grade cytology. 
Women aged <30 years of age, when compared to women ≥30 years, can have higher 
rates of CIN3+ with non-HPV 16 and 18 high risk subtypes[251] and a quarter of my study 
population were <30. My findings suggest that women who are 16 and / or 18 negative 
but positive to other high risk subtypes still have a significant risk of CIN2+ and should not 
be discharged to primary care without further assessment. This result is supported by 
other recent studies[252, 253] and may be of greater significance than previously reported as 
women vaccinated against HPV 16 and 18 are now eligible for screening. Modelling 
studies have also reported that subtypes not covered by the vaccination programme may 
‘replace’ those that are[254] (Section 1.3.1).  
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As outlined in 1.3.1, there is no denying that the introduction of a HPV vaccine will reduce 
the prevalence of cervical cancer but until a vaccine is developed which provides broad 
spectrum immunity, to boys and girls, there will continue to be a need for cervical 
screening and colposcopic assessment. Furthermore, the effects of the vaccine on the PPV 
of screening[74] mean that the development of methods which improve the diagnostic 
accuracy of the screening test, such as biomarkers, will be of increasing relevance. 
Vaccination status was not adjusted for in Chapter 7 and it would be of interest for future 
studies to assess this. Moreover, viral load may improve the specificity of screening as 
women who are high risk HPV positive may have a low-viral load secondary to immuno-
clearance [255]. The presence of HPV 16 or 18 does not mean integration into the host’s 
genome, nor the presence of CIN2+, which may account for the reduced predictability of 
genotyping. Studies which had assessed viral load were evaluated when I was writing the 
protocol for the study described in Chapter 7, but the range that constituted a ‘significant’ 
viral load differed in each of the papers that reported this finding and this range varied 
with different subtypes. Standardization of testing is currently difficult but may become 
more robust. 
Patient factors also need to be considered when assessing the impact of genotyping; HPV 
16 infection does not always equate to CIN3 but if women are informed of their positivity 
to this subtype they may request a LLETZ irrespective of the underlying pathology. 
 
8.4.5 Histological scoring protocol for dual-stained curettings 
Unlike my study in Chapter 7, to the best of my knowledge previous studies which have 
assessed the utility of endocervical curettings alone, have not evaluated their diagnostic 
accuracy in conjunction with both p16 and Ki67, corroborated all outcomes with definitive 
histology, been prospective or correlated the variables which led to increased diagnostic 
yield with topographical position of the TZ[120, 256]. Previously reported staining patterns 
were in studies where the epithelium was intact (not fragmented) and their criteria for 
negative expression included focal and sporadic staining in isolated cells and small 
clusters[137, 257] 
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To improve diagnostic accuracy I evaluated the inter-rater reliability and predictability of 
diagnosing CIN2+ by different immunostaining and diagnostic categories. As reported in 
other studies[257], CIN2 has poor reproducibility when LLETZ and punch biopsy H&E slides 
are interpreted but the addition of p16 and Ki67 immunostains improved diagnostic 
accuracy and inter-rater reliability. 
Due to the nature of the endocervical curettings the epithelium was fragmented and 
scattered dysplastic cells with focal staining were common. The scoring protocols were 
adapted to record positive expression if scattered cells showed morphological changes or 
dual-staining was seen in fragmented strips of epithelium. Full thickness Ki67 staining and 
strong staining of p16 had better predictability for CIN2+ than ‘any grade’ of staining. P16 
in conjunction with Ki67 improved the inter-rater reliability when compared to outcomes 
with the individual stains and was of use when interpreting scanty or fragmented samples. 
For example, strong p16 staining was present when HPV alone was reported at LLETZ and 
in these cases the addition of Ki67 was particularly useful in illustrating the nuclei’s 
morphology and possible pleomorphism. To validate these findings a bigger sample size 
is required to assess the impact of p16  and Ki67 alone and in conjunction on the specificity 
of endocervical curettings. 
 
8.4.6 Management of women with low grade cytology and a TZ3 
My findings suggest that dual-stained cytology (CINtec) could improve the diagnostic 
accuracy of a low grade screening result. Women negative to dual-stained cytology did 
not have CIN2+ at LLETZ indicating that a negative result can reassure women and 
colposcopists that cytological follow-up is a safe management option. In women who are 
dual-stain positive, offering a LLETZ would seem reasonable considering the significant 
risk of high grade CIN observed in women with borderline nuclear change and a TZ3. 
Although the specificity of dual-stained cytology is moderate (30% of women would have 
a negative LLETZ), this is a substantial improvement when compared to the referral test 
specificity (~20%) -  on which colposcopists currently base their decision-making[258].  
A recent multicentre prospective trial conducted in five European countries[215] compared 
dual-stained cytology to HPV testing in women with ASCUS and LSIL. Although they 
reported a higher PPV for dual-staining, when compared to routine screening, in women 
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of all ages with both ASCUS (16.3 vs 10%) and LSIL (26.5 vs 18.6%), these values were less 
than half of what I observed (58.1%). Potential reasons for this difference could include 
their inclusion of women with all TZ types with their lower rates of CIN2+ (4.2% for ASCUS 
and 16.4% for LSIL), differences in dual-stain tests and population variances. Half of my 
study sample were aged 25 - 39 and if the TZ is positioned more proximally to the 
ectocervix in younger women[108], cellular adequacy may have been affected by this.  
All women with dual-stain positive cytology had high risk HPV but the converse was not 
true. This suggests that integration of HPV, rather than infection, may influence the 
outcome of the test. Despite this, reasons for the moderate PPV need to be explored and 
a potential reason may be failure of dual-staining to account for women who have current 
HPV integration but will go on to clear the virus. Further studies which assess the 
progression rate of CIN in women who are dual-stain positive but initially have normal 
histology would be useful. Although some studies have promoted the improved inter-
rater reliability of dual-staining when compared to cytology alone[259], I did not observe 
this. A potential reason may be the extensive experience of the cytologists who were 
interpreting these slides. 
Processing limitations can contribute to the specificity of dual-stained cytology. The 
brown DAB staining can be trapped within mucus or cell debris increasing the intensity 
and distribution of background staining. The FastRed reaction can ‘bleed’ into the 
cytoplasm and neutrophils leading to false positive staining patterns or slides which are 
difficult to interpret. With clusters, individual cells are difficult to assess in the same plane 
of focus. The fast red stain can fade if it is exposed to alcohol, cracking artefact can arise 
with incomplete drying of the aqueous mounting media (Figure S7.1 in appendix 7) and 
‘cornflaking’ of the cells can occur if there is air drying before the aqueous mounting 
media is applied (Figure S7.2 in appendix 7). 
The relevance for clinical practice needs to be considered. The cost of a liquid based 
cytology test and dual-stained cytology slide are approximately £40 each. The addition of 
dual-staining to the referral cytology doubles the laboratory costs but in comparison a full 
genotyping array costs £120 and a LLETZ treatment is approximately £650. Given that pre-
term births significantly increase neonatal mortality and cost the British economy £939 
million a year[260], reducing iatrogenic factors will have considerable economic as well as 
patient outcome implications.  
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My data also supports current literature which reports a 20% incidence of a TZ3 [4, 197], 
illustrating this is a significant proportion of women who will be reviewed, potentially 
accounting for more than 25,000 of the 127,171 women seen annually in the UK with low 
grade cytology [87]. Although half of these women will be >40, these patients may choose 
improved diagnostic accuracy in preference to an unnecessary treatment and efforts 
should be made to assess patient preferences. 
Currently, the availability of dual-stained cytology within NHS trusts is for research 
purposes only. For UK wide access, the NHS CSP would need to endorse the utility of this 
test and larger studies are needed to corroborate these findings and assess the cost-
benefit ratio. 
 
8.4.7 Management of women with high grade cytology and a TZ3 
In my study, women with high grade cytology and a TZ3 had a 75.6% risk of CIN2+. Data 
from the survey (Chapter 6) showed that in women aged 25 - 39, 10% of colposcopists 
recommend three month cytological follow-up and 30% will refer to the MDT. This is of 
concern considering my data from Chapter 7 showed younger women with a TZ3 are three 
times more likely to have CIN2+ at LLETZ than women >40. Based on these data, and 
national screening statistics, it seems safest to offer women with high grade cytology a 
LLETZ. The caveat is reliable attenders who are at high-risk of treatment morbidity; in 
these women immunostained curettings could be considered as no-one with CIN2+ was 
missed, false positive screening was detected in 72% and inter-rater reliability was very 
good. Furthermore, the use of these immunostains is relatively cheap (~£30). 
The sensitivity of the curettings was improved in women with high grade cytology when 
compared to low grade cytology and a potential reason is the sampling method; to allow 
correlation with the LLETZ histology quadrants were sampled rather than circumferential 
stripping. This technique may have missed focal areas of CIN2+ in women with low grade 
cytology. Furthermore, scattered dysplastic cells (as discussed in 2.4.5.3), could have been 
‘lost’ during processing, which may account for the poorer sensitivity.  
If multi-centre studies do corroborate the diagnostic value of p16/Ki67 stained curettings 
in women with high grade cytology, education in the use of endocervical curettage would 
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also need to be promoted as data from the focus groups and national survey suggest this 
is rarely offered by colposcopists due to their inexperience with the technique. 
Dual-stained cytology improved the sensitivity but not the specificity of routine screening 
in women with high grade cytology. Recent studies assessing the use of dual-staining in 
women with high grade cytology support this finding[148, 261]. There is no current evidence 
which explains the potential reason for this but in the study sample in Chapter 7, more 
women with high grade cytology, when compared to women with low grade cytology, had 
multiple high risk HPV subtypes and high risk subtypes which have a lower prevalence. 
The prevalence of a disease, as discussed in 2.4.7, can affect the PPV of a diagnostic test. 
Finally, the utility of the immunostained curettings needs to be tempered with the 
practical aspects of the test; these include patient choice, patient reliability to attend 
follow-up, the invasiveness of the procedure and the proportion of women this will affect 
in practice. A TZ3 could account for 6377 of the 31,886 women reviewed annually with 
high grade cytology[87] but half of these women may have completed their family or prefer 
immediate treatment in view of the cytological grade and inability to visualize the TZ.  
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8.5 Future Work 
8.5.1 Shared care modelling 
The management preferences of patients when the cytology is low grade and the TZ is 
visible have been reported[232, 262]. Patient preferences in the presence of a TZ3 have not 
been assessed and this, in conjunction with their acceptability of adjuncts, needs to be 
determined. The use of oestrogen, particularly in view of the high proportion of young 
women who use progesterone-only contraceptive, would be useful in evaluating the 
relevance of diagnostic adjuncts and for the provision of guideline recommendations. 
 
8.5.2 Availability and acceptability of adjuncts within the NHS 
Colposcopists’ knowledge, access, training and acceptability of adjuncts, including an 
economic assessment comparing these tests to standard practice, would be of benefit 
when planning a national consensus strategy. 
 
8.5.3 Relevance to practice 
The assessment of outcomes in women with high risk HPV, a TZ3 and negative or 
persistent inadequate cytology would be of benefit, particularly in view of the imminent 
introduction of national HPV screening.  
 
8.5.4 Cytological follow-up in women with a TZ3 
To inform interval lengths in women who are managed cytologically, prospective studies 
which assess the progression rate of CIN in women with a TZ3 who a.) have low grade 
cytology and b.) are dual-stain cytology negative would be of use. 
To validate my findings that cytological follow-up using a Cervex-Brush in the community 
provides equivalent accuracy to the cytobrush and Cervex-Brush combined, large 
prospective studies which adjust for age and parity, and include efficacy of primary care 
sampling, are needed. 
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8.5.5 Depth of LLETZ 
Studies which adjust for age and parity when assessing the mean distal and proximal 
margins of the TZ in women with a TZ3 would be of use to guide treatment 
recommendations. Proximal margins would be of use if a diagnostic LLETZ, rather than a 
treatment excision, is recommended. 
 
8.5.6 Further evaluation of adjuncts 
The impact of vaccination status on the diagnostic accuracy of the biomarkers would be 
of use, as would the assessment of viral load and the use of mRNA testing as better assays 
become available. Multicentre studies which adjust for age, parity and cytological grade 
(dividing low grade cytology into BNC and mild dyskaryosis) and studies which evaluate 
outcomes based on multiple sample takers are needed to corroborate the benefits of 
dual-stained cytology in women with low grade cytology and a TZ3.  
The evaluation of dual-staining in women with high grade cytology may provide better 
understanding of the biological activity of multiple HPV infections and subtypes with a 
lower prevalence. Studies which assess the progression rate of CIN in women who are 
dual-stain cytology positive but initially have normal histology would help determine if 
dual-stain positivity predicts future CIN or fails to recognize immuno-clearance. 
Although the sensitivity of the immunostained curettings was too low to be used in 
women with low grade cytology, outcomes based on circumferential stripping may be of 
use but this will be difficult to validate if the reference standard has limited epithelium to 
base a diagnosis upon.  
 
  




A TZ3 is a common condition occurring in 20% of the women reviewed in colposcopy, 
potentially accounting for more than 25,000 women who are reviewed with low grade 
cytology and 6000 women with high grade cytology in the UK each year. Epidemiological 
data reported in this thesis suggests a TZ3 is not a condition restricted to poorly 
oestrogenised older women who are at low-risk of treatment morbidity. More than half 
of the women assessed will be of reproductive age; these women are at highest risk of 
treatment morbidity, have four times the risk of CIN2+ when compared to women >40 
and are also the demographic cohort in whom the use of oestrogen may not be applicable 
or acceptable. The introduction of primary HPV testing in 2019 will improve the sensitivity 
of cervical screening but the specificity will still be poor in women with low grade cytology 
and this is compounded in women with a TZ3 where histological selection for treatment 
cannot be undertaken. 
My analysis of the focus groups and national survey identified that anxiety of missing a 
cancer when the TZ cannot be visualised is compounded by a lack of guidance in this 
cohort. This anxiety deters colposcopists from recommending long-term cytological 
follow-up in women with low grade cytology and a TZ3. Although HPV triage of low grade 
cytology has decreased the incidence of negative LLETZ by 25%, through its very high 
NPV[197], this does not benefit the decision-making of colposcopists as they will only review 
women who test positive for high risk HPV. Without the reassurance of diagnostic 
colposcopy, differentiation of HPV integration from infection is impossible and, as 
identified in Chapters 3, 4 and 6, colposcopists are risk adverse, resulting in higher than 
anticipated treatment rates in women with a TZ3 and low grade cytology[101]. 
A positive high risk HPV result is not an indicator of high grade disease, as illustrated by 
the poor PPV in women with low grade screening results (16%)[91], but women with a TZ3 
have double the risk of CIN2+ when compared to women where the TZ is visible. 
Population data from my diagnostic study (Chapter 7) indicates that this risk is highest in 
women aged 25 – 39. My findings are not strong enough to support a ‘see and treat’ for 
all women with a TZ3 and low grade cytology but they do suggest that adjuncts which 
improve diagnostic accuracy are required prior to offering long term cytological follow-
up.  
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In women with high grade cytology, HPV genotyping did not improve the sensitivity or 
specificity of the screening test result to an acceptable level. The effect of the vaccination 
programme on the prevalence of high risk subtypes may account for this lower than 
expected accuracy and illustrates that women who are positive to other high risk subtypes 
still have a significant risk of CIN2+. The specificity of dual-stained cytology for CIN2+ in 
women with high grade cytology was half of that observed in women with routine 
screening; potential reasons for the difference in diagnostic accuracy between low grade 
and high grade cytology when dual-staining is used is not currently clear.  
In order for experts to analyse information they need to utilise cognition as well as the 
emotional impact from their past experiences. However, in areas of clinical uncertainty 
when decisions are dominated by emotive factors, clinical guidance can reduce the 
difficulty and anxiety of decision-making. The studies outlined in this thesis were designed 
to help guide a national consensus strategy and, as such, I have proposed areas of 
guidance to aid in areas of uncertainty: 
 High grade cytology and a TZ3:  
o There is an 80% risk of high grade CIN in these women and those aged 25 - 39 are 
four times more likely, than women aged >40, to have CIN2+ at LLETZ. Until 
population specific information is available it would seem safest to offer a see 
and treat LLETZ to these women. 
o The caveat is reliable attenders who are at high-risk of treatment morbidity; in 
these women the use of immunostained curettings improves the sensitivity of 
screening from 59.1% to 100% and has an equivocal specificity (80%). 
 
 Low grade cytology and a TZ3: 
o Initial Management: Women with low grade cytology, high risk HPV and a TZ3 
have a 36% risk of CIN2+. Prior to offering long-term cytological follow-up, the 
use of dual-stained cytology could provide an excellent sensitivity and improve 
the specificity of screening (negative LLETZ) from 19.3% to 71.7%.  
o Clinical setting and collection method for cytological follow-up: The use of the 
Cervex-Brush alone, which could be offered in a primary care setting, provides 
equivocal sensitivity and specificity to the Cytobrush used in conjunction with the 
Cervex-Brush. 
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 Repetition of the referral cytology:  
To reduce the risk of false negative screening, the referral cytology should not be 
repeated at the first colposcopy appointment unless the interval between is greater 
than three months. The absence of endocervical cells does not appear to reduce 
detection of dysplasia. 
 Depth of LLETZ:  
To reduce false negative histology, and until studies adjust for age and parity when 
assessing the distal margins of a TZ3, national excision guidance (15-25mm) should be 
adhered to. 
 
Clinicians strive for improvement in patient outcomes in their day-to-day life. Continued 
exploration of the themes identified within my work may help in the continuing global 
efforts to diagnose and prevent progression of cervical intraepithelial neoplasia and 
improve outcomes in women with a TZ3. My data confirms the 20% incidence of a TZ3 
and suggests, for the first time, that in the presence of low grade cytology, these women 
have double the risk of CIN2+ when compared to women where the TZ is visible, 
establishing the relevance and utility of adjuncts which improve diagnostic accuracy in 
this cohort.  
With the imminent introduction of primary HPV screening my findings are of increasing 
importance for the provision of management guidance and for the introduction of new 
technologies which may improve outcomes in women with a TZ3 and optimise service 
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ACORN STUDY INFORMATION SHEET: Discussion Groups 
Endocervical Curettage & Cytology with p16/Ki-67 to diagnose pre-cancerous          
cervical change in women with a TZ3 
 
 You are being invited to take part in the ACORN study discussion group. 
 Before you decide to take part, we would like to explain the reason for this research 
and what is involved. 
 Please feel free to use the contact details below if you would like more information.  
    
 
Introduction – What are we trying to find out? 
There is a paucity of guidance to aid colposcopists’ decision-making in women with a TZ3. 
We would like to investigate colposcopists’ opinions on the different management 
options for women with a TZ3 (unsatisfactory colposcopy). As part of a University of 
Bristol project, we would like to hear colposcopist’s views on current practices in this 
cohort of women. We aim provide recommendations for management of a TZ3, which may 
guide a consensus opinion. 
 
Why have I been asked to take part? 
We are asking you to help because you manage women with a TZ3 and may institute 
management protocols that are different to policies at University Hospitals Bristol NHS 
Trust. 
 
Do I have to take part? 
It is entirely your decision to take part. If you do agree to join the ACORN Study Discussion 
Group, we will seek your written consent. You are free to change your mind and withdraw 
from the study at any time and you do not need to give your reasons.  
 
What will taking part involve? 
Taking part will involve joining one focus group, which will take about an hour. We would like 
a minimum of four colposcopists to take part. It will occur in a location of your convenience. 
Questions will focus on your experiences and views of the management of women with a 
TZ3. The discussions will be audio recorded and transcribed. We welcome your honest 
answers and views, both positive and negative. 
 
Are there any possible benefits? 
We aim to improve care by providing recommendations for management of a TZ3, which 









Is there any possible harm? 
We do not envisage any harm coming to you as a consequence of taking part in the focus 
(discussion) group. If any problems arise during the discussion group, the research team will 
be happy to facilitate referral to other members of the research team for further guidance. 
 
If you have any concerns or other questions about this study or the way it has been carried 
out you should contact the Patient Support & Complaints Team, Trust Headquarters, 
University Hospitals Bristol, Marlborough Street, Bristol, BS1 3NU.                           
Tel No: 0117 342 3604 email: pals@uhbristol.nhs.uk 
 
Will the information I give in this study be kept confidential? 
All the data collected from you during the course of the study will be strictly confidential and 
anonymity will be preserved. All audio data will be stored securely and confidentially on 
password-protected computers in a locked research office. Files will be destroyed after 5 
years in line with NHS regulations. Identifiable information will not be included in the 
transcription of the audio files.  
Anonymous quotes from the interview discussions may be used in medical articles or 
presentations. Quotes will be free of personal identifiable information. In the event that you 
lose the capacity to consent during the study, the research team will retain your previous 
contributions for use in the study. Anonymity and confidentiality will be maintained. 
 
Who has reviewed the study? 
The NRES Committee South West, Frenchay Research Ethics Committee has reviewed and 
agreed to this study. 
 
What do I do now? 
If you have read this information sheet and want to take part, please contact one of the 
research team members using the contact details provided. One of the project team will then 





















ACORN STUDY DISCUSSION GROUP CONSENT FORM 
Endocervical Curettage & Cytology with p16/Ki-67 to diagnose pre-cancerous cervical 




1. I confirm that I have read and understand the information sheet (v1.6) 
dated 25.02.14 for the above study.  
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason. 
3. I understand that the focus group discussion will be audio recorded. 
4. I agree that anything I say may be published as quotes in written 
publications, other academic and quality improvement work and reports, 
after identifying information is removed so that I cannot be recognised. 
5. I agree to take part in the above study and I understand that relevant 
sections of data collected during the study may be looked at by individuals 
from the research team, from regulatory authorities, or from the NHS trust, 
where it is relevant to my taking part in this research. I give permission for 
these individuals to have access to the data. 
 
..........................................................     ..................         ................................ 
Name of participant (Block capitals)          Date                Signature 
 
......................................................     .................          ................................ 
          Person taking Consent           Date    Signature 
 
....................................................      ...............             .............................. 









 Please initial the 
boxes below: 
Version 1.4: 25/02/2014 
  




ACORN STUDY INFORMATION SHEET: Survey Validity 
Endocervical Curettage & Cytology with p16/Ki-67 to diagnose pre-
cancerous cervical change in women with a TZ3 
 
You are being invited to take part in the ACORN Survey Validity Study. 
Before you decide to take part, we would like to explain the reason for this research and 
what is involved. 
Please feel free to use the contact details below if you would like more information.  
    
 
Introduction – What are we trying to find out? 
There is a paucity of guidance to aid colposcopists’ decision-making in women with a TZ3. 
We would like to investigate colposcopists’ opinions on the different management 
options for women with a transformation zone type 3 (unsatisfactory colposcopy). As part 
of a University of Bristol project, we have developed a national survey to evaluate current 
UK practice, but need to assess the psychometric properties of the survey before it is 
released to BSCCP members. If you have any questions please do not hesitate to contact 
the research team using the contact details at the end of this information sheet. 
 
Why have I been asked to take part? 
We are asking you to help because you manage women with a TZ3 and may institute 
management protocols that are different to policies at University Hospitals Bristol NHS 
Trust. 
 
Do I have to take part? 
It is entirely your decision to take part. If you do agree to participate, we will seek your 
written consent. You are free to change your mind and withdraw from the study at any 
time and you do not need to give your reasons.  
 
What will taking part involve? 
In order to achieve our goal, we need to work out if colposcopists read the questions in 
the same way. We would like you to complete the survey in front of a researcher and then 
discuss what you think each question is asking, discuss whether you feel all the areas of 
interest relating to a TZ3 have been included and evaluate whether the design of the 
questionnaire is user friendly.  
 
Are there any possible benefits? 








Is there any possible harm? 
We do not envisage any harm coming to you as a consequence of taking part in this study. If 
any problems arise during the discussion, the research team will be happy to facilitate 
referral to other members of the research team for further guidance. 
 
If you have any concerns or other questions about this study or the way it has been carried 
out you should contact the Patient Support & Complaints Team, Trust Headquarters, 
University Hospitals Bristol, Marlborough Street, Bristol, BS1 3NU.                           
Tel No: 0117 342 3604  email: pals@uhbristol.nhs.uk 
 
Will the information I give in this study be kept confidential? 
All the data collected from you during the course of the study will be strictly confidential and 
anonymity will be preserved. All data will be stored securely and confidentially on password-
protected computers in a locked research office. Files will be destroyed after 5 years in line 
with NHS regulations. 
Anonymous quotes from the interviews may be used in medical articles or presentations. 
Quotes will be free of personal identifiable information. In the event that you lose the 
capacity to consent during the study, the research team will retain your previous 
contributions for use in the study. Anonymity and confidentiality will be maintained. 
 
Who has reviewed the study? 
The NRES Committee South West, Frenchay, Research Ethics Committee has reviewed and 
agreed to this study. 
 
What do I do now? 
If you have read this information sheet and want to take part, please contact one of the 
research team members using the contact details provided. One of the project team will then 























ACORN STUDY Survey Validity CONSENT FORM 
Endocervical Curettage & Cytology with p16/Ki-67 to diagnose pre-cancerous cervical 
change in women with a TZ3 
 
 
1. I confirm that I have read and understand the information sheet (v1.2) 
dated 17.04.2014 for the above study.  
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason. 
3. I agree to allow the researcher to use anonymous direct quotes from 
my responses in the questionnaire and interview in articles or 
presentations. 
4. I agree to take part in the above study. 
 
......................................................     ..................         ................................ 
Name of participant (Block capitals)          Date                Signature 
 
......................................................     .................          ................................ 
          Person taking Consent           Date    Signature 
 
....................................................      ...............             .............................. 















Please initial the 
boxes below: 
Participant ID: ………….. 





ACORN STUDY INFORMATION SHEET: Survey Reliability 
Endocervical Curettage & Cytology with p16/Ki-67 to diagnose pre-cancerous 
cervical change in women with a TZ3 
 
 You are being invited to take part in the ACORN Survey Validity Study. 
 Before you decide to take part, we would like to explain the reason for this research 
and what is involved. 
 Please feel free to use the contact details below if you would like more information.  
    
 
Introduction – What are we trying to find out? 
There is a paucity of guidance to aid colposcopists’ decision-making in women with a 
transformation zone type 3 (TZ3). We would like to investigate colposcopists’ opinions on 
the different management options for women with a TZ3 (unsatisfactory colposcopy). As 
part of a University of Bristol project, we have developed a national survey to evaluate 
current UK practice, but need to assess the psychometric properties of the survey before 
it is released to BSCCP members. In order to achieve our goal, we need to work out if the 
results of the test are consistent i.e. if a colposcopist completed the survey weeks apart 
would they still answer the questions in the same way. If you have any questions please 
do not hesitate to contact the research team using the contact details at the end of this 
information sheet. 
 
Do I have to take part? 
It is entirely your decision to take part. If you do agree to participate, we will seek your 
written consent. You are free to change your mind and withdraw from the study at any 
time and you do not need to give your reasons.  
 
What will taking part involve? 
We would like you to complete the survey at a convenient time for you and then complete 
the survey two weeks later. The link to this survey can either be emailed to you or a hard 
copy can be provided, dependent on your preferences. There are 15 questions overall and 
it should take no more than 15 minutes to complete. Some background questions ask for 
simple facts and will be answerable easily. Other questions may take more time as they 
invite you to indicate your management preferences in areas that currently have little 
guidance.  
 
Are there any possible benefits? 









Is there any possible harm? 
We do not envisage any harm coming to you as a consequence of taking part in this study. If 
any problems arise during the discussion, the research team will be happy to facilitate 
referral to other members of the research team for further guidance. 
 
If you have any concerns or other questions about this study or the way it has been carried 
out you should contact the Patient Support & Complaints Team, Trust Headquarters, 
University Hospitals Bristol, Marlborough Street, Bristol, BS1 3NU.      
Tel No: 0117 342 3604  email: pals@uhbristol.nhs.uk 
 
Will the information I give in this study be kept confidential? 
All the data collected from you during the course of the study will be strictly confidential and 
anonymity will be preserved. All data will be stored securely and confidentially on password-
protected computers in a locked research office. Files will be destroyed after 5 years in line 
with NHS regulations. 
Anonymous quotes from the survey may be used in medical articles or presentations. Quotes 
will be free of personal identifiable information. In the event that you lose the capacity to 
consent during the study, the research team will retain your previous contributions for 
use in the study. Anonymity and confidentiality will be maintained. 
 
Who has reviewed the study? 
The NRES Committee South West, Frenchay Research Ethics Committee has reviewed and 
agreed to this study. 
 
What do I do now? 
If you have read this information sheet and want to take part, please contact one of the 
research team members using the contact details provided. One of the project team will then 






















ACORN STUDY Survey Reliability CONSENT FORM 
Endocervical Curettage & Cytology with p16/Ki-67 to diagnose pre-cancerous cervical 
change in women with a TZ3 
 
 
1. I confirm that I have read and understand the information sheet (v1.1) 
dated 21.04.2014 for the above study.  
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason. 
3. I agree to allow the researcher to use anonymous direct quotes from 
my responses in the survey in articles or presentations. 
4. I agree to take part in the above study. 
 
......................................................     ..................         ................................ 
Name of participant (Block capitals)          Date                Signature 
 
......................................................     .................          ................................ 
          Person taking Consent           Date    Signature 
 
....................................................      ...............             .............................. 


















Please initial the 
boxes below: 
Participant ID: ………….. 






ACORN STUDY INFORMATION SHEET: 
Endocervical Curettage & Cytology with p16/Ki-67 to diagnose  
pre-cancerous cervical change in women with a TZ3 
 
You are being invited to take part in a University of Bristol research study. Before deciding 
whether you wish to take part, it is important you understand why the research is being 
done and what it involves. The aim of the study is to use a new test to improve the 
diagnosis of pre-cancerous change in the cervix. We are asking you because you are 
attending the colposcopy clinic after the results of your smear test.   
 
 
What is the purpose of the study? 
After the results of your smear test, assessment at a colposcopy clinic (viewing the skin of 
the cervix and taking a tissue sample) helps to decide who needs treatment. In women 
whose cells are tucked inside the cervix, normal and abnormal cells cannot be directly 
seen and a LLETZ (removing a core of tissue) may be recommended. In 7 out of 10 women 
with mildly abnormal smears these results will be reassuring but the LLETZ can put them 
at risk of pre-term labour (2 out of 20 women) or make future smear assessments more 
difficult (3 out of 100 women). This project aims to compare the results of a new test to 
the LLETZ you may already be having, to improve the diagnosis of pre-cancerous cervical 
change and reduce the side effects of treatment. 
 
 
What will happen if I take part? 
If you are having a LLETZ because the cells of interest are tucked inside your cervix, you 
will be able to take part in this study. 
1. As part of your routine treatment, a smear will be taken from inside the cervix. We 
would like to do an additional laboratory test on this sample – this does not involve 
extra tests to you.  
2. After the local anaesthetic for your LLETZ we would like to take up to 4 small scrapings 
of tissue (1mm) from the cervix. This will take about 20 seconds. After the scrapings 
you will have your LLETZ as planned. A new laboratory test will be used on the 
scrapings and these will be compared to your LLETZ result. 
3. If the new test shows the same results as the LLETZ, we will invite you to participate 
in a discussion group 6 months after your LLETZ. This will focus on your experiences 
and views of the available treatments. It will take up to an hour and will take place at 
St. Michael’s Hospital. If you would like to attend, with or without having the new 
investigation, please indicate on the consent form and further information will be sent 
to you. 
We will inform your GP that you are helping with the study. 
 
 
Do I have to take part? 
It is entirely your decision to take part. You are free to change your mind and withdraw 
from the study at any time and you do not need to give your reasons. It will not affect 









Are there any possible benefits to me? 
Your samples from the new test may help us to improve the diagnosis of pre-cancerous 
change within the cervix. It is possible that the new test may find pre-cancerous cells 
further up your cervix than would be found by the LLETZ - identifying potential problem 
cells earlier. If this happens, a full review of your case will be undertaken and any changes 
to your treatment will be discussed with you. 
 
Is there any possible harm to me? 
The new test does not cause more side effects than the LLETZ procedure you will already 
be having. Side effects of the LLETZ include mild to moderate bleeding and mild period 
cramps for up to 6 weeks. Possible side effects from the new test include mild bleeding 
or mild period cramps for up to 5 days.  
If you have any concerns about this study or the way it has been carried out you should 
contact the Patient Support & Complaints Team, Trust Headquarters, University Hospitals 
Bristol, Marlborough Street, Bristol, BS1 3NU. 
                            Tel No: 0117 342 3604         email: pals@uhbristol.nhs.uk 
 
What happens to the tissue samples / data? 
The tissue samples will be given a laboratory number and anonymised (your name and 
other personal details will not be used). After the study, tissue slides are stored for at least 
5 years as part of your medical records, as they may help in your future treatment. There 
will be no left over tissue as we are taking very small samples. All information you give 
will be confidential and kept for 5 years in line with NHS regulations. Destruction of this 
information will be compliant with the Data Protection Act 1998. 
 
Will I be informed of the study results? 
The results will be presented in medical journals and conferences to increase our 
understanding of the diagnosis of cervical cancer. Your name and other personal details 
will not be published. 
 
Who has agreed to this study? 
The National Research Ethics Committee South West (Frenchay REC) has reviewed and 
agreed to this study. 
 
What do I do now? 
If you are happy to participate in this study and would like further information, please use 

















(please leave a message and a 
research associate will return the call). 




ACORN STUDY CONSENT FORM 
Endocervical Curettage & Cytology with p16/Ki-67 to diagnose pre-cancerous cervical 





1. I confirm that I have read and understand the information sheet (v1.7) 
dated 26.02.14 for the above study.  
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time. If I withdraw consent, samples already taken will 
be disposed of under NHS Trust guidelines.  
 
3. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from 
regulatory authorities or from the NHS Trust, where it is relevant to my 
taking part in this research. I give permission for these individuals to 
have access to my records. 
 
4. I consent to the removal, storage and use of my tissue samples for the 
above study in line with the Human Tissue Act 2004. 
 
5. I consent to my GP being informed of my participation in this study. 
 
6. I understand my responses may be published anonymously in articles 
or presentations. 
 
7. I agree to allow data to be retained in anonymised form for five years 
after the completion of this study in line with NHS regulations. 
 
8. I agree to take part in the above study. 
 
....................................................        ............................        ………………………………..   
Name of Patient (Block Capitals)      Date                Signature 
 
...................................................          ............................         …………......................                            
Name of person taking consent       Date   Signature 
 
....................................................        .............................         ................................ 
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Table S4.1: Negative LLETZ study variable and code definitions for ExCel 
VARIABLE CODE 
Age Raw data 
Smoking Per/day 
Contraceptive 0 – none 
1 – COCP 
2 – Progesterone (POP, depo-provera, nexplanon, 
mirena coil, postmenopausal) 
Parity Raw data 
Referral Smear 0 – negative 
1 – low grade cytology 
2 – high grade cytology 
3 – no result 
Cytology to colposcopy 
interval 
In weeks 
TZ type 0 – unsatisfactory (TZ3) 
1 – Satisfactory (TZ1 or 2) 
Colposcopy to LLETZ interval In weeks 
Reason for LLETZ 0 - HG cytology / TZ3 
1 - HG cytology & HG colp 
2 - CIN2 on biopsy 
3 - CIN3 on biopsy 
4 - CIN1 >24m 
5 - LG cytology / TZ3 
6 – cGIN 
7 - other 
See and Treat 0 – Yes 
1 - No 
Date of LLETZ DD/MM/YY 
LLETZ result 0 – Normal / HPV 
1 – CIN1 
2 – CIN2 
3 – CIN3 
4 – cGIN 
5 - Invasive 
Excision Depth millimetres 
TZ in LLETZ 0 – Yes 
1 - No 
Limiting Factors 0 – metaplasia 
1 – TEM 
2 – fragmentation 
3 – denudation 
4 – diathermy artefact 
Total follow-up period In months 
Screening result post LLETZ 0 – Negative 
1 – HPV positive, negative cytology 
2 – low grade cytology 
3 – high grade cytology 




Histology post LLETZ 0 – Normal 
1 – HPV 
2 – CIN1 
3 – CIN2 
4 – CIN3 
5 – cGIN 
6 – invasion 
























I am a Research Fellow in Colposcopy at St Michaels Hospital, Bristol. The focus of 
my thesis is the diagnosis and management of CIN in women with a TZ3. There is 
currently a paucity of guidance to aid Colposcopists’ decision-making in these 
women. I aim to evaluate practice within the UK to assess areas of consensus and 
uncertainty. 
 
I am hoping to recruit Colposcopists from different NHS trusts to participate in 
discussion (focus) groups at their own hospitals. I have attached a study 
information sheet and sample consent form.  
 
If you would like to participate or require further information please use the 






Dr Kristyn Manley MB BS, DFSRH, FHEA 


































Dear BSCCP Member, 
Currently, there is limited guidance on the management and follow up of women 
who present with a transformation zone type 3 (unsatisfactory colposcopy). This 
survey will explore colposcopist’s experience of managing these women and 
specifically evaluate the management choices for: 
1. Women who attend their first appointment with low or high grade cytology, 
with an interest in assessing if age or parity influences decision-making 
2. Length, technique and clinical setting of cytological follow-up for women with 
low grade cytology and a TZ3 
3. Average depth of LLETZ in women with a TZ3 and whether choice is influenced 
by age, parity or cytological grade 
If you have any questions about the survey please contact Dr Kristyn Manley, Research 
Fellow (Colposcopy), University Hospitals Bristol NHS Trust: 
  
The survey will take no more than 15 minutes, and the deadline for completion is Friday 
29th April 2019. We appreciate your time and views in helping to complete this. 




Colposcopist’s experience in managing unsatisfactory colposcopy (a TZ3): 









Figure S4.5: ACORN patient demographic proforma 
 
ACORN Study Baseline Information Proforma 
1. Age…………………………………………………………… 
2. Parity……………………….................................... 
3. Smoking status…………………………………………. 
4. Contraceptive…………………………………………… 
5. Referral screening test result (circle) 
BNC     Mild     Moderate     Severe     Invasive  
HR HPV result………………………………………………… 
6. Biopsy prior to LLETZ? 
No  Yes  Result………………………................. 
7. Previous LLETZ?  Yes  No 
Result…………………………….
 Margins……………………………………  
Timescale prior to recruitment (months) …………………………….... 
8. Able to pass the cytobrush  YES  NO 








Figure S4.6: ACORN treatment checklist 
ACORN STUDY: Treatment Checklist 
Endocervical Curettage & Cytology with p16/Ki-67 to diagnose pre-cancerous cervical 
change in women with a TZ3 
1. Confirm consent and file in notes           � 
 
2. Confirm study eligibility (TZ3, squamous cytology, not pregnant)       � 
 
3. Broom and brush sample            � 
a. Put ACORN study sticker on pot 
b. Trial Participant number ONLY on pot 
c. Mark for Kath Hunt (NBT) 
d. Complete cytology form with trial sticker and ID only 
 
4. Inject citonest as per standard LLETZ treatment                      � 
 
5. 4 quadrant ECC (1 scrape each at depth of 2.0 cm)                      � 
 
6. Place curettage in separate histology pot to LLETZ          � 
a. Put ACORN study sticker (with participant ID only) on pot 
b. Mark for Joya Pawade (UH Bristol) 
 
7. Complete curettings histology form (separate to LLETZ form)                      � 
a. Put ACORN study sticker (with participant ID only) on form 
b. Mark for Joya Pawade (UH Bristol) 
 
8. Continue with standard LLETZ – label pot and complete form as normal   �                                                                          
 
9. Give the patient the emergency contacts letter           � 
 
10. Complete the patient demographic information sheet          � 





Figure S4.7: ACORN patient emergency contact letter 











Thank you for participating in the ACORN study.  
 
Please do not hesitate to use the contact details above in the event of a query 






Dr Kristyn Manley MBBS, DFSRH, FHEA 
Research Fellow (Colposcopy), St Michael’s Hospital.  




Figure S4.8: ACORN GP letter 




Dear Dr ………………………………….. 
R.E.       DOB  
The above named patient has consented to enrolment in the ACORN Study. The aim of 
this project is to use a cytobrush and endocervical curettage in conjunction with surrogate 
biomarkers (p16 and Ki67) for Human Papillomavirus infection. These tests are taken 
immediately prior to the LLETZ they are already scheduled to have. 
 
Side effects of this procedure are no different than those of a standard LLETZ – mild per 
vaginam bleeding for up to 6 weeks and mild period pain. All participants have been given 
a colposcopy helpline and a research office contact (see above) in the event of a query or 
an adverse reaction. Follow up will be as per national protocols i.e. cytology 6 months 
post LLETZ. 
 
This study has been sanctioned by the Research and Development Department at 
University Hospitals Bristol NHS Trust and by NRES South West – Frenchay Research Ethics 
Committee. 
 




Dr Kristyn Manley MBBS, DFSRH, FHEA 
Research Fellow (Colposcopy), St Michael’s Hospital. 



































































































TABLE S5.1 Face validity - raw data of items completed by participants 
 
PARTICIPANT 

























13 - 15 
(3) 
1 4 N/A 1 1 4 4 4 4 4 4 1 N/A 3 
2 4 4 1 1 4 4 4 4 4 4 1 N/A 3 
3 4 N/A 1 1 4 4 4 4 4 4 1 N/A 3 
4 4 N/A 1 1 4 4 4 4 4 4 1 N/A 2 
5 4 N/A 1 1 4 4 4 4 4 4 1 N/A 3 
6 4 4 1 1 4 4 4 4 4 4 1 N/A 3 
7 4 N/A 1 1 4 4 4 4 4 4 1 1 3 
8 4 4 1 1 4 4 4 4 4 4 1 N/A 3 
9 4 4 1 1 4 4 3 4 4 4 1 N/A 3 
10 4 4 1 1 4 4 4 4 4 4 1 N/A 3 
11 4 N/A 1 1 4 4 4 4 4 4 1 N/A 3 
12 4 N/A 1 1 4 4 4 4 4 4 1 N/A 3 
Missing item 0% 0% 0% 0% 0% 0% 2.1% 0% 0% 0% 0% 0% 2.8% 

























Table S6.1: Association between respondents’ years of experience, job title and 
gender 
 YEARS OF EXPERIENCE 
N (%), 95% CI TOTAL 
0-2 years 3-4 years 5-10 years >11 years 
Nurse 2 (6.3%) 
0.8 - 20.8%  
2 (6.3%) 
0.8 - 20.8% 
16 (50%) 
31.9 - 68.1% 
12 (37.5%) 






0 - 12.8% 
0 
0 - 12.8% 
2 (7.4%) 
0.9 - 24.3% 
25 (92.6%) 






1.5 - 10.1% 
6 (5.4%) 
1.9 - 11.3% 
22 (19.6%) 
12.7 – 28.2% 
79 (70.5%) 
61.2 – 78.8% 
112 
55.2% 
Registrar  3 (37.5%) 
8.5 - 75.5% 
1 (12.5%) 
3.2 - 52.7% 
4 (50%) 
15.7 - 84.3% 
0 






0.1 - 21.1% 
2 (8.3%) 
1 - 27% 
4 (16.7%) 
4.7 - 37.4% 
17 (70.8%) 
48.9 - 87.4% 
24 
11.8% 
TOTAL 11 (5.4%) 11 (5.4%) 48 (23.5%) 133 (65.2%)  
 
FEMALE 6 (4.7%) 11 (8.7%) 39 (30.7%) 71 (55.9%) 127 
63.5% 






Table S6.2: Association between respondents’ job title and gender 
 GENDER 


























Table S6.3: Association between respondents’ years of experience in colposcopy 
and their use of adjuncts to improve diagnosis 
Method to improve 
diagnosis with a TZ3 
Years of experience 
Total p 



























































































































































































































Table S6.4: Association between respondents’ job title and their use of adjuncts 
to improve diagnosis 
Method 
  Job title 



























































































































































































































































































MDT Other TOTAL 
 
  N (%) 95% CI 
 
25 - 39, 
nulliparous 
96 (46.8%) 
39.8 - 53.9 
24 (11.1%) 
7.8 - 17.1 
8 (3.9%) 
1.8 - 7.8 
1 (0.5%) 






28.2 - 41.6 
5 (2.4%) 
0.9 - 5.9 
205 
25 - 39, family 
incomplete 
118 (57.6%) 
50.5 - 64.4 
18 (8.8%) 
5.4 - 13.7 
7 (3.4%) 








22.3 - 35.1 
4 (1.9%) 





62.4 - 75.4 
14 (6.8%) 
3.9 - 11.4 
3 (1.5%) 





0 42 (20.5%) 
15.3 - 26.8 
4 (1.9%) 






81.8 - 91.4 
4 (1.9%) 













5.4 - 13.7 
3 (1.4%) 









Table S6.6: Colposcopists’ reasons for choice of LLETZ in women with low grade 
cytology and a TZ3 
1. The LLETZ can be repeated if diagnostic for CIN (n=99, 48.3%, CI 41.3-55.3%) 
 25 - 39 nullip, 
n=82 







≤6 n=17 (20.7%) n=13 (16.7%) n=8 (12.9%) n=1 (2.8%) 0.09 
7-10 n=58 (70.7%) n=58 (74.4%) n=45 (72.6%) n=19 (54.3%) 0.17 
11-14 n=7 (8.5%) n=7 (8.9%) n=7 (11.3%) n=11 (31.4%) 0.003 
≥15 n=0 n=0 n=0 n=4 (11.4%) <0.001 
P value <0.0001 <0.0001 <0.0001 <0.0001 - 
2. A deeper LLETZ will excise an endocervical TZ (n=123, 60%, CI 53.1-66.4%) 
 25 - 39 nullip, 
n=25 







≤6 n=0 n=0 n=0 n=0 - 
7-10 n=0 n=1 (3.2%) n=0 n=0 0.1 
11-14 n=23 (92%) n=27 (87.1%) n=53 (81.5%) n=74 (71.8%) 0.06 
≥15 n=2 (0.8%) n=3 (9.7%) n=12 (18.5%) n=29 (28.2%) 0.03 
P value <0.0001 <0.0001 <0.0001 <0.0001 - 
3. The risk of cervical stenosis (n=60, 29.3%, CI 23.2-36.1%) 
 25 - 39 nullip, 
n=47 







≤6 n=11 (23.4%) n=9 (20.9%) n=5 (14.3%) n=1 (5.8%) 0.36 
7-10 n=31 (65.9%) n=28 (65.1%) n=19 (54.3%) n=8 (47.1%) 0.42 
11-14 n=4 (8.5%) n=4 (9.3%) n=8 (22.9%) n=5 (29.4%) 0.08 
≥15 n=0 n=0 n=0 n=0 - 
P value <0.001 <0.001 <0.001 0.002 - 
4. Fertility IS an issue (n=164, 84.1%, CI 74.4-87.2%) 
 25 - 39 nullip, 
n=141 







≤6 n=17 (12.1%) n=14 (10.4%) n=7 (6.9%) n=0 <0.001 
7-10 n=102 (82.3%) n=99 (73.9%) n=70 (69.3%) n=0 <0.001 
11-14 n=22 (15.6%) n=21 (15.7%) n=24 (23.7%) n=0 <0.001 
≥15 n=0 n=0 n=0 n=0 - 
P value <0.001 <0.001 <0.001 - - 
5. Fertility is not an issue (n=123, 60%, CI 52.9 – 66.7%) 
 25 - 39 nullip, 
n=2 







≤6 0  0 0 0 - 
7-10 1 (50%) 4 (44.4%) 10 (38.5%) 26 (21.8%) 0.15 
11-14 1 (50%) 5 (55.6%) 12 (46.2%) 72 (60.5%) 0.59 
≥15 0 0 4 (15.3%) 20 (16.8%) 0.67 
P value 0.44 0.006 <0.001 <0.001  
6. Most of these women have reassuring histology (n=80, 39%, CI 32.4 - 46.1%) 
 25 - 39 nullip, 
n=75 







≤6 n=14 (18.7%) n=11 (16.4%) n=6 (11.5%) n=1 (2.6%) 0.10 
7-10 n=50 (66.7%) n=47 (70.1%) n=32 (61.5%) n=17 (44.7%) 0.05 
11-14 n=11 (14.7%) n=9 (13.4%) n=13 (25%) n=19 (50%) <0.001 
≥15 n=0 n=0 n=1 (1.9%) n=1 (2.6%) 0.34 




7. They are HPV positive (n=44, 21.4%, CI 16.8 – 27.8%) 
 25 - 39 nullip, 
n=32 







≤6 n=7 (21.8%) n=5 (15.6%) n=4 (10%) n=1 (3.1%) 0.13 
7-10 n=22 (68.7%) n=22 (68.7%) n=22 (55%) n=10 (32.2%) 0.01 
11-14 n=3 (9.3%) n=4 (12.5%) n=13 (32.5%) n=18 (58%) <0.001 
≥15 n=0 n=1 n=1 (2.5%) n=2 (6.4%) 0.5 



























Table S6.7: Colposcopists’ reasons for choice of LLETZ in women with high grade 
cytology and a TZ3 
1. LLETZ can be repeated if diagnostic for CIN (n=96, 46.8%, CI 39.8 – 53.9%) 
 25 - 39 nullip, 
n=84 







≤6 n=8 (9.5%) n=5 (6.6%) n=2 (3.6%) n=0 0.21 
7-10 n=58 (69%) n=55 (72.3%) n=39 (70.9%) n=19 (59.4%) 0.59 
11-14 n=18 (21.4%) n=16 (21%) n=14 (25.4%) n=13 (40.6%) 0.14 
≥15 n=0 n=0 n=0 n=0 - 
P value <0.001 <0.001 <0.001 <0.001 - 
2. A deeper LLETZ will excise an endocervical TZ (n=140, 68.3%, CI 61.3 – 74.5%) 
 25 - 39 nullip, 
n=49 







≤6 n=0 n=0 n=0 n=0 - 
7-10 n=15 (30.6%) n=15 (28.8%) n=21 (23.9%) n=16 (13.1%) 0.02 
11-14 n=28 (57.1%) n=40 (76.9%) n=55 (62.5%) n=79 (64.7%) 0.18 
≥15 n=6 (12.2%) n=7 (13.5%) n=12 (13.6%) n=27 (22.1%) 0.23 
P value <0.001 <0.001 <0.001 <0.001 - 
3. Fertility is NOT an issue (n=125, 60.9%, CI 53.9 – 67.6%) 
 25 - 39 nullip, 
n=5 








≤6 n=0 n=0 n=0 n=0 - 
7-10 n=0 n=0 n=0 n=0 - 
11-14 n=3 (60%) n=3 (60%) n=20 (80%) n=103 (79.2%) 0.65 
≥15 n=2 (40%) n=2 (40%) n=5 (20%) n=27 (20.8%) 0.55 
P value 0.07 0.07 <0.001 <0.001 - 
4. Fertility IS an issue (n=132, 64.4%, CI 57.3 – 70.8%) 
 25 - 39 nullip, 
n=126 







≤6 n=6 (4.7%) n=4 (3.4%) n=2 (2%) n=0 0.75 
7-10 n=85 (67.4%) n=83 (69.7%) n=56 (57.7%) n=0 0.28 
11-14 n=35 (27.7%) n=32 (26.8%) n=35 (36%) n=0 0.37 
≥15 n=0 n=0 n=4 (4.1%) n=0 0.22 
P value <0.001 <0.001 <0.001 - - 
5. The risk of cervical stenosis (n=42, 20.4%, CI 15.3 – 26.8%) 
 25 - 39 nullip, 
n=31 







≤6 n=0 n=0 n=0 n=0 - 
7-10 n=23 (74.2%) n=23 (76.7%) n=14 (45.2%) n=4 (23.5%) <0.001 
11-14 n=8 (25.8%) n=7 (23.3%) n=17 (54.8%) n=13 (76.5%) <0.001 
≥15 n=0 n=0 n=0 n=0 - 
P value <0.001 <0.001 <0.001 <0.001  
6. Most of these high grade histology (n=114, 55.6%, CI 48.5 – 62.8%) 
 25 - 39 nullip, 
n=91 







≤6 n=0 n=0 n=0 n=0 - 
7-10 n=61 (67%) n=62 (65.9%) n=48 (45.7%) n=4 (4%) <0.001 
11-14 n=27 (29.7%) n=29 (30.8%) n=49 (46.7%) n=13 (13%) <0.001 
≥15 n=3 (3.3%) n=3 (3.2%) n=8 (7.6%)   n=0 0.03 
























Figure S7.1: Cracking artefact on a dual stain cytology slide secondary to 




Figure S7.2: ‘Cornflaking’ artefact of cells on a dual-stain cytology slide secondary 
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